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Abstract 
 
The prevalence of type 2 diabetes mellitus is rising, especially in low- and 
middle-income countries, where the situation is worsened because around half 
of cases are unaware of the disease. Universal screening utilizing blood markers 
can be challenging in resource-constrained settings. The identification of these 
individuals can be potentially addressed using risk scores and neuropathy 
assessment tools. This study aimed to assess the diagnostic accuracy of the 
FINDRISC, a blood-free risk score, three neuropathy assessment tools 
(EZSCAN, pupillometer, and biothesiometer), alone and in combination. 
A population-based study was conducted enrolling a sex-stratified random 
sample of participants from Tumbes, a semiurban area in the north of Peru. 
Undiagnosed T2DM was the outcome, defined using WHO OGTT thresholds. 
Diagnostic accuracy of the FINDRISC and neuropathy tools was evaluated 
using the area under the ROC curve (aROC) and respective 95% confidence 
intervals (95%CI). 
Data from 1609 participants were analysed, mean age 48.2 (SD: 10.6) years, 
810 (50.3%) females. A total of 176 (10.9%) individuals had T2DM, and only 
71 (4.7%) had undiagnosed T2DM. The diagnostic accuracy of the FINDRISC 
was aROC = 0.69 (95% CI: 0.64–0.74), with a sensitivity of 69% and 
specificity of 67%. Among devices, the EZSCAN (aROC = 0.59; 95%CI: 0.53–
0.66; sensitivity of 59% and specificity of 54%) and biothesiometer in the third 
metatarsal head (aROC = 0.60; 95%CI: 0.53–0.67; sensitivity of 31% and 
specificity of 85%) performed best. A combination of the FINDRISC and the 
biothesiometer had the best diagnostic accuracy, with a similar aROC of 
FINDRISC alone (AROC = 0.69; 95%CI: 0.68–0.78), with a sensitivity of 79% 
and a specificity of 59%. 
Our results confirm that combination of the FINDRISC and biothesiometer can 
improve diagnostic accuracy of the FINDRISC and biothesiometer alone, 
increasing sensitivity without affecting specificity or the area under the ROC 
curve.   
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Chapter I: Introduction 
 
1.1 Burden of T2DM in low and middle income countries 
Globally, there is an increase in the burden of type 2 diabetes mellitus 
(T2DM): the age-standardised prevalence of T2DM has increased from 
4.3% to 9.0% among men, and from 5.0% to 7.9% among women in the 
last four decades [1]. Moreover, T2DM is responsible for about 2 million 
deaths every year worldwide [2, 3], it is one of the leading causes of 
disability [4], and between USD$ 727 and 825 billion are estimated to be 
spent in T2DM-related healthcare [1, 5]. 
The burden of T2DM has increased faster during the last years in low- and 
middle-income countries (LMIC) compared to high-income countries [1]. 
In addition, T2DM imposes an extra risk among individuals from 
resource-constrained settings as, on average, 50% (range: 38% to 69%) of 
subjects with T2DM are not aware of their diagnosis [5]. Individuals with 
undiagnosed T2DM are usually asymptomatic until further complications, 
at the micro- and macro-vascular level, are clinically evident [6]; 
nevertheless, the scarcity of economic, human and infrastructure resources 
in resource-constrained setting might reduce the identification of T2DM 
cases.  
 
1.2 Diagnosis of T2DM 
Oral glucose tolerance test (OGTT) is considered one of the gold 
standards for T2DM diagnosis according to international guidelines [5, 7]. 
Despite of this, conventionally, fasting glucose is used in most of 
healthcare facilities in the world. OGTT and FG require at least eight 
hours of fasting; and in addition, OGTT also needs the patient to drink a 
75-gram glucose solution and two blood samples, one at the beginning of 
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the test, and then wait two hours before drawing the second blood sample 
[7]. Based on international standards, individuals who are not aware of 
having T2DM diagnosis and have fasting glucose level ≥126 mg/dL (≥7.0 
mmol/L) or 2-hour plasma glucose ≥200 mg/dL (≥11.1 mmol/L) are 
classified as having screen-detected T2DM or newly-diagnosed T2DM. 
For our purposes, this definition is compatible with the definition of 
undiagnosed T2DM. 
In 2009, the American Diabetes Association suggested that glycated 
haemoglobin (HbA1c) could be used as a diagnostic tool for T2DM [8] 
and is included in the current guidelines [7, 9]. HbA1c can give an idea of 
individual’s plasma glucose levels over the previous 8 to 12 weeks [10], 
and assessment does not require fasting, but it can be expensive, 
especially in resource-constrained settings. In addition, HbA1c results 
need to be traceable to the Diabetes Control and Complications Trial 
reference study as certified by National Glycohemoglobin Standardization 
Program [11], which requires high-quality laboratory processes and 
standards. Moreover, a relatively recent pooled analysis found that HbA1c 
is not sensitive enough to detect cases of undiagnosed T2DM when 
compared to FG at the population level [12]. This latter pooled analysis 
also showed that HbA1c sensitivity varied across different world regions 
perhaps because of discrepancies between glycated haemoglobin and 
glycaemia in different racial and ethnic groups [13], as well as setting 
characteristics. In that sense, the relationship between glucose levels and 
HbA1c seems to be no evident at high-altitude areas compared to settings 
at the sea level [14]. Thus, the relationship between HbA1c and fasting 
plasma glucose looks quadratic at the sea level, whereas it was linear at 
high altitude, which turns in less reliable estimates. For instance, using 
recommended HbA1c cut-offs for T2DM screening would translate in 
major discrepancies in diagnostic performance (i.e. reduction of 
sensitivity from 89% at the sea level to 41% at high altitude settings) [14]. 
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1.3 The Peruvian context 
There are relatively scarce population-based studies estimating the 
prevalence and incidence of T2DM in Peru. Two national representative 
surveys, conducted at least five years apart, have estimated the prevalence 
of T2DM in Peru using fasting glucose to define cases of type 2 diabetes 
mellitus. The National Survey of Nutritional and Biochemical Indicators 
for Non-communicable Diseases (ENINBSC in Spanish), carried out 
between August 2004 and April 2005, found a T2DM prevalence of 5% 
[15]; whereas a most recent report, the PERUDIAB Study, conducted 
between 2010 and 2012, but including only Peruvian urban areas, found a 
prevalence of 7% [16]. Nevertheless, a relatively recent report also show 
that T2DM prevalence, defined using fasting glucose, differed according 
to study setting characteristics; thus, prevalence of T2DM varied from 
3.1% in rural high-altitude areas to 10.3% in semiurban coastal settings 
[17]. Thus, no previous study has estimated the prevalence of T2DM in 
Peru using OGTT.  
According to the Global Burden of Disease, T2DM prevalence in Peru is 
in the average (8.8%) [18]; however, the proposed area has rates over 10% 
[17]. Thus, the prevalence of the proposed setting is comparable to that in 
the Middle East and North Africa and mainly the North America (Mexico) 
and Caribbean region. In addition, prevalence of overweight and obesity is 
on average similar to other Andean Latin American countries (i.e. Bolivia 
and Ecuador) as well as Central Latin America (i.e. Colombia, Panama 
and Mexico). As all of these countries have similar socioeconomic profile 
(i.e. emerging economies), results of the proposed study may be useful for 
these similar areas. 
Levels of awareness, treatment and control are also worrying. Using data 
of the PERU MIGRANT Study [19], overall T2DM diagnosis awareness 
was 71%, yet estimates ranged from 0% in rural settings to 74% in urban 
areas [20]. Among those aware of diagnosis, only 40.6% were on 
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treatment, and among those in treatment, none was appropriately 
controlled using the HbA1c criteria (<7%). On the other hand, results 
using the baseline of the CRONICAS Cohort Study [17] showed that, 
among all T2DM cases, 61.3% were aware of their diagnosis; among 
those aware, 71.4% were on treatment, and 63.2% were appropriately 
controlled. 
From the longitudinal perspective, only two studies have reported 
incidence rates of T2DM in our context: one of them found an elevated 
incidence rate, around 2% per year [21]; whereas the other one reported a 
similar incidence estimates but also found no urban to rural gradient in 
T2DM incidences [22]. Nevertheless, this latter manuscript reported 
higher risk of developing T2DM among those living in high-altitude areas, 
possibly due to changes in lifestyle and nutrition transition occurring in 
these settings.  
 
1.4 Alternative methods for T2DM screening 
A relevant approach to prevent or delay T2DM complications is to 
identify those individuals with undiagnosed T2DM [6, 23], though, 
universal screening for T2DM at the population level is still controversial 
[24]. Thus, although, the American Diabetes Association recommends 
T2DM testing for all adults starting at age 45 years regardless of weight, 
or those who are overweight or obese and have one or more additional risk 
factor for T2DM [7]; the Disease Control Priorities Group recommends 
testing individuals at high-risk of T2DM: age≥40 years, individuals with 
family history of T2DM, obesity, physical inactivity, dyslipidemia, etc 
[24]. Moreover, recently, the US Preventive Services Task Force has 
recommended expanding the current criteria for diabetes screening to 
improve undiagnosed T2DM and dysglycaemia cases [25]. 
Because of limited economic, human and infrastructure resources in low- 
and middle-income countries, the identification of cases of T2DM can be 
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better addressed using a two-step approach: in the first step, a risk score –
defined as “an objective assessment of the probability of the presence or 
future development of an adverse health condition” [26]– can be applied 
to identify subjects at high risk of having or developing T2DM, and, in the 
second step, a confirmatory test (fasting glucose, OGTT or glycated 
haemoglobin) can be performed, but only among those categorised as high 
risk in the previous step [27].  
Although the risk scores and neuropathy assessment tools evaluated in this 
document have been used to detect cases of undiagnosed T2DM and for 
instance, will be the topic of this thesis, the same methods can be used to 
consider cases of pre-diabetes and impaired glucose tolerance, potentially 
evaluable in further work. 
 
1.5 Methods to estimate diagnostic accuracy 
According to literature, there are different methods to estimate the 
diagnostic accuracy and performance of screening methods [28, 29]. 
Among these, the most simple and familiar techniques are sensitivity and 
specificity followed by positive and negative predictive values (i.e. 
including the receiver operating characteristic (ROC) curve) [30]. Thus, 
the ROC curve is commonly utilised to assess clinical utility for 
diagnostic models however, evaluation of these models should not only 
rely on the ROC curve as this technique does not assess both 
discrimination and calibration [31]. In addition, decision-analytic 
techniques allow assessment of clinical outcomes but can require new data 
collection, but decision curve analysis has emerged as a good option [32, 
33]. 
On the other hand, net reclassification indices try to quantify whether a 
new test provides clinically relevant improvements in prediction; 
however, these methods have been mainly used for novel blood 
biomarkers [34]. Besides, a variation of net reclassification index, known 
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as the integrated discrimination improvements have also been suggested 
as alternative to increase the area under the ROC curve for evaluation the 
performance of assessment algorithms but for phenotypic or genetic 
markers [35]. Therefore, the analysis of this thesis will mainly focus in 
standard diagnostic accuracy techniques as they are simple and 
understandable for clinicians.   
 
1.6 Risk scores for T2DM screening 
Different risk models, also known as risk scores, have been developed to 
detect T2DM cases. Some of them are useful to detect undiagnosed 
(prevalent) T2DM cases, whereas other ones predict the development of 
new (incident) T2DM cases [36]. In addition, blood-free risk scores and 
those based on self-reported information have been also created to detect 
cases of undiagnosed T2DM [26].  
Many of the existing scores are well-known and widely used but have 
been mainly developed in high-income countries [37-40]. Among the 
scores created in LMIC, most of them are from China, India, and other 
countries of Asia [41-43]. There is, however, great variability in the 
performance and variables included in risk score for undiagnosed T2DM, 
supporting the need of developing or at least calibrate/validate a risk score 
before using them in different regions and contexts. 
Of all the risk scores available, to our knowledge, only three models have 
been developed in Latin America countries, one in Brazil [44], one in 
Colombia [45], and finally, one in Peru [46].  
The Brazilian risk score was created using a specific urban area and 
fasting glucose as the gold standard [44]. The risk score comprised only 
three variables (age, body mass index, and known hypertension) and 
accuracy was moderated (area under the Receiver Operating Characteristic 
[ROC] of 0.72). The Colombian risk score comprised [45], on the other 
hand, four variables (age, waist circumference, use of blood pressure 
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medication, and family history of T2DM) in the final model. Using OGTT 
as the gold standard, the Colombian risk score had also a moderate 
accuracy for detecting cases of undiagnosed T2DM, with an area under 
the ROC curve of 0.74. However, results of both risk scores might not be 
extrapolated, especially in a country with an evident geographical 
variation such as Peru. Thus, the Peruvian Risk Score was developed by 
the author of this thesis and is detailed in the next chapter. 
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Chapter II: The Peruvian Risk Score 
 
In this chapter, the development and performance of the Peruvian Risk Score is 
detailed as part of the first paper for PhD dissertation [46], although adapted to 
the TRIPOD statement [47]. 
 
2.1 Source of data 
The development of the Peruvian Risk Score entailed two different 
population-based surveys: the National Survey of Nutritional and 
Biochemical Indicators for Non-Communicable Diseases (ENINBSC, 
Spanish acronym, whose data is freely available) [15], and the data of the 
CRONICAS Cohort Study [48].  
 
2.2 Participants  
The ENINBSC is a national population-based survey conducted in Peru 
(August 2004 and April 2005) to estimate the prevalence of hypertension, 
T2DM and other risk factors for non communicable diseases at the 
national and regional level [15]. Potential participants were those aged 
≥20 years, habitual residents in the study area, and able to provide consent 
for participating in the study. Pregnant women and those currently 
breastfeeding were excluded from the study. The ENINBSC sample was 
stratified according to Peru’s five major regions: Lima, rest of the Coast, 
urban Highlands, rural Highlands, and Jungle. In each stratum, cluster of 
blocks were chosen using single random sampling techniques. Within 
each cluster, a random sample of households and participants was 
selected.  
The CRONICAS Cohort Study is an ongoing cardiopulmonary 
longitudinal prospective study aimed to estimate the prevalence and 
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incidence of hypertension, T2DM, chronic obstructive pulmonary disease, 
and obesity in four different settings in Peru differing in terms of 
urbanicity and altitude: Pampas de San Juan de Miraflores, was the 
highly-urbanized setting located in Lima, the capital of Peru; Puno in the 
altitude (3,825 meter above the sea level) contributing with rural and 
urban areas; and Tumbes, a semi-urban area in the northern coast of Peru 
[48]. The study started in September 2010 and two follow-up visits were 
scheduled 15 and 30 months from baseline. A sex- and age-stratified 
sample was randomly selected for each of the settings and all participants 
aged ≥35 years, full time residents in the study area, and able to consent, 
were enrolled. Only baseline and 30-month follow-up data was used for 
analyses. 
 
2.3 Study procedures 
The ENINBSC procedures have been described elsewhere [15]. Briefly, 
two different visits were scheduled. The first one lasted 40 minutes on 
average and collected information, applying a face-to-face questionnaire, 
regarding household characteristics, demographics, lifestyles behaviours, 
risk factors, as well as blood pressure measurements. The second visit 
lasted 30 minutes on average and was planned to have an appropriate 
period of fasting for blood sampling for glucose, lipid profile, and the 
remaining anthropometric measures (height, weight, and waist 
circumference) using standardised procedures. 
Similarly, the procedures of the CRONICAS Cohort Study have been 
previously published [48]. Participants responded to a face-to-face 
questionnaire applied by trained community health workers. Data 
collected comprised cardiovascular risk factors based on a modified 
version of the WHO STEP approach questionnaire for surveillance of 
non-communicable disease [49]. A period of 8 to 12 hours of fasting was 
required for blood sampling to collect fasting glucose and lipid profile. 
Height, weight and waist circumference were also assessed, and blood 
26 
 
pressure was measured in triplicate after a 5-minute resting period using 
an automatic monitor (OMRON HEM-780) previously validated in adult’s 
population [50]. 
 
2.4 Outcome 
In both studies, T2DM was defined as any of the following conditions: 
fasting glucose ≥7.0 mmol/L (≥126 mg/dL) and/or self-report of physician 
diagnosis. Fasting glucose was assessed by an enzymatic colorimetric 
method (glucose oxidase GOD-PAP) in both studies. After excluding 
individuals aware of disease, undiagnosed T2DM was used to develop and 
validate the risk score [7]. 
 
2.5 Predictors 
Variables used to create the risk score were built in similar way in both 
studies: sex, age (<55, and ≥55 years), education (in years); self-reported 
smoking (current vs. never/former smoker); alcohol use (user vs. never 
user); self-reported T2DM in first-degree relatives (participant’s parents 
and/or siblings), and physical activity levels (low vs. moderate/high 
levels, based on the transport-related domain of the IPAQ). 
Anthropometric measurements included in the analysis were body mass 
index ([BMI], <25, 25–29.9, and ≥30 Kg/m2), waist circumference (<90, 
90–99.9, and ≥100 cm), waist to height ratio (<0.50, 0.50–0.59, 0.60–0.69, 
and ≥070) [51], and hypertension (measured or previously diagnosed) 
[52]. 
 
2.6 Sample size and missing data 
A total of 4206 participants were enrolled in the ENINBSC, but only 
2,472 were included in the analyses. Reasons for exclusion were: 1524 
because age <35 years to make both databases comparable, 129 because 
no data about fasting plasma glucose levels was available and 81 because 
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known diagnosis of T2DM. In the CRONICAS Cohort Study, 3601 
participants were enrolled at baseline but only 2948 records were analysed 
as 465 had no data about glucose levels, and 188 were excluded because 
previous diagnosis of T2DM. In addition, data from only 2577 
participants was used in the longitudinal assessment of the risk score.  
 
2.7 Statistical analysis methods 
Analyses were performed using STATA 13.0 (StataCorp, College Station, 
TX, US). Firstly, population characteristics of both studies were tabulated 
using proportions in the case of categorical variables, and mean and 
standard deviation (SD) in the case of numerical variables. Then, the 
prevalence and 95% confidence intervals (95% CI) of total T2DM and 
undiagnosed T2DM were estimated in each study. After that, all cases of 
known T2DM were excluded from subsequent analyses. 
2.7.1 Risk score development 
The risk score was derived from the ENINBSC survey taking into account 
the multistage sampling strategy of the study. Each potential risk factor 
(i.e. sex, age, family history of T2DM, etc.) was assessed in bivariate 
models using logistic regression and undiagnosed T2DM as the dependent 
variable. Then, risk factors with a p-value <0.10 in the bivariate analysis 
were included in a multiple logistic regression model using stepwise 
backward elimination with a significance level of 5%. The Hosmer-
Lemeshow goodness-of-fit test was used to assess how well the predicted 
prevalence matched the observed prevalence of undiagnosed T2DM (i.e. 
p-values over 0.20 indicates that model fits well) [53]. As we sought for 
an easily applicable and implementable risk score, the risk factors in the 
final model were each assigned a weighted score by rounding up all 
regression coefficients in the final model to the nearest integer as in a 
previous report [38]. 
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For the evaluation of the risk score, the area under the receiver operating 
characteristic (ROC) curve, as well as sensitivity, specificity, positive and 
negative predictive values (PPV and NPV) were calculated. The optimal 
cut-off was determined using the Youden index, a single statistic that 
captures the performance of a diagnostic test (i.e. sensitivity + specificity 
– 1) [54]. As one of the main aims of a non-laboratory risk score is to 
identify people who warrant having a blood test (i.e. FG, OGTT, or 
HbA1c), the cut-off with the highest sensitivity was also described. 
2.7.2 Risk score validation 
We assessed the performance of the risk score using bootstrap techniques 
as well as carrying out an external validation using the CRONICAS 
Cohort Study. Bootstrapping was utilised to estimate confidence intervals 
for the area under the ROC curve in our study population. A total of 1,000 
random samples with replacement were taken from the development 
database. The resulting 1,000 prediction models were then assessed to 
estimate the bootstrap area under the ROC curve using the bias-corrected 
version of the confidence intervals [55]. In addition, using baseline data 
from the CRONICAS Cohort Study, validation measures (sensitivity, 
specificity, predictive values and likelihood ratios) were also estimated. 
To evaluate the performance of the risk score, this was compared to 
previously published models for undiagnosed T2DM: the Brazilian risk 
score [44], the Qingdao score [56], the Indian risk score [57], the Kuwaiti 
risk score [58], the patient self-assessment score [38], and the Rotterdam 
risk score [37] using the c-statistic. Finally, using the follow-up data of the 
CRONICAS Cohort Study, the risk score was evaluated to detect incident 
cases of T2DM by excluding those with diabetes diagnosis at baseline.  
 
2.8 Results 
Participants from the CRONICAS Cohort Study were, on average, 5 years 
older, reported consuming lower levels of alcohol, and were less 
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physically active than those from the ENINBSC survey. The 
characteristics of participants in both studies are detailed in Table II-1. 
2.8.1 Prevalence of T2DM and undiagnosed T2DM 
In the ENINBSC survey, the T2DM prevalence was 5.1% (129/2538; 95% 
CI: 4.2%–5.9%), whereas that prevalence was 8.7% (272/3135; 95% CI: 
7.7%–9.7%) in the baseline of the CRONICAS Cohort Study. After 
excluding those with known T2DM, undiagnosed T2DM was present in 
2.0% (48/2457; 95% CI: 1.4%–2.5%) in the ENINBSC survey and in 
2.9% (85/2948; 95% CI: 2.3%–3.5%) in the CRONICAS Cohort Study.  
2.8.2 Development of the risk score 
After stepwise backward logistic regression, age, diabetes in first-degree 
relatives, and waist circumference were independently associated with 
undiagnosed T2DM (Table II-2). The Hosmer-Lemeshow test showed that 
the final model fitted relatively well (p=0.21). The Peruvian Risk Score 
was constructed based on the coefficients of that final regression model. 
The score gave an area under the ROC curve of 0.73 (95% CI: 0.65–0.78), 
and the optimal cut-off for undiagnosed T2DM using the Youden index 
was ≥2 (Figure II-1). With this cut-off, about 34.8% of participants were 
categorised as at high risk of T2DM: sensitivity 69.6%, specificity 65.8%, 
and PPV and NPV of 3.9% and 99.1% respectively. With a cut-point ≥1, 
69.8% of participants would be at high risk of T2DM with improved 
sensitivity (93.5%) but lower specificity (30.6%). Table II-3 shows the 
performance of the risk score for detecting undiagnosed T2DM at 
different cut-offs.  
2.8.3 Cross-sectional validation of the risk score 
Using bootstrap, the performance of the Peruvian Risk Score was very 
similar to the obtained in the development model (area under the ROC 
curve = 0.72; 95% CI: 0.65–0.78). Besides, when the risk score was 
evaluated using data of the CRONICAS Cohort Study’s population, the 
area under the ROC curve for undiagnosed T2DM was 0.68 (95% CI: 
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0.62–0.73). At the suggested cut-off of ≥2, 42% would be categorised as 
undiagnosed T2DM with sensitivity, specificity, PPV and NPV of 70.2%, 
58.9%, 4.8%, and 98.5%, respectively (Table II-4).  
When previous published algorithms for undiagnosed T2DM were applied 
to the CRONICAS Cohort Study, the performance of the Rotterdam score 
(p<0.001), Indian score (p<0.001), and Qingdao score (p<0.01) were 
poorer than our score; however, our model performed similar to other 
assessed models, such as the Brazilian risk score (p=0.93), the Kuwaiti 
score (p=0.26), and the Patient Self-assessment score (p=0.74), but having 
only three variables. 
2.8.4 Longitudinal assessment of the risk score 
The performance of this risk score was also assessed to predict incident 
cases of T2DM using the longitudinal data from the CRONICAS Cohort 
Study. One hundred twenty one new cases of T2DM were found 
accounting for 6207 person-years at risk, with an overall incidence of 1.95 
(95% CI: 1.63–2.33) cases per 100 person-years of risk. The area under 
the ROC curve of the score was 0.66 (95% CI: 0.61–0.71). With a cut-off 
≥2, 42.5% of participants were categorised as at high risk of developing 
T2DM: sensitivity, specificity, PPV and NPV were 69.4%, 58.9%, 7.8%, 
and 97.4%. 
 
2.9 Discussion and limitations 
Using a national population-based survey, a simple non-blood risk score, 
based on age, history of diabetes in first-degree relatives, and waist 
circumference, was built and shown to perform moderately in detecting 
undiagnosed T2DM when externally validated. Moreover, the 
performance of the score was almost similar for detecting incident cases 
of T2DM in the Peruvian population. This developed risk score does not 
require a blood test or laboratory services and, for instance, it might be 
easily implementable in clinical practice. Thus, the Peruvian Risk Score 
31 
 
can be potentially self-administered as this asks for general information 
(age and diabetes in first-degree relatives), and is complemented by a 
simple anthropometric measure of waist circumference.  
According to our results, any patient aged 55 years and above and having 
at least one first-degree relative with T2DM has greater probability of 
having undiagnosed diabetes, but also is at risk of developing diabetes in 
the future. In addition, a greater central obesity, i.e. 100 cm or more, 
independent of the other terms of the score is alone a good predictor of 
diabetes as reported in previous studies [51]. Our algorithm included waist 
circumference instead of body mass index as other risk scores, providing a 
better indicator of accumulation of visceral fat and metabolic dysfunction 
in our context [59]. 
Despite of the moderate performance of the Peruvian Risk Score, some 
limitations need to be highlighted. The OGTT was not used as gold 
standard for T2DM diagnosis as it is not usual to be performed in 
epidemiological studies. Thus, the Peruvian Risk Score need to be 
evaluated or calibrated appropriately. In addition, as secondary databases 
were used to create the risk score model, information regarding diet 
patterns and history of gestational T2DM among women, was not 
evaluated. Finally, the model was based on the idea of risk stratification 
instead of individualization; thus, numerical variables were categorised 
instead of being preserved in their original form. Nevertheless, the 
objective of the original paper was to develop a simple and easily 
applicable score to detect undiagnosed T2DM. 
 
2.10 Further steps and implications 
There is a need of assessing existing risk scores for undiagnosed T2DM 
screening at the population level in resource-constrained settings such as 
Peru. Moreover, there is limited information in Latin American countries 
evaluating the performance of risk scores using OGTT as the gold 
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standard. From the perspective of LMIC, these risk scores should include 
objective and easily evaluable measurements. 
As other risk models, the Peruvian risk score needs to be assessed before 
it can be used in other populations. Thus, further scrutiny, using OGTT as 
gold standard should be guaranteed. In addition, the inclusion of other 
variables in the model requires a more detailed assessment of 
sociodemographic, but specially, lifestyle behaviours and anthropometric 
characteristics of participants.  
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Figure II-1: Receiver operating characteristic (ROC) curve for the risk score in 
predicting undiagnosed T2DM: Development database 
 
 
 
  
The area under the ROC curve was 0.73 (95% CI: 0.65 – 0.78) for the risk 
score.
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Table II- 1: Sociodemographic characteristics of participants without history of 
T2DM according to study 
 
 
 ENINBSC Study CRONICAS Study 
 (n = 2,472) (n = 2,945) 
Demographic variables   
Sex (% females) 1,209 (48.9%) 1,500 (50.9%) 
Age [mean (SD)] 50.5 (12.1) 55.3 (12.7) 
Education in years [mean (SD)] 7.8 (4.9) 8.0 (4.9) 
Behavioural variables   
Current smoking (%) 391 (15.9%) 369 (11.5%) 
Alcohol use (%) 2,323 (94.1%) 1,600 (54.3%) 
Family history of diabetes (%) 268 (11.2%) 351 (11.9%) 
Physical activity (% low level) 606 (24.5%) 938 (31.9%) 
Anthropometric measures   
Body mass index [mean (SD)] 25.7 (4.5) 27.6 (4.6) 
Waist circumference [mean (SD)] 91.0 (11.4) 91.5 (11.0) 
Waist-to-height ratio [mean (SD)] 0.58 (0.08) 0.59 (0.07) 
Systolic blood pressure [mean (SD)] 114.5 (18.5) 117.2 (18.9) 
Diastolic blood pressure [mean (SD)] 71.1 (11.9) 73.4 (11.1) 
Hypertension (%) 579 (23.8%) 705 (24.0%) 
Total cholesterol [mean (SD)] 174.2 (36.9) 199.7 (39.6) 
HDL cholesterol [mean (SD)] 43.5 (5.3) 41.7 (11.5) 
 
SD = standard deviation, HDL = high-density lipoprotein 
*Results may not add due to missing values 
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Table II-2: Risk factors and beta coefficients for undiagnosed T2DM: Final 
regression model using ENINBSC database (N = 2,367) 
 
 
 Crude model Final model* 
Score 
 OR (95% CI)  β (SE) OR (95% CI) 
Sex      
Male (vs. female) 0.68 (0.38 – 1.21)    
Age     
≥55 (vs. <55 years) 2.05 (1.16 – 3.64) 0.61 (0.18) 1.85 (1.30–2.63) 1 (vs. 0) 
Current smoking     
Current (vs. never/formers) 0.34 (0.11 – 1.12)    
Alcohol user      
User (vs. never user) 1.46 (0.34 – 6.27)    
Diabetes in relatives      
Yes (vs. no) 2.90 (1.48 – 5.66) 0.85 (0.42) 2.34 (1.04–5.31) 1 (vs. 0) 
Physical activity     
Low (vs. moderate/high level) 2.24 (1.25 – 4.01)    
Body mass index     
Overweight (vs. normal) 1.07 (0.54 – 2.13)    
Obese (vs. normal) 2.23 (1.11 – 4.49)    
Waist circumference     
90.0 to <99.9 cm (vs. <90 cm) 1.93 (0.91 – 4.10) 0.74 (0.33) 2.09 (1.09–4.02) 1 (vs. 0) 
100+ cm (vs. < 90 cm) 4.10 (1.99 – 8.44) 1.40 (0.23) 4.07 (2.60–6.40) 2 (vs. 0) 
Waist-to-height ratio     
0.50 – 0.59 (vs. <0.50) 1.41 (0.41 – 4.86)    
0.60 – 0.69 (vs. <0.50) 2.97 (0.88 – 10.0)    
0.70+ (vs. <0.50) 4.84 (1.27 – 18.5)    
Hypertension     
Yes (vs. no) 1.68 (0.91 – 3.09)    
 
* The model was created using backward elimination from the initial full model 
until we reached a final model with statistically significant covariates.  
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Table II-3: Performance of different cut-offs for detecting undiagnosed T2DM in 
the development database 
 
 
Total 
score 
At 
high 
risk* 
Sensitivity Specificity PPV NPV 
Correctly 
classified 
LR+ LR- 
≥ 1 69.8% 93.5% 30.6% 2.6% 99.6% 31.8% 1.34 0.21 
≥ 2 34.9% 69.6% 65.8% 3.9% 99.1% 65.9% 2.04 0.46 
≥ 3 11.0% 30.4% 89.4% 5.4% 98.5% 88.3% 2.87 0.78 
≥ 4 1.3% 2.2% 98.7% 3.2% 98.1% 96.8% 1.68 0.99 
 
PPV = Positive predictive value; NPV = Negative predictive value; LR+ = 
Positive likelihood ratio, LR- = Negative likelihood ratio 
* Those at high risk are the proportion of participants over the total score. 
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Table II-4: Performance of different T2DM risk scores compared to Peruvian Risk Score using the CRONICAS Study 
(validation sample) 
 
 
Method (proposed cutoff) 
# of 
variables 
AUC Sensitivity Specificity PPV NPV LR+ LR- 
Brazilian risk score (≥18) 3 0.65 66.7% 61.9% 4.9% 98.4% 1.75 0.54 
Qingdao risk score (≥17 & ≥14)* 4 0.58 83.3% 33.3% 3.6% 98.5% 1.25 0.50 
Indian risk score (≥21) 5 0.54 94.0% 15.5% 3.1% 98.9% 1.11 0.39 
Kuwaiti risk score (≥32) 4 0.62 45.2% 78.4% 5.8% 98.0% 2.09 0.70 
Patient self-assessment score (≥5) 6 0.64 61.4% 66.8% 5.1% 98.3% 1.85 0.58 
Rotterdam risk score (≥36) 6 0.55 94.0% 16.8% 3.2% 99.0% 1.13 0.35 
Peruvian risk score (≥2) 3 0.68 70.2% 58.9% 4.8% 98.5% 1.71 0.51 
 
AUC = Area under the ROC curve; PPV = Positive predictive value; NPV = Negative predictive value; LR+ = Positive 
likelihood ratio, LR- = Negative likelihood ratio 
* Different cut-offs for males (≥17) and females (≥14).  
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Chapter III: EZSCAN for undiagnosed T2DM: a 
systematic review and meta-analysis 
 
3.1 Background 
In addition to the existence of risk score models, there are devices focused on 
assessing autonomic dysfunction, as a way to increase the probability to 
detect cases or individuals at risk of T2DM. Autonomic dysfunction is an 
early, and many times subclinical, consequence of hyperglycaemia. Diabetic 
autonomy neuropathy is one of the least recognized complications of T2DM, 
but it can be of clinical significance due to cardiovascular, gastrointestinal, 
sudomotor, and ocular autonomic neuropathy complications [60]. 
There are different tests to assess autonomic dysfunction but usually require 
well-trained health staff, some of them are time consuming, and require active 
patient participation. As early damage of nerves can be found since the onset 
of T2DM [61], some devices has emerged to assess small-fibers autonomic 
dysfunction [62]. The EZSCAN, developed by Impeto Medical (Paris, 
France), is a non-invasive device that, based on sudomotor function 
assessment, may help to detect both, cases of undiagnosed T2DM and cases 
at risk of developing T2DM.  
As the EZSCAN requires minimal training required and obtained results are 
not human dependent, this chapter is focused in a systematic review and 
meta-analysis conducted to assess the performance (i.e. area under the ROC 
curve, sensitivity and specificity) of the EZSCAN for detecting undiagnosed 
T2DM cases (Second paper for PhD dissertation) [63].  
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3.2 Eligibility criteria 
We searched for observational studies assessing the diagnostic accuracy of 
the EZSCAN for undiagnosed T2DM, conducted in different parts of the 
world, but reported in English. Studies were excluded if they were only 
abstracts or review articles, enrolled individuals aged <18 years or cases with 
type 1 diabetes mellitus, and defined type 2 diabetes mellitus (T2DM) by 
using blood markers other than OGTT or FG (i.e. HbA1c). The rationale for 
this decision was based on discrepancies between HbA1c and glycaemia in 
different racial and ethnic groups and that HbA1c is not commonly used for 
undiagnosed T2DM. 
 
3.3 Information sources and searches 
A comprehensive literature search using the Ovid database (PubMed-
Medline, Embase, Global Health, and Health Management Information 
Consortium) as well as CINAHL, and SCOPUS, until March 29, 2017, was 
conducted. The following keywords were utilised for the systematic 
searching: type 2 diabetes mellitus, hyperglycaemia, EZSCAN, SUDOSCAN, 
and sudomotor function [62]. The term SUDOSCAN was also included in the 
search strategy as it uses the same principle (i.e. sudomotor function 
assessment) for detecting diabetic neuropathy [64, 65]. The search strategy of 
Ovid is available in Table III-1. The Impeto Medical website was also 
searched to find other published manuscripts [66]. 
 
3.4 Study selection, data extraction and quality assessment 
Titles and abstracts of retrieved articles were reviewed independently by two 
investigators to select potentially relevant articles, and disagreements were 
discussed and solved by consensus. Using a standardised data extraction 
40 
 
form, we collected information on lead author, publication year, country, 
study design, inclusion criteria, used gold standard, sample size, mean age, 
percentage of male participants, and different indicators of the performance of 
the EZSCAN to detect undiagnosed T2DM (outcome, area under the ROC 
curve, cut-off, sensitivity, specificity, among others). 
Quality assessment of individual studies was performed to identify potential 
sources of bias and to limit, if possible, the effect of these biases on the 
conclusions of the review. For this, the Revised Version of the Quality 
Assessment of Diagnostic Accuracy Studies (QUADAS-2) checklist was used 
[67]. This tool included risk of bias assessment (i.e. participant selection, 
index test, reference standard, and flow and timing) as well as applicability. 
 
3.5 Synthesis of results and meta-analysis 
The primary outcome of interest was undiagnosed T2DM (i.e. newly-
diagnosed T2DM) identified by OGTT or FG. Secondary outcomes included 
other glucose metabolism disorders such as impaired glucose tolerance, 
impaired fasting glucose and, dysglycaemia. 
Statistical analyses were performed using Stata version 13 for Windows 
(StataCorp, College Station, TX, US). For report purposes the Preferred 
Reporting Items for Systematic Review and Meta-analysis of Diagnostic Test 
Accuracy Study (PRISMA-DTA) was used [68] as well as the Cochrane 
Handbook for Diagnostic Test Accuracy Reviews [69]. Initially, the studies 
included in the systematic review were described, including: publication year, 
country, study design, inclusion criteria, gold standard, sample size, mean 
age, and proportion of males. In addition, the performance of the EZSCAN in 
each study was tabulated, and the area under the receiver operating 
characteristic (ROC) curve, best cut-off, sensitivity, and specificity, and their 
respective 95% confidence intervals (95%CI) were reported, if available. 
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A meta-analysis of the performance of the EZSCAN was conducted using 
data from studies with undiagnosed T2DM as outcome. Information used in 
meta-analysis was taken as proposed by manuscripts according to the best 
EZSCAN threshold cut-off reported. The “metaprop” command in STATA 
was used to estimate sensitivity, specificity and positive (PPV) and negative 
(NPV) predictive values and their respective 95% CI [70]. The “metaprop” 
command obtains a pooled estimate as a weighted average, by fitting the 
logistic-normal random-effects model without covariates but random 
intercepts. The pooled estimate was then calculated using the Freeman-Tukey 
Arcsine Transformation to stabilize variances as suggested in literature [71]. 
In addition, a graph containing the plot of the Hierarchical Summary Receiver 
Operating Characteristic (HS-ROC) model [72], a summary point of 
sensitivity and specificity and the 95% confidence region for that point was 
obtained by using the “metandiplot” command [73]. Heterogeneity of 
estimates and 95%CI was determined using the I
2
 measure [74]. 
 
3.6 Results 
3.6.1 Selection and characteristics of studies 
A total of 1461 citations were identified through our systematic search, with a 
further 16 citations identified using the Impeto Medical website. After 
excluding duplicates (n=330), a total of 1147 citations were independently 
screened, of which 31 were retrieved for detailed assessment (agreement 
between reviewers, 97.2%, kappa = 0.61, p<0.001). Of the 31 revised 
manuscripts, 27 did not fit our inclusion criteria (Figure III-1); therefore, four 
studies were included in the systematic review. 
The characteristics of the studies included in the systematic review are shown 
in Table III-2. All the four studies were cross-sectional in nature. A total of 
7720 individuals were included from all the studies, but 5824 subjects came 
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from a single study [75]. This latter study enrolled individuals from the 
general population, whereas the remaining three studies recruited participants 
at clinics, mainly individuals going for healthy check-ups. 
3.6.2 Risk of bias 
Overall, participant selection bias was present in 3 out of 4 of the studies 
included in the meta-analysis [76-78]: individuals under healthy check-ups 
were enrolled in the original studies (Table III-3). In addition, flow and 
timing was unclear in the same three studies, and OGTT was not used as gold 
standard in one of the four studies [78]. 
3.6.3 Meta-analysis: EZSCAN performance for undiagnosed T2DM 
Undiagnosed T2DM was the outcome of interest in the four studies (Table 
III-4). Other outcomes evaluated in these papers included impaired glucose 
tolerance [76, 77], impaired fasting glucose [78], and dysglycaemia [75]. 
When undiagnosed T2DM was the outcome, only two studies reported results 
of area under the ROC curve ranging from 53% to 73% [76, 78]. In addition, 
only two studies used 50% as the suggested EZSCAN cut-off for undiagnosed 
T2DM screening [76, 77], whereas one used 34% [78], and the last one 
utilised 30% [75]. Sensitivity varied from 53% to 81%, whilst specificity 
ranged from 43% to 70%. Finally, positive predictive values (PPV) varied 
from 10% to 40%, whereas negative predictive values (NPV) ranged from 
71% to 98%. 
When using HS-ROC (Figure III-2), summary sensitivity was 72.0% (95%CI: 
60.0% – 83.0%), specificity was 56.0% (95%CI: 38.0% – 74.0%), PPV was 
24% (95%CI: 12.0% – 37.0%), and NPV was 89% (95%CI: 82.0% – 97.0%). 
In addition, positive and negative likelihood ratios were 1.68 (95%CI: 1.35 – 
2.10) and 0.48 (95%CI: 0.36 – 0.66), respectively, whereas the DOR was 3.49 
(95%CI: 2.18 – 5.57). Heterogeneity for sensitivity was 79.2% (95%CI: 
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44.0% – 92.0%), whereas for specificity was 99.1% (95%CI: 98.5% – 
99.6%). 
 
3.7 Discussion and limitations 
According to the results of this systematic review and meta-analysis, the 
performance of the EZSCAN in the detection of undiagnosed T2DM cases 
can be considered moderately acceptable especially in the case of sensitivity, 
and even comparable to different well-known T2DM risk scores [37, 40]. To 
put in context our findings, the sensitivity of HbA1c, using a cut-off ≥6.5% 
(48 mmol/mol), for detecting undiagnosed diabetes was 52.8% using OGTT 
as the gold standard [12]. Thus, apparently, the EZSCAN might perform 
better that HbA1c although other studies are needed to corroborate these 
findings. 
There are, however, some limitations that need to be highlighted. First, there 
is a risk of bias based on participant selection that can complicate 
extrapolation of results: many of the studies were performed in clinical 
context (i.e. clinical check-ups) instead of using population level assessments. 
Second, a high level of heterogeneity between studies was found (greater than 
75%) in all estimations (i.e. sensitivity, specificity, etc). Since a small number 
of studies were included in the meta-analysis; results need to be cautiously 
interpreted despite of the fact that random effect models were used in 
calculations [79]. In addition, heterogeneity in results of the EZSCAN 
performance can be secondary to characteristics of the context and 
individuals: predictive values as well as likelihood ratios can depend on 
baseline risk of evaluated subjects. For example, the association of body mass 
index –one of the variables used in scoring individuals through EZSCAN– 
with the risk of diabetes may vary in different populations [80], and explain 
variability found in this report. Third, characteristics of the study population 
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were poorly reported and this is reflected in the quality assessment. As all the 
studies assessing EZSCAN were recently published (from 2010 and 
onwards); authors should have been utilised the Standards for Reporting 
Diagnostic Accuracy Studies (STARD) to guide their manuscripts’ writing 
[81, 82]. Future studies should follow these guidelines to guarantee an 
appropriate reporting of diagnostic studies. Fourth, as the EZSCAN is a 
commercial device, underlying algorithms for estimating the risk of T2DM 
are not freely available; and for instance, they are unknown. Finally, given the 
limited number of studies assessed, EZSCAN threshold was not meta-
analysed as the performance of the diagnostic test depends on the population 
in which the test is used. Thus, for our analyses, pooled sensitivity and 
specificity were calculated using the best cut-off reported by studies and not 
the same in all cases. In addition, there is limited data evaluating the potential 
impact of EZSCAN for undiagnosed T2DM at the population level. Future 
studies should be focused on population-based samples instead of referral 
health facilities, but also in different ethnic groups as only studies from China 
and India were used in this review. A study from Mexican population was 
also included in the meta-analysis, but the selection of the sample was biased 
and FG was used as gold standard [78]. Moreover, as the number of studies 
included in the analysis was small, publication bias was not assessed (usual 
tests for publication bias are underpowered when <10 studies are evaluated). 
 
3.8 Update of the systematic review and meta-analysis 
As April 22, 2018, a new manuscript assessing the performance of the 
EZSCAN as a screening tool for undiagnosed T2DM in Chinese individuals 
was published in May 2017 [83]. Subjects were recruited in a third-level 
hospital as part of a routine health check. OGTT was used for detecting cases 
of undiagnosed T2DM, excluding those with previous diagnosis of T2DM or 
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pre-diabetes. A total of 6270 subjects were enrolled, 63.1% males. The area 
under the ROC curve was 81.3% (95% CI: 78.4% - 84.2%), with an empirical 
cut-off of 44.5, and a sensitivity and specificity of 73.2% and 83%, 
respectively. Thus, results of this manuscript were included in a new re-
assessment of the meta-analysis (HS-ROC).  
Using HS-ROC (See Figure in Appendix C), summary sensitivity was 73.6% 
(95% CI: 65.6% - 80.3%), specificity was 63.2% (95% CI: 49.1% - 75.4%), 
PPV was 28.0% (95% CI: 16.0% - 40.0%), and NPV was 92.0% (95% CI: 
88.0% - 95.0%). In addition, positive and negative likelihood ratios were 2.00 
(95% CI: 1.40 – 2.86) and 0.42 (95% CI: 0.31 – 0.57), respectively, whereas 
the DOR was 4.80 (95% CI: 2.60 – 8.87). Heterogeneity for sensitivity was 
79.0%, whereas for specificity was 99.0%.  
On the other hand, when the only study using FG was excluded from analyses 
[78], summary sensitivity was 73.0% (95%CI: 62.8% – 81.3%), summary 
specificity was 61.3% (95%CI: 44.0% – 76.2%), whereas PPV was 33.0% 
(95%CI: 24.0% – 43.0%), NPV was 89.0% (95%CI: 84.0% – 94.0%), 
positive likelihood ratios was 1.89 (95% CI: 1.24 – 2.88), negative predictive 
value was 0.44 (95% CI: 0.30 – 0.65), and the DOR was 4.30 (95% CI: 2.02 – 
9.15). See Figure in Appendix D. 
 
3.9 Other potential methods for T2DM screening 
In addition to the EZSCAN, other devices to assess neuropathy dysfunction 
can have an impact on T2DM screening: pupillometry and biothesiometry. 
3.9.1 Pupillometry for T2DM screening 
Although there are different manuscripts assessing the differences in pupil 
parameters between T2DM cases (with and without complications) and 
apparently healthy subjects [84-90], quite a few has focused on the potential 
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of the pupil parameters for detecting underdiagnosed T2DM cases [91]. 
Several methods have been described to evaluated pupil size and reflex 
among T2DM cases, including a great number of parameters, mainly 
explained because the static and dynamic characteristics of the pupil function. 
Thus, to assess the static characteristics of the pupil, only a camera (and then 
callipers) or a portable pupillometer is needed. However, to evaluate the pupil 
dynamics, in addition to the pupillometer, a computer and software are 
needed to appropriately interpret and obtained results. Moreover, only some 
of the parameters can be obtained using static pupillometry, but when 
software is utilised, a great number of pupil parameters can be easily and fast 
acquired after some minutes of darkness-adaptation, as well as after diverse 
light stimuli strategies (1 flash, 25 flashes, etc) [92]. 
The most common parameters reported in the literature when comparing 
T2DM cases and apparently healthy individuals were latency time to pupil 
constriction (dynamic pupillometry) [86, 87, 89], and pupil diameter and 
pupil area (static pupillometry) [85, 87, 93]. Overall, manuscripts reported 
differences in diverse pupil indicators when comparing populations of 
interest, yet these pupillometry parameters have been used as a screening tool 
for T2DM neuropathy instead of undiagnosed T2DM [88, 90].  
In Peru, Lerner et al [91], using dynamic pupillometry, found that diagnostic 
accuracy of several pupil measurements were fair enough for T2DM 
screening with an area under the ROC curve ≥0.60. Of these parameters, 
pupil diameter and amplitude of pupil reaction were those with better 
performance. Nevertheless, the paper focused on differences in pupil 
measurements comparing individuals with and without T2DM, and not for 
undiagnosed cases. In addition, a hospital-based sample was used instead of a 
population-based sampling. 
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3.9.2 Biothesiometry in T2DM 
The biothesiometer is a device used to assess the threshold of appreciation of 
vibration in human subjects (vibration perception threshold) [94]. Although 
this tool can be utilised in different neurological diseases [95], the use of 
biothesiometry in T2DM has been restricted to the screening of diabetic 
neuropathy among T2DM cases [96]. In fact, to our knowledge, there is no 
study reporting the usability of biothesiometry in the screening of 
undiagnosed T2DM. As previously mentioned, small nerves damage occurred 
in early stages of T2DM, and even before the diagnosis of the disease; as a 
result, this study will take advantage on that and assess the performance of 
biothesiometry as a screening tool for undiagnosed T2DM cases. 
 
Overall, the performance of different devices based on neurological assessment and 
function, such as EZSCAN, pupillometry and biothesiometry for screening of 
T2DM need to be evaluated, including the potential combination of these devices 
with risk score models (i.e. anthropometric measurements or sociodemographic 
information). The form to combine risk scores and neuropathy assessment tools can 
be easily conducted by using basic operations of Boolean algebra [97], with a 
potential improving in sensitivity if using disjunction terms (alternative logic: OR) 
instead  of conjunction terms (sequential logic: AND).  
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Figure III-1: Flowchart of database searches and articles included in the 
systematic review.  
 
 
T2DM: Type 2 diabetes mellitus, HbA1c = glycated haemoglobin, IGM = impaired 
glucose metabolism. 
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Figure III- 2: Performance of EZSCAN in the screening of T2DM: Meta-analysis 
using HSROC.  
 
 
 
Sensitivity = 72.0% (95%CI: 60.0% - 83.0%); specificity = 56.0% (95%CI: 38.0% 
- 74.0%); likelihood ratio positive = 1.68 (95%CI: 1.35 – 2.10); likelihood ratio 
negative = 0.48 (95%CI: 0.36 – 0.66); DOR = 3.49 (95%CI: 2.18 – 5.57). HSROC 
curve is shown only for sensitivities and specificities at least as large as the 
smallest study-specific estimates. 
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Table III-1: OVID search strategy for EZSCAN 
 
 
Databases included: 
Global Health 1910 to 2017 Week 11; HMIC Health Management Information 
Consortium 1979 to January 2017; Journals@Ovid Full Text March 29, 2017; Ovid 
MEDLINE(R) 1946 to March Week 4 2017; PsycINFO 1806 to March Week 3 
2017; Embase 1974 to 2016 March 29. 
 
 
# Searches Results 
1 type 2 diabetes.mp. 382,642 
2 diabet*.mp. 2,257,087 
3 hyperglycem*.mp. 225,801 
4 T2D*.mp. 69,504 
5 DBM.mp 4,657 
6 (#1 or #2 or #3 or #4 or #5) 2,329,381 
7 exp Diabetes Mellitus 1,249,251 
8 exp Diabetes Mellitus, Type 2/ 311,830 
9 (#7 or #8) 1,249,251 
10 (#6 or #9) 2,335,634 
11 EZScan.mp. 81 
12 SUDOSCAN.mp 167 
13 sudom*.mp 4,932 
14 (#11 or #12 or #13) 5,021 
15 (#10 and #14) 1,345 
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Table III-2: Characteristics of the studies included in the systematic review 
 
 
Study, 
publication 
year 
Country 
Study 
design 
Inclusion 
criteria 
Gold 
standard 
Size 
Mean 
age 
% 
male 
Chen X, 2015 
[76] 
China 
Cross-
sectional 
Subjects in 
routine health 
check visiting 
a Community 
Hospital, at 
risk of T2DM 
(age ≥ 45 
years). 
OGTT 270 58.6 32% 
Ramachadran 
A, 2010 [77] 
India 
Cross-
sectional 
Individuals in 
specific clinics 
aged between 
21-75 years. 
OGTT 212 43.4 45% 
Sanchez-
Hernandez O, 
2015 [78] 
Mexico 
Cross-
sectional 
Individuals 
recruited in a 
clinic in 
Mexico; ≥18 
years, 
apparently 
healthy and 
attending a full 
check-up. 
FG 1,414 44.7 50% 
Yang Z, 2013 
[75] 
China 
Cross-
sectional 
Individuals 
from two 
communities 
in Shanghai 
aged 40+ 
years. 
OGTT 5,824 58.3 40% 
 
FG = fasting glucose; OGTT = oral glucose tolerance test. 
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Table III-3: Quality assessment of the studies included in the systematic review (QUADAS-2) 
 
 
  
Study, publication year 
Risk of bias Applicability 
Patient 
selection 
Index  
test 
Reference 
standard 
Flow and 
timing 
Patient 
selection 
Index  
test 
Reference 
standard 
Chen X, 2015 [76] High Low Low Unclear Unclear Low Low 
Ramachadran A, 2010 [77] High Low Low Unclear High Low Low 
Sanchez-Hernandez O, 2015 [78] High Unclear High Unclear High Unclear High 
Yang Z, 2013 [75] Low Low Low Low Low Low Low 
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Table III-4: Performance of the EZSCAN in the studies included in the systematic review 
 
Study, publication year Outcome AUC Cut-off Sensitivity Specificity 
Chen X, 2015 [76]  IGT 
78%  
(72% - 83%) 
37% 82% (72% - 90%) 63% (55% - 71%) 
Chen X, 2015 [76] T2DM 
53%  
(43% - 62%) 
50% 53% (36% - 69%) 59% (47% - 70%) 
Ramachadran A, 2010 [77] IGT -- 50% 70% (not reported) 54% (not reported) 
Ramachadran A, 2010 [77] T2DM -- 50% 75% (not reported) 54% (not reported) 
Sanchez-Hernandez O, 2015 
[78] 
IFG 
65%  
(not reported) 
27% 69% (not reported) 56% (not reported) 
Sanchez-Hernandez O, 2015 
[78] 
T2DM 
73%  
(not reported) 
34% 73% (not reported) 70% (not reported) 
Yang Z, 2013 [75] 
IFG, IGT or 
T2DM 
-- 30% 73% (71%-75%) 46% (45%-48%) 
Yang Z, 2013 [75] T2DM -- 30% 81% (78%-83%) 43% (42%-44%) 
 
IFG = Impaired fasting glucose; IGT = Impaired glucose tolerance; T2DM = type 2 diabetes mellitus; AUC = area under the curve.  
Values in brackets are 95% confidence intervals (95%CI). 
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Chapter IV: Materials and Methods 
 
In this chapter, we describe the research question, objectives and hypotheses, as 
well as materials and methods utilised during fieldwork activities. 
 
4.1 Research question 
What is the diagnostic accuracy of existing blood-free risk scores and 
neuropathy assessment tools (i.e. EZSCAN, pupillometer and biothesiometer) 
to detect cases of undiagnosed T2DM at the population level? 
 
4.2 Primary objectives  
4.2.1 Primary objective 1: 
To assess the diagnostic accuracy of blood-free risk scores and neuropathy 
assessment tools to detect cases of undiagnosed T2DM at the population level 
in a semiurban area in Peru. 
Hypothesis 1: Using the area under the ROC curve, we expect a sensitivity of 
at least 75% compared to the oral glucose tolerance test. 
4.2.2 Primary objective 2: 
To compare the diagnostic accuracy of the EZSCAN and other neuropathy 
assessment devices and existing blood-free risk scores to detect cases of 
undiagnosed T2DM in a semiurban area in Peru. 
Hypothesis 2: We hypothesised that EZSCAN will have a better diagnostic 
accuracy compared to the other devices (pupillometer and biothesiometer), 
and its performance will be similar to other blood-free risk scores (Finnish 
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Diabetes Risk Score – FINDRISC, the Latin America FINDRISC, and the 
Peruvian Risk Score). 
4.2.3 Primary objective 3: 
To evaluate, if possible, the performance of a combination of blood-free risk 
scores and neuropathy assessment devices for detecting cases of undiagnosed 
T2DM in a population-based sample of a semiurban area in Peru. 
Hypothesis 3:  We hypothesised that this combination, using Boolean 
algebra, will have at least a sensitivity of 75% compared to oral glucose 
tolerance test. 
 
4.3 Secondary objectives  
In addition to the aforementioned objectives, this document will also focus 
on: 
Secondary objective 1: To determine the prevalence of T2DM and 
undiagnosed T2DM on a population-based sample of a semiurban area in 
Peru. 
Secondary objective 2: To evaluate the performance of the EZSCAN for 
detecting cases of undiagnosed T2DM in a population-based sample of a 
semiurban area in Peru. 
Secondary objective 3: To evaluate the performance of pupil parameters 
using static pupillometry for detecting cases of undiagnosed T2DM in a 
population-based sample of a semiurban area in Peru. 
Secondary objective 4: To evaluate the performance of the biothesiometer 
for detecting cases of undiagnosed T2DM in a population-based sample of a 
semiurban area in Peru. 
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Secondary objective 5: To assess the performance of some of the existing 
blood-free risk scores (FINDRISC and Peruvian Risk Score) for detecting 
cases of undiagnosed T2DM in a population-based sample of a semiurban 
area in Peru. 
 
4.4 Methods 
4.4.1 Study design and setting 
A population-based cross-sectional study was conducted enrolling a random 
sample of participants from Tumbes, a semiurban area in the north of Peru 
(See Figure IV-1 for detailed location). According to projections of the last 
national census, Tumbes has 243,000 inhabitants in an area of 4,670 km
2
 
[98]. Approximately 61% of inhabitants have a health insurance, 80% of 
households have drinking water, and life expectancy is 75 years. As 
semiurban area, the setting comprises traditional agricultural and fishing 
villages intermixed with rapidly growing urban sections. 
The rationale for selecting this setting was because prevalence of obesity, by 
body mass index (32% vs. 18%), and T2DM, by fasting plasma glucose (10% 
vs. 7%), is over the national average [17]. Besides, data of the CRONICAS 
Cohort Study shows a relatively high population-level incidence of T2DM 
(2.0; 95%CI: 1.6 – 2.3) per 100 person-years), as high as in Lima, the largest 
and most urbanized region in Peru [22]. 
4.4.2 Participants and sampling 
Eligible participants were those aged between 30 and 69 years, full time 
resident in the study area (i.e. ≥6 months) and able to understand procedures 
and provide informed consent. Women that reported being pregnant or 
individuals having any physical disability preventing anthropometric 
measurements (weight, height, blood pressure or waist circumference) or 
those bedridden were excluded from the study. 
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Secondary selection criteria were also applied depending on the device 
assessment tool used. For EZSCAN evaluation, exclusion criteria involved 
the self-report of use of implantable electrical devices (i.e. pacemaker) or 
known sensitivity to nickel as the standard electrodes are made of that 
material [99, 100]. For pupillometry evaluation, those participants who self-
reported having severe neurological conditions (i.e. Parkinson’s disease, 
Alzheimer’s diseases or multiple sclerosis) or those with ocular complications 
such as corneal lesions, glaucoma or severe cataracts, were excluded from the 
study. The reason for exclusion was based on the fact that these conditions 
might interfere with the proper interpretation of pupillometry results [91]. 
A sex-stratified, single-stage random sampling strategy was conducted using 
the most updated census available in the study area (2014). To avoid potential 
clustering of behavioural factors, only one participant per household was 
invited to participate in the study. 
 
4.5 Test methods 
4.5.1 Reference standard 
Undiagnosed T2DM was the outcome variable of interest. The variable was 
defined according to the World Health Organization threshold using the 
OGTT. For our purposes, individuals who were not aware of having T2DM 
diagnosis and had fasting glucose level ≥126 mg/dL (≥7.0 mmol/L) or 2-hour 
plasma glucose ≥200 mg/dL (≥11.1 mmol/L) were classified as undiagnosed 
T2DM. 
In addition, those with 2-hour plasma glucose ≥126 mg/dL (≥7.8 mmol/L) 
and <200 mg/dL (<11.1 mmol/L), but fasting plasma glucose <126 mg/dL 
(<7.0 mmol/l) were classified as having impaired glucose tolerance. On the 
other hand, impaired fasting glucose was defined as fasting plasma glucose 
≥110 mg/dL (≥6.1 mmol/L) but <126 mg/dL (<7.0 mmol/L), and 2-hour 
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plasma glucose <140 mg/dL (<7.8 mmol/L). Finally, dysglycaemia was 
defined as the presence of impaired fasting glucose, impaired glucose 
tolerance or T2DM [7]. 
4.5.2 Index tests 
Two groups of variables were used as index test of interest: those related to 
autonomic devices and those related to risk scores for undiagnosed T2DM. 
Autonomic devices: 
EZSCAN
TM
: It is a non-invasive device developed to identify individuals at 
increased risk of T2DM (Impeto Medical, Paris, France). The evaluation does 
not require fasting and results reproducibility are supposed to be better than 
glycaemia indicators [100]. The EZSCAN device is based on the fact that 
small fiber neuropathies are common in people with insulin resistance and 
pre-diabetes [101]. The device assesses sweat gland function by applying a 
small direct current in both hands and feet to measure chloride ions 
conductance [100]. The EZSCAN process evaluates sweat gland function in 
relation to sweat innervations and results are derived by using complementary 
individual information (height, weight, sex and age). Results are expressed in 
both colours: green (no risk), yellow (moderate risk, orange (high risk), and 
red (very high risk), and percentages with pre-specified values: no sweat 
dysfunction (<50%), median sweat dysfunction (50%-65%), and high sweat 
dysfunction (>65%). For study purposes, EZSCAN results will be used as 
continuous variables to assess suggested provider’s cut-off or define 
appropriately a cut-off for our population. 
Pupillometer: Human pupil size varies, on average, from 1 mm to 9 mm. 
Pupil reflex is mediated by acetylcholine and nor-adrenaline, causing miosis 
and mydriasis, respectively. Changes in pupil size in response to light 
stimulus is based on a functional equilibrium between sympathetic and 
parasympathetic activity [102]. Small-fiber dysfunction has been reported 
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even from impaired fasting glucose [103]; and as a result, it is expectable to 
find differences in pupil diameter between undiagnosed T2DM and 
individuals without T2DM. Measurements were performed using the VIP
TM
-
200 (NeurOptics, California, US), a battery operated, handheld optical 
scanner to measure pupil size (i.e. pupil diameter). This instrument can 
measure pupils in darkness for 2 seconds in no background illumination 
(“Light off” mode) with an accuracy of 0.1 mm. Under “Variable” mode, 
pupil diameter can be measured under three different background light 
conditions: scotopic (light off), low mesopic (0.3 lux), and high mesopic (3 
lux) for a total of 10 seconds. For thesis purposes, pupil diameters were 
measured using the variable mode of the pupillometer and point estimates and 
standard deviation were obtained and recorded as continuous variables, both 
in millimetres. 
Biothesiometer: T2DM can produce peripheral neuropathy causing pain or 
sensory loss especially in toes and feet [104]. The damage at vibration 
perception has been observed in obese individuals even with normal glycemic 
levels [105]; therefore, it is possible to be used as a screening tool for 
undiagnosed T2DM. The biothesiometer is a hand-held device used to 
measure the threshold of vibration perception (appreciation) in human 
subjects. Although this device can be used for several neurological diseases, it 
is superior to a tuning fork in accuracy for T2DM neuropathy [106]. A digital 
biothesiometer model “Vibrometer-VPT” (Diabetik Foot Care India Pvt Ltd, 
Chennai, India) was used for individuals’ assessment. Usually a cut-off of 25 
mV is utilised to detect cases of polyneuropathy [104] and a cut-off of 9 mV 
has been described as abnormal vibration perception threshold [107], but for 
thesis purposes continuous results were obtained and recorded for analysis. 
Variables related to risk scores for undiagnosed T2DM: 
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Three different risk scores were also assessed and compared to neuropathy 
assessment tools, the Finnish Diabetes Risk Score (FINDRISC), the Latin 
American version of the FINDRISC (LA-FINDRISC), and the Peruvian Risk 
Score.  
The FINDRISC is a questionnaire to identify individuals at high risk of 
developing T2DM. It was created using a prospective cohort study of 
individuals aged between 35 and 64 years [108]. For easy application, the 
potential responses of the questions were categorised. The FINDRISC is a 
blood-free risk score whose original questions included age, body mass index, 
waist circumference, physical activity, daily consumption of fruits, berries or 
vegetables, history of anti-hypertensive drug treatment, and history of high 
blood glucose [109]. However, later studies included family history of T2DM 
to the model and modified diet patterns and physical activity questions. The 
English version is available in Appendix E. 
Despite the fact that the FINDRISC has been widely used for estimating the 
risk of developing T2DM within the following ten years, this score has been 
also evaluated as a tool to identify undiagnosed T2DM, abnormal glucose 
tolerance, dysglycaemia, and metabolic syndrome [40, 110, 111]. In addition, 
this tool has been used, adapted and validated in Latin America settings such 
as Colombia [112, 113], and therefore, it is a valid instrument to be assessed 
in our population. 
On the other hand, the Latin America version of the FINDRISC (LA-
FINDRISC) was also included in this evaluation. This questionnaire is very 
similar to the original FINDRISC, but has been used for detecting cases of 
impaired glucose regulation and options regarding waist circumference has 
been adapted for Latin American populations [114]. Thus, cut-offs used for 
this anthropometric measurement are 94 cm for men and 90 cm for women. 
The English version is available in Appendix E. Finally, the Peruvian Risk 
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Score, developed as part of this thesis, was also assessed by using oral 
glucose tolerance test as the gold standard instead of fasting glucose as 
originally done [46]. 
 
4.6 Demographic and other variables 
Sociodemographic variables (age, sex, education level, socioeconomic status, 
etc.), medical and familial history of T2DM, and lifestyle behaviours 
(smoking, alcohol consumption, physical activity level, diet patterns, etc.) 
were taken into account to describe the study population (Definitions are 
available in Table IV-1, IV-2 and IV-3).  
 
4.7 Data collection methods 
After informed consent, participants’ information was collected using tablets 
and measurements were obtained by well-trained clinical personnel. The 
research team was comprised by five fieldworkers: two staff members were 
responsible for participant’s invitation (i.e. going household by household 
looking for eligible participant according to selection framework); other two 
were in charge of data collection and measurements (application of 
questionnaires and device and anthropometrical assessments), and the latter 
one person was in charge of blood sampling. 
4.7.1 Questionnaires 
Participants responded to a face-to-face questionnaire applied by trained 
health workers using computer-based formats. The Spanish version of the 
questionnaire is available in Appendix F. An application built using Open 
Data Kit (ODK: http://opendatakit.lshtm.ac.uk) was utilised using tablets. 
Using the application, we obtained data about factors potentially associated 
with T2DM, including sociodemographic variables (age, sex, years of 
education, socioeconomic variables, etc), behavioural variables (lifestyles 
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comprising smoking habits, alcohol consumption, physical activity levels, 
diet patterns, clinical symptoms, etc), medical history (T2DM, hypertension, 
myocardial infarction, and other cardiovascular diseases), and familial 
medical history focused mainly on glucose metabolism disorder, but also in 
hypertension and cardiovascular disease. 
A modified version of the WHO STEPwise approach to surveillance (WHO 
STEP) questionnaire for surveillance of chronic non-communicable diseases 
was used to build the application for data collection [49]. Questions of 
specific T2DM risk scores (i.e. Peruvian risk score, FINDRISC, among 
others) were also included. 
4.7.2 Clinical assessment 
After completing questionnaires, the anthropometric characteristics of 
participants were also assessed. Measurements of standing height were 
carried out using a stadiometer and standardised procedures. Weight was 
assessed using a bio-electrical impedance device (TBF-300A, TANITA 
Corporation, Tokyo, Japan), as well as waist circumference was assessed in 
triplicate using standard techniques. Heart rate, systolic and diastolic blood 
pressure were also evaluated in triplicate using an automatic monitor 
OMRON HEM-780 (OMRON Healthcare, Illinois, US), previously validated 
for adult population [50]. Finally, the EZSCAN assessment, pupillometer and 
biothesiometer evaluation were also performed. Evaluators were blinded to 
the OGTT results. 
EZSCAN assessment: 
This evaluation was conducted following the guidelines of the provider [66]. 
Briefly, the participant was asked to take off his shoes and socks, and then put 
his/her hands and feet on the electrodes of the EZSCAN. A small electric 
tension was applied to the surface of hands and feet during about 2 minutes. 
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After that, percentage of risk is given to indicate the probability of the 
participant of having/developing T2DM. This result was recorded. 
Pupillometry assessment: 
Similar to the EZSCAN, evaluation using the pupillometer was carried out 
using the provider’s manual. Both participant eyes were assessed using the 
“Variable” mode. For this, initially, the lighting of the assessment room was 
reduced, and at least five minutes were left before starting evaluation (pupil’s 
dark adaptation). Then, the participant’s head was aligned with the device to 
minimize any tilting of the device. The three forms of assessment were used: 
scotopic (light off), low mesopic (0.3 lux), and high mesopic (3 lux) for a 
total of 10 – 12 seconds for each eye. All the measurement were recorded in 
the device and then downloaded to a computer for analysis purposes.  
Biothesiometer assessment: 
As recommended in the device manual and previous guidelines [115], four 
sites were tested in each feet: first, third and fifth metatarsal heads and the 
pulp of the hallux (plantar surface of distal hallux). Measurement in the pulp 
of the hallux was performed in triplicate to determine the vibration perception 
threshold as recommended for neuropathy assessment [116]. For evaluation, 
the participant was asked to be in lying supine position. Then, the stylus of 
the device was placed over the first point (i.e. first metatarsal head) and the 
amplitude was increased up to the participant could detect the vibration. The 
resulting number was the vibration perception threshold. The same procedure 
was repeated for each point and foot and values were recorded. 
4.7.3 Blood sampling 
Trained laboratory staff explained procedures for blood sample collection. 
Participants were asked to provide venous blood sample for OGTT after a 
minimum of 8 and a maximum of 12 hours of fasting. First blood sampling 
was obtained at the first moment of the appointment, after verifying fasting 
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period was accomplished. A total of 7.5 ml of venous blood sample was 
drawn to assess fasting glucose. After that, a load of 75 grams of anhydrous 
glucose in a volume of 300 ml was used as recommended by the WHO [7]. 
Two hours after, a new blood sample was obtained to measure glucose levels. 
In the mid-time, questionnaires and clinical measurements were performed. 
Thus, we took advantage of the two hours between blood samples to complete 
questionnaires and to obtain anthropometric and clinical assessments. 
Blood testing was carried out by a certified Peruvian laboratory located in 
Lima (MEDLAB: http://www.medlab.com.pe) using its qualified personnel to 
do all sampling procedures (blinded to index tests) and to be in charge of 
transport of samples to the laboratory’s facilities. Glucose was measured in 
serum using a Cobas Modular Platform automated analyzer and reagents 
supplied by Roche Diagnostics. Quality control for glucose measurements 
had <1 for the coefficient of variation, a reference range provided by Bio-
Rad, an independent assessment company (www.biorad.com). 
 
4.8 Statistical analysis 
Following careful data cleaning and consistency checking, descriptive 
statistics using tabulations and graphical methods was conducted. Analysis 
was performed using STATA 13.0 for Windows (Stata Corp, College Station, 
TX, US). Report was conducted using the STARD guidelines [82] and the 
TRIPOD statement [47] as recommended. 
4.8.1 Descriptive analysis 
Initially, characteristics of study population were tabulated using proportions 
in the case of categorical variables, and mean and standard deviation (SD) for 
continuous variables. After overall participants’ description, all cases of 
known T2DM were excluded from further analyses. Then, the prevalence and 
95% confidence interval (95% CI) of undiagnosed T2DM, impaired fasting 
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glucose, impaired glucose tolerance, and dysglycaemia were estimated. In 
addition, comparison of results obtained using risk scores and neuropathy 
assessment tools according to OGTT status were also tabulated. 
4.8.2 Diagnostic accuracy of scores and neuropathy assessment tools 
As measurements of pupillometer and biothesiometer were obtained in each 
eye and feet, respectively, summary and correlation of results were presented. 
Correlation was evaluated using Spearman test as non-normal distribution 
was expected [117]. According to that, the average of each measurement of 
the pupillometer (i.e. scotopic, low- and high-mesopic) and biothesiometry 
(first, third and fifth metatarsal head and pulp of the hallux) were estimated 
and used for further analysis. In the case of the biothesiometer, measurements 
of the pulp of the hallux were emphasized for analysis as previously 
recommended [116]. 
We estimated the diagnostic accuracy of the FINDRISC, the LA-FINDRISC 
and the Peruvian Risk Score using the c-statistic and the area under the ROC 
curve. Sensitivity and specificity were also determined as well as optimal 
empirical cut-off following the method suggested by Youden [54]. Logistic 
regression was used to evaluate the coefficients of the FINDRISC in Peruvian 
population and simplify and recalibrate the model. The factors independently 
associated in the simplified model were each assigned a weighted score, for 
instance, by dividing the regression coefficients in the final model by the 
lower coefficient and then rounding them up to the nearest integers as in a 
previous report [38].  
Diagnostic accuracy of the EZSCAN, pupillometer and biothesiometer 
measurements was also evaluated as with risk scores. Comparison between 
the performances of risk scores and neuropathy assessment tools was also 
conducted using the roccomp command in STATA. In addition, a 
combination of potential devices and risk scores using Boolean algebra was 
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also assessed using logistic regression and a two-step approach as previously 
described [118]. 
 
4.9 Ethical considerations 
The protocol, informed consent and questionnaires were approved by Ethical 
Institutional Committee at the Universidad Peruana Cayetano Heredia, Lima, 
Peru, and London School of Hygiene and Tropical Medicine, London, United 
Kingdom. 
The aims of the study were explained to each participant and informed 
consent was obtained before commencing any of the activities. Protocol, 
informed consent forms and questionnaire were reviewed and approved in 
their Spanish and English versions. 
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had no role in study design, data collection, data analysis, or decision to 
publish or preparation of the thesis.  
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Figure IV-1: Map of the study setting 
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Table IV-1: Definition of sociodemographic variables 
 
Variable Type Categories Definition 
Age Continuous  Based on date of birth 
Age group Categorical <40 years  
  40 – 49 years  
  50 – 59 years  
  ≥60 years  
Sex Categorical Female Based on self-report 
  Male 
Education level Categorical < 7 years Based on the number of 
years of education 
obtained at the moment 
of interview 
  7 – 11 years 
  ≥12 years 
Socioeconomic 
status 
Categorical Lowest Based on household 
assets possession, and 
then split in tertiles [119, 
120] 
 Middle 
 Highest 
Marital status Categorical Never married Self-reported 
 Married 
 
Previously 
married 
Currently working Categorical No Self-reported 
  Yes   
Monthly personal 
income 
Categorical Up to 100 PEN Self-reported, 
categorisation based on 
national minimum wage 
(750 PEN) during 
previous 12 months 
 101 – 750 PEN 
  
>750 PEN 
History of 
migration 
Categorical No Self-reported based on 
response to: “Have you 
live in Tumbes during all 
your live? 
 Yes 
Health insurance Categorical No Self-reported, based on 
current affiliation to 
health insurance   Yes 
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Table IV-2: Definition of lifestyle behaviour variables 
 
 
Variable Type Categories Definition 
History of T2DM 
in first-degree 
relatives 
Categorical No Self-reported 
 Yes  
Current smoking Categorical Do not smoke Self-reported, based on 
question of WHO 
STEPs.   
Smoke 
occasionally 
  Smoke daily 
History of 
smoking 
Categorical Never smoked Self-reported, based on 
question of WHO 
STEPs. 
 Smoked before 
 Currently smoke 
Alcohol 
consumption 
Categorical Never Self-reported, based on 
frequency of alcohol 
consumption 
 < One per month 
 
1+ times per 
month 
Alcohol disorder Categorical No Based on the Alcohol 
Use Disorder 
Identification Test 
(positive if ≥8 points) 
[121] 
  Yes 
Physically active 
for at least 30 
min/day 
Categorical No Self-reported, based on 
FINDRISC question 
 Yes  
MET score Categorical Low Estimates based on the 
short version of the 
International Physical 
Activity Questionnaire 
(IPAQ) 
  Moderate 
  High 
Watching 
television 
Categorical  <2 hours/day 
Self-reported, based on 
the number of hours 
watching TV during 
weekdays and weekends 
(last week) 
  
≥2 but <4 
hours/day 
  4+ hours/day 
Fruits and 
vegetables 
Categorical < 1 per day 
Self-reported, based on 
FINDRISC question 
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  ≥ 1 per day 
Sweetened juices 
consumption 
Categorical Up to once/week Self-reported, based on 
question of Young Lives 
Study  
More than 
once/week 
Soda 
consumption 
Categorical Up to once/week Self-reported, based on 
question of Young Lives 
Study  
More than 
once/week 
History of high 
glucose levels 
Categorical No Self-reported, based on 
FINDRISC question 
 Yes 
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Table IV-3: Definition of anthropometric variables 
 
Variable Type Categories Definition 
Weight (in kg.) Continuous  Measured using a bio-
impedance scale 
   
Height (in meters) Continuous  Measured in standing 
position using a 
stadiometer    
Body mass index Continuous  
Based on weight and 
height 
Body mass index 
(categories) 
Categorical Normal  Based on usual definition 
of the WHO (<25 kg/m
2
, 
25 but <30 kg/m
2 
and 
≥30 kg/m2)  
 Overweight  
 Obese 
Waist 
circumference (in 
cm.) 
Continuous  In triplicate and average 
of three measures is used 
  
Waist 
circumference 
Categorical Normal 
Based on different 
definitions for men and 
women   Obese 
Systolic blood 
pressure 
Continuous  Based on three 
measurements after 5 
minutes of resting 
period. Average of two 
last measures was used 
for calculations [52]. 
  
Diastolic blood 
pressure 
Continuous  
  
Blood pressure 
treatment 
Categorical No Self-reported 
 Yes 
Hypertension 
status 
Categorical No 
Based on blood pressure 
levels, self-reported 
diagnosis and current 
treatment. 
  Yes 
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Chapter V: Feasibility and Pilot Study 
 
5.1 Objectives 
The feasibility part of the study aimed to evaluate the logistical and 
acceptability of using the proposed screening devices in fieldwork. On the 
other hand, the pilot study was focused on crucial components of the study, 
including time, costs, staff, and study design before conducting the full-
scale project. Secondary objectives comprised the optimisation of practical 
aspects of the study, including recruitment, paperwork, and data collection. 
 
5.2 Materials, methods and execution 
Between August and September 2015, a pilot study was conducted in 
Tumbes, the area proposed for the main study. A convenience sample of 
participants with and without T2DM (ratio 1:1), matched by sex and age 
(±2 years), was planned.  
For the pilot purposes, a sample of participants from the CRONICAS 
Cohort Study, originally enrolled in Tumbes, was re-contacted to be 
recruited in this study. Details of the CRONICAS Cohort Study have been 
published elsewhere [48]. Briefly, 3601 participants aged ≥35 years were 
assessed in 2010-2011 (baseline) and in 2013-2014 (follow-up) to 
determine the incidence of T2DM among other cardiovascular risk factors. 
However, for this pilot, only participants from Tumbes were re-contacted. 
The reference test was based on two fasting glucose assessments. A positive 
test was defined as an individual with two fasting plasma glucose 
measurements (at baseline and follow-up) ≥126 mg/dL or self-reporting 
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anti-diabetic medication, whereas a negative test was defined as an 
individual with both measurements of glucose <126 mg/dL. 
Once individuals were contacted, the objectives of the study were explained 
and an informed consent was read to confirm participation. A short 
questionnaire containing information regarding age, sex, lifestyle 
behaviours, and questions of the Finnish Diabetes Risk Score (FINDRISC 
questionnaire) was also applied [40]. Anthropometric measurements 
(height, weight, and waist circumference) as well as blood pressure, after 
five minutes of resting and in triplicate, were also obtained. Finally, 
ascertainment with the EZSCAN (sudomotor function) and pupillometry 
(scotopic, low mesopic and high mesopic diameters) was also undertaken. 
For analyses purposes, comparison between individuals with and without 
T2DM was performed using the Student t-test for independent samples in 
the case of numerical variables, and Chi-squared test or Fisher exact test for 
categorical variables. Area under the ROC curve, sensitivity and specificity 
were also estimated using collected information considering diabetes status 
as the gold standard. In addition, acceptability of tests (defined as 
individuals accepting device assessment) was also evaluated. 
 
5.3 Results 
A total of 50 individuals with T2DM and 50 controls were enrolled. Mean 
age among those with T2DM (60.8 years; SD: 10.1) was similar to that of 
controls (60.7 years; SD: 10.1). Comparisons of demographic 
characteristics, behaviours, anthropometric measurements and devices 
results between cases and controls are shown in Table V-1. Of importance, 
there was significant difference in the low mesopic and high mesopic 
diameters using pupillometry as well as the FINDRISC score between 
T2DM cases and controls.  
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Information regarding the performance of proposed screening devices and 
risk scores is shown in Table V-2. A better performance was obtained using 
the FINDRISC score (area under the ROC curve = 0.87), whilst the 
performance was moderate when using the high mesopic diameter of 
pupillometry (area under the ROC curve = 0.65). 
Finally, of the 82 cases with T2DM re-contacted from the CRONICAS 
Cohort Study, 20 (24.4%) only accepted questionnaires; thus, only 62 
completed assessment including questionnaires and device evaluations, but 
only 50 could be matched with an appropriate individual without T2DM.  
 
5.4 Utility of results 
This pilot study demonstrated that it was possible to perform the study in 
the selected setting. Measurements were easily obtained and individuals 
were prone to participate. Additionally, it suggest the possibility to get 
better performance of the selected devices and scores when applied in the 
general population and using the OGTT as the gold standard for T2DM 
diagnosis. 
This pilot study suggested that a relatively large research team (4 to 5 health 
personnel) were needed to conduct the study. In addition, the order of the 
proposed procedures needed to be pre-specified to appropriately use the two 
hours gap between OGTT blood samples. 
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Table V-1: Comparison between individuals with and without T2DM  
 
 
With  
T2DM 
Without 
T2DM p-value 
 (n = 50) (n = 50) 
Sex, female (%) 28 (56.0%) 28 (56.0%) -- 
Age, mean (SD) 60.8 (10.1) 60.7 (10.1) -- 
Current smoking (%) 4 (8.0%) 4 (8.0%) 0.99 
Regular physical activity (%) 23 (46.9%) 32 (64.0%) 0.09 
Waist, mean (SD) 100.3 (11.5) 96.8 (11.5) 0.10 
Body mass index, mean (SD) 28.5 (5.4) 29.3 (4.9) 0.45 
Systolic blood pressure, mean (SD) 129.0 (18.7) 125.5 (20.5) 0.39 
Diastolic blood pressure, mean (SD) 76.6 (10.7) 79.0 (11.9) 0.28 
Hypertension (%) 28 (56.0%) 18 (36.7%) 0.06 
Pupillometry    
Scotopic diameter, mean (SD) 4.09 (0.89) 4.48 (1.04) 0.05 
Low mesopic diameter, mean (SD) 4.01 (0.86) 4.47 (1.03) 0.02 
High mesopic diameter, mean (SD) 3.86 (0.81) 4.33 (0.98) 0.01 
Scores    
FINDRISC score, mean (SD) 18.6 (4.4) 11.6 (4.4) < 0.001 
EZScan    
Sudomotor function, mean (SD) 41.0 (16.4) 36.0 (12.3) 0.09 
Insulin resistance, mean (SD) 57.1 (15.9) 51.4 (9.3) 0.03 
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Table V-2: Comparison of performance between diagnostic tests 
 
Technique AUC Sensitivity Specificity 
Pupillometry    
Scotopic diameter 0.60 (0.49 – 0.71) 72.0% 50.0% 
Low mesopic diameter 0.63 (0.52 – 0.74) 70.0% 52.1% 
High mesopic diameter 0.65 (0.54 – 0.76) 64.0% 62.5% 
Scores    
FINDRISC score 0.87 (0.80 – 0.94) 91.3% 64.6% 
EZScan    
Sudomotor function 0.59 (0.47 – 0.70) 50.0% 60.0% 
  
AUC = Area under the ROC curve 
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Chapter VI: Descriptive Results  
 
6.1 Response rates 
A total of 2114 individuals were invited to participate in the study. Of them, 
486 (22.9%) rejected participation, and 16 (0.8%) women were pregnant and 
excluded. Of the 1612 (76.3% of the invited) participants enrolled in the 
study, three did not complete all the procedures; therefore, only 1609 were 
further analysed. Details of the enrolling procedures are shown in a flowchart 
in Figure VI-1. 
 
6.2 Characteristics of the study population 
6.2.1 Sociodemographic characteristics 
Main sociodemographic characteristics are detailed in Table VI-1. There were 
similar number of males and females (49.7% vs. 50.3%), and the overall age 
mean was 48.2 (SD: 10.6). Of note, almost a third of participants had less 
than 7 years of education, 80.4% were married, and 25.7% were migrants. 
6.2.2 Lifestyle behaviour characteristics 
Among the most important lifestyle behaviours, only 92 (5.7%) reported daily 
smoking, whereas 121 (7.5%) had alcohol disorder. More than two thirds 
(68.2%) of the population reported to be physically active (at least 30 min per 
day); however, using the IPAQ, only 28.2% had high levels of physical 
activity. Regarding diet patterns, 841 (52.3%) of participants reported 
consuming at least one fruit or vegetable per day (Table VI-2). 
6.2.3 Anthropometric measurements 
From the anthropometrical perspective, based on body mass index results, 
708 (44.0%) were overweight and 476 (29.6%) were obese. The proportion of 
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individual with obesity using waist circumference and International Diabetes 
Federation (IDF) definition [122] was 79.4% (n = 1277) and 417 (25.9%) had 
hypertension. Details of the anthropometric characteristics of study 
participants are in Table VI-3. 
 
6.3 Prevalence of T2DM and glucose disorders 
Based on OGTT results, 176 individuals had T2DM (11.0%; 95%CI: 9.4% - 
12.5%), and 105 (59.7%) were aware of their diagnosis. Thus, only 71 (4.7%; 
95%CI: 3.7% - 5.8%) individuals had undiagnosed T2DM; whereas this 
number was 56 (3.5%; 95% CI: 2.6% - 4.5%) when only using fasting 
glucose.  
Regarding glucose disorders, 1159 (77.2%) subjects were normoglycemic, 
whereas 17 (1.1%; 95% CI: 0.7% - 1.8%) had impaired fasting glucose, and 
255 (17.0%; 95% CI: 15.1% - 19.0%) had impaired glucose tolerance. Thus, a 
total of 343 (22.8%; 95% CI: 20.7% - 25.0%) individuals had dysglycaemia. 
When sociodemographic, lifestyle behaviour, and anthropometric 
characteristics of the study population was evaluated after excluding 
participants aware of T2DM diagnosis (n = 105), they were very similar to 
the total sample (Table VI-1, Table VI-2, and Table VI-3), except in the case 
of self-reported high glucose levels. 
 
6.4 Risk scores and neuropathy assessment tools by OGTT results 
Overall, the mean of the three risk scores were greater among those with 
undiagnosed T2DM than those without T2DM (See Table VI-4). In the case 
of neuropathy assessment tools, the score using EZSCAN was also greater 
among those with undiagnosed T2DM (p < 0.001). This difference was also 
present in results of biothesiometer but in the first (p = 0.001), third (p < 
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0.001), and fifth (p < 0.001) metatarsal head, and not in the pulp of the hallux 
(p = 0.05). There were no differences in the three pupillometer diameters. 
 
6.5 Sex subgroup analysis 
There was no difference in the prevalence of undiagnosed T2DM by sex 
(3.9% among males and 5.6% among females, p = 0.11). Behavioural 
characteristics of the study population according to sex are shown in 
Appendix G. Of note, there was difference in all the behavioural variables 
evaluated. 
On the other hand, although males had more weight than females (75.8 kg vs. 
69.1 kg, p < 0.001); females had more obesity using body mass index and 
waist circumference (See Appendix H). Males had higher levels of systolic 
and diastolic blood pressure (p < 0.001 for both blood pressure levels), but 
there was no difference in hypertension prevalence (p = 0.08). 
Finally, when comparing result of risk scores and neuropathy assessment 
tools according to sex (Appendix I), females had higher total scores in the 
FINDRISC (p < 0.001) and LA-FINDRISC (p< 0.001) results, but not in the 
Peruvian Risk Score (p = 0.06). Similarly, values of the EZSCAN and 
biothesiometer assessments were higher among women than men. 
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Figure VI-1: Flowchart of study participants 
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Table VI-1: Sociodemographic characteristics of the total study population 
and those with OGTT results 
 
 
Total 
population 
With OGTT 
results 
 N = 1609 N= 1504 
Sociodemographic characteristic N (%) N (%) 
Sex Female 810 (50.3%) 750 (49.9%) 
Age Mean (SD) 48.2 (10.6) 47.6 (10.6) 
Education level < 7 years  519 (32.3%) 466 (31.0%) 
 7 – 11 years 749 (46.6%) 708 (47.1%) 
 12+ years 341 (21.2%) 330 (21.9%) 
Socioeconomic status 
(tertiles) 
Lowest 540 (33.6%) 497 (33.1%) 
 Middle 550 (34.2%) 517 (34.4%) 
 Highest 519 (32.3%) 490 (32.6%) 
Marital status Never married 163 (10.1%) 156 (10.4%) 
 Married 1293 (80.4%) 1211 (80.5%) 
 Previously married 153 (9.5%) 137 (9.1%) 
Currently working Yes 1091 (67.8%) 1035 (68.8%) 
Monthly personal 
income 
Up to 100 PEN 542 (33.7%) 491 (32.7%) 
101 – 750 PEN 485 (30.2%) 459 (30.5%) 
 >750 PEN 581 (36.1%) 553 (36.8%) 
History of migration Yes 413 (25.7%) 385 (25.6%) 
Health insurance Yes 1469 (91.3%) 1368 (91.0%) 
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Table VI-2: Behavioural characteristics of the total study population and 
those with OGTT results 
 
Behavioural characteristic 
Total 
population 
With OGTT 
results 
N = 1609 N= 1504 
 N (%) N (%) 
T2DM in first-degree relatives Yes 539 (33.5%) 468 (31.1%) 
Smoking    
Current smoking Do not smoke 1390 (86.4%) 1295 (86.1%) 
 Smoke occasionally 127 (7.9%) 123 (8.2%) 
 Smoke daily 92 (5.7%) 86 (5.7%) 
Self-reported history of smoking  Never smoked 992 (61.7%) 923 (61.4%) 
 Smoked before 390 (24.2%) 365 (24.3%) 
 Currently smoke 227 (14.1%) 216 (14.4%) 
Alcohol use    
Alcohol consumption Never 686 (42.6%) 618 (41.1%) 
 < One per month 770 (47.9%) 736 (48.9%) 
 1+ times per month 153 (9.5%) 150 (10.0%) 
Alcohol disorder Yes 121 (7.5%) 121 (8.1%) 
Physical activity    
Physically active (≥ 30min/day) Yes  1098 (68.2%) 1036 (68.9%) 
MET score (IPAQ) Low 605 (37.6%) 550 (36.6%) 
 Moderate 551 (34.2%) 519 (34.5%) 
 High 453 (28.2%) 435 (28.9%) 
Watching television (hours/day) < 2 hours/day 590 (36.7%) 541 (36.0%) 
 ≥2 but <4 hours/day 541 (33.6%) 513 (34.1%) 
 4+ hours/day 478 (29.7%) 450 (29.9%) 
Diet patterns    
Fruits and vegetables  At least one per day 841 (52.3%) 789 (52.5%) 
Sweetened juices consumption ≥ Once per week 164 (10.2%) 157 (10.4%) 
Soda consumption ≥ Once per week 287 (17.8%) 279 (18.6%) 
High glucose levels Yes 159 (9.9%) 56 (3.7%) 
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Table VI-3: Anthropometric characteristics of the total study population 
and those with OGTT results 
 
 
Total 
population 
With OGTT 
results 
 N = 1609 N= 1504 
Anthropometric characteristic N (%) N (%) 
Weight (kg) Mean (SD) 72.3 (13.3) 72.5 (13.3) 
Height (m) Mean (SD) 1.61 (0.1) 1.61 (0.1) 
Body mass index (kg/m
2
) Mean (SD) 28.0 (4.6) 28.0 (4.7) 
Body mass index (categories) Normal 425 (26.4%) 399 (26.5%) 
 Overweight 708 (44.0%) 655 (43.6%) 
 Obese 476 (29.6%) 450 (29.9%) 
Waist circumference (cm) Mean (SD) 93.7 (10.4) 93.6 (10.4) 
Waist circumference (IDF categories) Normal 332 (20.6%) 318 (21.1%) 
 Obese 1277 (79.4%) 1186 (78.9%) 
Systolic blood pressure (mmHg) Mean (SD) 119.9 (16.7) 119.5 (16.3) 
Diastolic blood pressure (mmHg) Mean (SD) 79.7 (10.4) 79.5 (10.3) 
Blood pressure treatment Yes 128 (8.0%) 106 (7.1%) 
Hypertension status Yes 417 (25.9%) 370 (24.6%) 
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Table VI-4: Comparison of results of risk scores and neuropathy 
assessment tools by undiagnosed T2DM  
 
 Undiagnosed T2DM by OGTT 
p-value*  No (N = 1433) Yes (N = 71) 
 Mean (SD) Mean (SD) 
Risk score     
FINDRISC 8.8 (4.2) 11.4 (3.4) < 0.001 
LA-FINDRISC 8.4 (4.4) 11.1 (3.6) < 0.001 
Peruvian Risk Score 1.5 (1.1) 2.0 (1.0) < 0.001 
Neuropathy assessment tool   
EZSCAN 27.0 (10.0) 31.3 (12.9) < 0.001 
Scotopic diameter 4.5 (0.9) 4.4 (0.8) 0.15 
Low mesopic diameter 4.5 (0.8) 4.4 (0.8) 0.17 
High mesopic diameter 4.3 (0.8) 4.2 (0.8) 0.42 
Pulp of the hallux 15.2 (8.5) 17.3 (10.2) 0.05 
First metatarsal head 13.6 (7.7) 16.7 (10.2) 0.001 
Third metatarsal head 13.5 (7.9) 17 (10.5) < 0.001 
Fifth metatarsal head 13.4 (7.8) 16.7 (10.1) < 0.001 
 
* P-values were estimated using Student t test for independent samples. 
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Chapter VII: Diagnostic accuracy of risk scores and 
neuropathy assessment tools 
 
Using a cross-sectional study to detect cases of undiagnosed (prevalent) T2DM, the 
diagnostic accuracy of different blood-free risk scores and neuropathy assessment 
tools was evaluated using the area under the ROC curve and other estimates, 
including sensitivity and specificity. In this chapter, these results are presented. 
 
7.1 Diagnostic accuracy of risk scores  
Performance of the FINDRISC, LA-FINDRISC and the Peruvian Risk Score 
are detailed in Table VII-1, including area under the ROC curve, empirical 
cut-off point, sensitivity, specificity, as well as PPV, NPV, likelihood ratio 
positive and negative, and diagnostic odd ratio (DOR). 
7.1.1 FINDRISC performance  
The mean score of the FINDRISC in the study population was 8.9 (SD: 4.2) 
points and values ranged from 0 to 24. When assessing the diagnostic 
accuracy of the FINDRISC for undiagnosed T2DM, the area under the ROC 
curve was 0.69 (95% CI: 0.64 – 0.74), with an empirical optimal cut-off point 
of 11. Using this cut-off, the FINDRISC sensitivity and specificity were 69% 
(95% CI: 57% - 80%) and 67% (95% CI: 64% - 69%), respectively. When 
using traditional cut-point of ≥12 as suggested in previous manuscripts [45, 
110, 112], sensitivity dropped to 51% (95% CI: 39% - 63%) whereas 
specificity increased to 74% (95% CI: 72% - 76%). 
7.1.2 LA-FINDRISC performance  
The mean score of the LA-FINDRISC in the study population was 8.6 (SD: 
4.4) points and values ranged from 0 to 24. When assessing the diagnostic 
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accuracy of the LA-FINDRISC for undiagnosed T2DM, the area under the 
ROC curve was 0.68 (95% CI: 0.63 – 0.74), with an empirical cut-off of 10. 
Using this cut-point, LA-FINDRISC sensitivity and specificity were 70% 
(95% CI: 58% – 81%) and 59% (95% CI: 57% - 62%), respectively.  
7.1.3 Peruvian Risk Score performance 
The mean score of the Peruvian Risk Score in the study population was 1.5 
(SD: 1.1) and values ranged from 0 to 4. When assessing the diagnostic 
accuracy of the Peruvian Risk Score for undiagnosed T2DM, the area under 
the ROC curve was 0.64 (95% CI: 0.58 – 0.70). When the empirical cut-point 
of ≥2 was used, the sensitivity of the Peruvian Risk Score was 65% (95% CI: 
53% - 76%), whereas the specificity was 54% (95% CI: 51% - 56%).  
7.1.4 Simplification of the FINDRISC 
Only four variables of the original FINDRISC were independently associated 
with undiagnosed T2DM in study population: waist circumference (p = 
0.005), blood pressure treatment (p = 0.004), history of high blood glucose (p 
= 0.005), and family history of T2DM (p = 0.02). Coefficients and scores of 
the simplified version of the FINDRISC are detailed in Table VII-2. The area 
under the ROC curve of the simplified FINDRISC was 0.71 (95% CI: 0.66 – 
0.76), and with an empirical cut-off ≥3, the sensitivity and specificity were 
86% (95% CI: 76% - 93%) and 46% (95% CI: 43% - 49%), respectively 
(Table VII-1).  
7.1.5 Comparison of diagnostic accuracy between risk scores  
The diagnostic accuracy of the FINDRISC (area under the ROC = 0.69; 
95%CI: 0.64 – 0.74) was slightly better than the LA-FINDRISC (area under 
the ROC = 0.68; 95%CI: 0.63 – 0.74) and the Peruvian Risk Score (area 
under the ROC = 0.64; 95%CI: 0.58 – 0.70), but results were not significant 
(p = 0.14). On the other hand, the diagnostic accuracy of the simplified 
version of the FINDRISC score was similar to the FINDRISC (p = 0.17) and 
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LA-FINDRISC (p = 0.12), but superior than the Peruvian Risk Score (p = 
0.01, Figure VII-1).  
 
7.2 Diagnostic accuracy of neuropathy assessment tools 
7.2.1 Performance of the EZSCAN 
The mean score of the EZSCAN results was 27.2 (SD: 10.2, range: 8 - 71). 
When assessing the diagnostic accuracy of the EZSCAN for undiagnosed 
T2DM, the area under the ROC curve was 0.59 (95% CI: 0.53 – 0.66). When 
the empirical cut-off of 26 was used, the sensitivity of the EZSCAN was 59% 
(95% CI: 47% – 71%) and the specificity was 54% (95% CI: 51% – 56%). 
When the cut-off recommended by the provider was used instead (i.e. 50), the 
sensitivity dropped to 17% (95% CI: 9% – 28%), whereas the specificity 
increased to 92% (95% CI: 90% – 93%). These results joined to those 
obtained using alternative cut-offs as suggested by literature are detailed in 
Table VII-3. 
7.2.2 Performance of the pupillometer 
Scotopic diameter: 
The mean score of the scotopic diameter in the right eye was 4.5 (SD: 0.9) 
mm similar to the left eye (mean = 4.5 mm; SD: 0.8), with a Spearman 
correlation coefficient of 0.85 (p-value < 0.001). The area under the ROC 
curve was 0.55 (95% CI: 0.49 – 0.62) with an empirical cut-off of 4.2 mm, 
and a sensitivity of 53% (95% CI: 40% – 65%) and a specificity of 62% (95% 
CI: 60% – 65%). See details in Table VII-4. 
Low-mesopic diameter: 
The mean score of the low-mesopic diameter in the right eye was 4.5 (SD: 
0.9) mm similar to the left eye (mean = 4.5 mm; SD: 0.9), with a Spearman 
correlation coefficient of 0.83 (p-value < 0.001). The area under the ROC 
curve was 0.55 (95% CI: 0.48 – 0.62) with an empirical cut-off of 4.4 mm, 
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and a sensitivity of 54% (95% CI: 42% – 67%) and a specificity of 57% (95% 
CI: 55% – 60%). Details are shown in Table VII-4. 
High-mesopic diameter: 
The mean score of the high-mesopic diameter in the right eye was 4.3 (SD: 
0.9) mm similar to the left eye (mean = 4.3 mm; SD: 0.8), with a Spearman 
correlation coefficient of 0.78 (p-value < 0.001). The area under the ROC 
curve was 0.52 (95% CI: 0.45 – 0.59) with an empirical cut-off of 4.3 mm, 
and a sensitivity of 53% (95% CI: 40% – 65%) and a specificity of 53% (95% 
CI: 50% – 55%). Details are shown in Table VII-4. 
7.2.3 Performance of the biothesiometer 
Using the pulp of the hallux (Table VII-5), the mean of vibration perception 
threshold in the right and left feet was 15.6 (SD: 9.1) and 14.6 (SD: 9.1), 
respectively. The Spearman correlation coefficient for both measurements 
was 0.83 (p-value <0.001). Using the average of right and left vibration 
perception threshold, the area under the ROC curve for undiagnosed T2DM 
was 0.55 (95% CI: 0.48 – 0.62) with an empirical cut-off of 20 and a 
sensitivity of 34% (95% CI: 23% – 46%) and specificity of 78% (95% CI: 
76% – 80%).  
Vibration perception threshold obtained from metatarsal heads had better 
diagnostic accuracy than that obtained from the pulp of hallux: areas under 
the ROC curve were 0.58 (95% CI: 0.51 – 0.65), 0.60 (95% CI: 0.53 – 0.67), 
and 0.60 (95% CI: 0.52 – 0.67) for the first, third and fifth metatarsal head, 
respectively. Results are detailed in Table VII-5. 
7.2.4 Comparison of diagnostic accuracy between neuropathy 
assessments tools 
Among all the pupillometry indicators, the diagnostic accuracy of the 
scotopic diameter was similar to the low mesopic diameter (p = 0.41) but 
slightly better than the high mesopic diameter (p = 0.01, See Figure VII-2). 
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Similarly, among all the biothesiometer indicators, the diagnostic accuracy of 
the vibration perception threshold of the first, third and fifth metatarsal heads 
was better than the pulp of the hallux (p = 0.03).  
The diagnostic accuracy of the EZSCAN, on the other hand, was better than 
any of the pupillometer diameters evaluated (p = 0.03), but similar to the 
results of the biothesiometer in the third and fifth metatarsal head (p = 0.98).  
 
7.3 Comparison between risk scores and neuropathy assessment 
tools 
The simplified FINDRISC had better diagnostic accuracy when compared to 
neuropathy devices. Thus, using the c-statistic, the simplified FINDRISC had 
better performance than the EZSCAN (p = 0.003), any pupillometer diameter 
(p <0.001 for all diameters), and any biothesiometer result (pulp of the hallux, 
p < 0.001; first metatarsal head, p = 0.005; third metatarsal head, p = 0.01; 
and fifth metatarsal head, p = 0.01). Similarly, the original FINDRISC had 
better diagnostic accuracy than the EZSCAN (p = 0.01), any pupil diameter 
(p < 0.001 for all diameters), and any biothesiometer result (p = 0.001). 
Detailed comparisons between risk scores and neuropathy assessment tools 
are shown in Table VII-6. 
 
7.4 Combination of risk scores and neuropathy assessment tools 
Based on the previous results, specific combinations of two neuropathy 
assessment tools (EZSCAN and biothesiometer) and the FINDRISC, the LA-
FINDRISC and the simplified FINDRISC were performed using Boolean 
algebra. Both, conjunction (AND) and disjunction (OR) combinations were 
conducted and evaluated. 
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7.4.1 Combination of the EZSCAN with blood-free risk scores 
EZSCAN and FINDRISC:  
A total of 526/1504 (35.0%) participants had a FINDRISC score ≥11 points 
and were considered at high risk of having undiagnosed T2DM. Among 
participants with FINDRISC ≥11, 318/525 (60.6%) had an EZSCAN result 
compatible with undiagnosed T2DM, whereas this number was 390/978 
(39.9%) among those who had a FINDRISC <11 points (p < 0.001). Subjects 
with both tests positive (i.e. FINDRISC ≥11 points and EZSCAN ≥26) had 
more than 5-fold (OR = 5.38; 95% CI: 2.73 – 10.6) increase in the probability 
of having undiagnosed T2DM compared to those with both tests negative (i.e. 
FINDRISC <11 points and EZSCAN <26, Table VII-7). If both tests were 
positive, the sensitivity was 45.1% (95% CI: 33.2% - 57.3%) and the 
specificity was 80.1% (95% CI: 77.9% - 82.1%). On the other hand, if any of 
the tests were positive (Table VII-8), the sensitivity and specificity were 
83.1% (95% CI: 72.3% - 91.0%) and 40.2% (95% CI: 37.7%- 42.8%), 
respectively.  
EZSCAN and LA-FINDRISC: 
A total of 636/1504 (42.3%) participants had a LA-FINDRISC score ≥10 
points and were considered at high risk of having undiagnosed T2DM. 
Among participants with LA-FINDRISC ≥10, 374/635 (58.9%) had an 
EZSCAN result compatible with undiagnosed T2DM, whereas this number 
was 334/868 (38.5%) among those who had a LA-FINDRISC <10 points (p < 
0.001). Subjects with both tests positive (i.e. LA-FINDRISC ≥10 points and 
EZSCAN ≥26) had more than 4-fold (OR = 4.74; 95% CI: 2.29 – 9.80) 
increase in the probability of having undiagnosed T2DM compared to those 
with both tests negative (i.e. LA-FINDRISC <10 points and EZSCAN <26, 
Table VII-7). If both tests were positive, the sensitivity was 43.7% (95% CI: 
31.9% - 56.0%) and the specificity was 76.1% (95% CI: 73.8% - 78.3%). On 
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the other hand, if any of the tests were positive (Table VII-8), the sensitivity 
and specificity were 85.9% (95% CI: 75.6% - 93.0%) and 36.6% (95% CI: 
34.1%- 39.1%), respectively.  
EZSCAN and simplified FINDRISC: 
A total of 835/1504 (55.5%) participants had a simplified FINDRISC score 
≥3 points and were considered at high risk of having undiagnosed T2DM. 
Among participants with a simplified FINDRISC ≥3, 449/834 (53.8%) had an 
EZSCAN result compatible with undiagnosed T2DM, whereas this number 
was 259/669 (38.7%) among those who had a simplified FINDRISC <3 
points (p < 0.001). Subjects with both tests positive (i.e. simplified 
FINDRISC ≥3 points and EZSCAN ≥26) had more than 7-fold (OR = 7.27; 
95% CI: 2.83 – 18.69) increase in the probability of having undiagnosed 
T2DM compared to those with both tests negative (i.e. simplified FINDRISC 
<3 points and EZSCAN <26, Table VII-7). If both tests were positive, the 
sensitivity was 52.1% (95% CI: 39.9% - 64.1%) and the specificity was 
71.3% (95% CI: 68.8% - 73.6%). However, if any of the tests were positive 
(Table VII-8), the sensitivity and specificity were 93.0% (95% CI: 84.3% - 
97.7%) and 28.3% (95% CI: 25.9%- 30.7%), respectively.  
7.4.2 Combination of biothesiometer and blood-free risk scores 
Biothesiometer and FINDRISC: 
Among participants with FINDRISC ≥11, 115/526 (21.9%) had a vibration 
perception threshold in the third metatarsal head compatible with 
undiagnosed T2DM, whereas this number was 119/978 (12.2%) among those 
who had a FINDRISC <11 points (p < 0.001). Subjects with both tests 
positive (i.e. FINDRISC ≥11 points and Biothesiometer in the third metatarsal 
head ≥21) had more than 8-fold (OR = 8.43; 95% CI: 4.00 – 17.76) increase 
in the probability of having undiagnosed T2DM compared to those with both 
tests negative (i.e. FINDRISC <11 points and biothesiometer <21, Table VII-
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9). If both tests were positive, the sensitivity was 21.1% (95% CI: 12.3% - 
32.4%) and the specificity was 93.0% (95% CI: 91.6% - 94.3%). However, if 
any of the tests were positive (Table VII-10), the sensitivity and specificity 
were 78.9% (95% CI: 67.6% - 87.7%) and 58.9% (95% CI: 56.3%- 61.5%), 
respectively.  
Biothesiometer and LA-FINDRISC: 
Among participants with LA-FINDRISC ≥10, 133 out of 636 (20.9%) had a 
vibration perception threshold in the third metatarsal head compatible with 
undiagnosed T2DM, whereas this number was 101/868 (11.6%) among those 
who had a LA-FINDRISC <10 points (p < 0.001). Subjects with both tests 
positive (i.e. LA-FINDRISC ≥10 points and Biothesiometer in the third 
metatarsal head ≥21) had more than 6-fold (OR = 6.85; 95% CI: 3.30 – 14.22) 
increase in the probability of having undiagnosed T2DM compared to those 
with both tests negative (i.e. LA-FINDRISC <10 points and biothesiometer 
<21, Table VII-9). If both tests were positive, the sensitivity was 22.5% (95% 
CI: 13.5% - 34.0%) and the specificity was 91.8% (95% CI: 90.3% - 93.2%). 
Nevertheless, if any of the tests were positive (Table VII-10), the sensitivity 
and specificity were 78.9% (95% CI: 67.6% - 87.7%) and 52.5% (95% CI: 
49.9% - 55.1%), respectively.  
Biothesiometer and simplified FINDRISC: 
Among participants with simplified FINDRISC ≥3, 135/835 (16.2%) had a 
vibration perception threshold in the third metatarsal compatible with 
undiagnosed T2DM, whereas this number was 99/669 (14.8%) among those 
who had a simplified FINDRISC <3 points (p = 0.47). Subjects with both 
tests positive (i.e. simplified FINDRISC ≥3 points and Biothesiometer in the 
third metatarsal head ≥21) had more than 13-fold (OR = 13.2; 95% CI: 5.4 – 
32.0) increase in the probability of having undiagnosed T2DM compared to 
those with both tests negative (i.e. simplified FINDRISC <3 points and 
biothesiometer <21, Table VII-9). If both tests were positive, the sensitivity 
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was 26.8% (95% CI: 16.9% - 38.6%) and the specificity was 91.9% (95% CI: 
90.4% - 93.3%). Nevertheless, if any of the tests were positive (Table VII-
10), the sensitivity and specificity were 90.1% (95% CI: 80.7% - 95.9%) and 
39.3% (95% CI: 36.7% - 41.9%), respectively.  
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Figure VII-1: Comparison of area under the ROC curves between FINDRISC, 
LA-FINDRISC, Peruvian Risk Score and simplified FINDRISC 
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Figure VII-2: Comparison of area under the ROC curves between pupil 
parameters: scotopic, low-mesopic and high-mesopic diameters 
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Table VII-1: Diagnostic accuracy of risk scores for undiagnosed T2DM 
 
 FINDRISC LA-FINDRISC Peruvian Risk Score Simplified FINDRISC 
 Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) 
Area under the ROC  
0.69  
(0.64 – 0.74) 
0.68  
(0.63 – 0.74) 
0.64  
(0.58 – 0.70) 
0.71  
(0.66 – 0.76) 
Empirical cut-off 11 10 2 3 
Sensitivity 
69.0%  
(56.9% – 79.5%) 
70.4%  
(58.4% – 80.7%) 
64.8%  
(52.5% – 75.8%) 
85.9%  
(75.6% – 93.0%) 
Specificity 
66.7%  
(64.2% – 69.2%) 
59.1%  
(56.5% – 61.7%) 
53.7%  
(51.0% – 56.3%) 
46.0%  
(43.4% – 48.6%) 
Positive predictive value 
9.3%  
(7.0% – 12.2%) 
7.9%  
(5.9% – 10.2%) 
6.5%  
(4.8% – 8.6%) 
7.3%  
(5.6% – 9.3%) 
Negative predictive value 
97.7%  
(96.6% – 98.6%) 
97.6%  
(96.3% – 98.5%) 
96.8%  
(95.4% – 97.9%) 
98.5%  
(97.3% – 99.3%) 
Likelihood ratio positive 2.1 (1.8 – 2.5) 1.7 (1.5 – 2.0) 1.4 (1.2 – 1.7) 1.6 (1.4 – 1.8) 
Likelihood ratio negative 0.5 (0.3 – 0.7) 0.5 (0.3 – 0.7) 0.7 (0.5 – 0.9) 0.3 (0.2 – 0.5) 
Diagnostic odd ratio 4.5 (2.7 – 7.4) 3.4 (2.1 – 5.8) 2.1 (1.3 – 3.5) 5.2 (2.7 – 10.1) 
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Table VII-2: Coefficients of the simplified FINDRISC for undiagnosed T2DM in Peruvian population 
 
 Bivariable model Final model* 
Score 
 OR (95% CI) Coef. (SE) OR (95% CI) 
Age (vs. <45 years)     
≥45 and <55 years  1.48 (0.84 – 2.62)    
≥55 and <65 years 1.29 (0.68 – 2.44)    
≥65 years 1.40 (0.52 – 3.74)    
Body mass index (vs. <25 kg/m
2
)     
≥25 and <30 kg/m2  1.58 (0.78 – 3.21)    
≥30 kg/m2 2.70 (1.34 – 5.43)    
Waist circumference (vs. F<80cm/M<94cm)     
F: ≥80 and <88 cm / M: ≥94  and <102 cm 2.82 (1.17 – 6.83) 0.97 (0.45) 2.63 (1.08 – 6.39) 2 (vs. 0) 
F: ≥88 cm / M: ≥102 cm 4.39 (1.97 – 9.83) 1.32 (0.41) 3.75 (1.66 – 8.45) 3 (vs. 0) 
Physical activity (vs. no)     
At least 30 min per day 1.14 (0.69 – 1.89)    
Fruits and vegetables intake (vs. no)     
At least once per day 0.96 (0.59 – 1.54)    
Blood pressure medication (vs. no)     
Yes  3.22 (1.71 – 6.10) 0.97 (0.33) 2.64 (1.37 – 5.09) 2 (vs. 0) 
History of high blood glucose levels (vs. no)     
Yes 3.74 (1.70 – 8.25) 1.18 (0.42) 3.26 (1.43 – 7.43) 2 (vs. 0) 
Family history of T2DM (vs. no)     
Parent, brother, sister or own child 1.87 (1.16 – 3.03) 0.61 (0.25) 1.84 (1.13 – 3.00) 1 (vs. 0) 
* The model was created by backward elimination, keeping variables significantly associated with undiagnosed T2DM. 
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Table VII-3: Diagnostic accuracy of EZSCAN for undiagnosed T2DM: comparison according to different cut-offs 
 
 EZSCAN 
Cut-off 24 26* 34 50 
 Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) 
Sensitivity 78.9% (67.6% – 87.7%) 59.2% (46.8% – 70.7%) 25.4% (15.8% – 37.1%) 16.9% (9.1% – 27.7%) 
Specificity 32.0% (29.5% – 34.4%) 53.5% (50.9% – 56.1%) 85.6% (83.7% – 87.4%) 91.7% (90.1% – 93.1%) 
Positive predictive value 5.4% (4.1% – 7.0%) 5.9% (4.3% – 8.0%) 8.0% (4.8% – 12.4%) 9.2% (4.8% – 15.5%) 
Negative predictive value 96.8% (94.8% – 98.2%) 96.3% (94.8% – 97.5%) 95.8% (94.6% – 96.9%) 95.7% (94.5% – 96.7%) 
Likelihood ratio positive 1.2 (1.0 – 1.3) 1.3 (1.0 – 1.6) 1.8 (1.2 – 2.7) 2.0 (1.2 – 3.5) 
Likelihood ratio negative 0.7 (0.4 – 1.0) 0.8 (0.6 – 1.0) 0.9 (0.8 – 1.0) 0.9 (0.8 – 1.0) 
Diagnostic odd ratio 1.8 (1.0 – 3.1) 1.7 (1.0 – 2.7) 2.0 (1.2 – 3.5) 2.2 (1.2 – 4.3) 
 
* Best cut-off according to Youden’s method. 
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Table VII-4: Diagnostic accuracy of pupil diameters for undiagnosed T2DM 
 
 Scotopic diameter Low-mesopic diameter High-mesopic diameter 
 Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) 
Area under the ROC curve 0.55 (0.49 – 0.62) 0.55 (0.48 – 0.62) 0.52 (0.45 – 0.59) 
Empirical cut-off 4.2 4.4 4.3 
Sensitivity 52.9% (40.4% – 65.2%) 54.4% (41.9% – 66.5%) 52.9% (40.4% – 65.2%) 
Specificity 62.2% (59.6% – 64.7%) 57.4% (54.8% – 60.0%) 52.6% (49.9% – 55.2%) 
Positive predictive value 6.3% (4.5% – 8.6%) 5.8% (4.1% – 7.9%) 5.1% (3.6% – 7.0%) 
Negative predictive value 96.5% (95.1% – 97.6%) 96.3% (94.8% – 97.5%) 95.9% (94.2% – 97.2%) 
Likelihood ratio positive 1.4 (1.1 – 1.8) 1.3 (1.0 – 1.6)  1.1 (0.9 – 1.4)  
Likelihood ratio negative 0.8 (0.6 – 1.0) 0.8 (0.6 – 1.0) 0.9 (0.7 – 1.2) 
Diagnostic odd ratio 1.9 (1.1 – 3.0) 1.6 (1.0 – 2.6) 1.3 (0.8 – 2.0) 
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Table VII-5: Diagnostic accuracy of biothesiometer indicators for undiagnosed T2DM 
 
 Pulp of hallux First metatarsal head Third metatarsal head Fifth metatarsal head 
 Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) 
Area under the ROC curve 0.55 (0.48 – 0.62) 0.58 (0.51 – 0.65) 0.60 (0.53 – 0.67) 0.60 (0.52 – 0.67) 
Empirical cut-off 20 21 21 21 
Sensitivity 33.8% (23.0% – 46.0%) 31.0% (20.5% – 43.1%) 31.0% (20.5% – 43.1%) 32.4% (21.8% – 44.5%) 
Specificity 78.1% (75.8% – 80.2%) 85.7% (83.8% – 87.5%) 85.2% (83.2% – 87.0%) 86.1% (84.2% – 87.8%) 
Positive predictive value 7.1% (4.6% – 10.4%) 9.7% (6.2% – 14.4%)  9.4% (6.0% – 13.9%) 10.4% (6.7% – 15.1%) 
Negative predictive value 96.0% (94.7% – 97.0%) 96.2% (95.0% – 97.1%) 96.1% (94.9% – 97.1%) 96.3% (95.1% – 97.2%) 
Likelihood ratio positive 1.5 (1.1 – 2.2) 2.2 (1.5 – 3.2) 2.1 (1.5 – 3.0) 2.3 (1.6 – 3.3) 
Likelihood ratio negative 0.8 (0.7 – 1.0) 0.8 (0.7 – 0.9) 0.8 (0.7 – 0.9) 0.8 (0.7 – 0.9) 
Diagnostic odd ratio 1.8 (1.1 – 3.0) 2.7 (1.6 – 4.5) 2.6 (1.5 – 4.3) 3.0 (1.8 – 5.0) 
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Table VII-6: Comparisons between risk scores and neuropathy assessment tools for undiagnosed T2DM 
 
Neuropathy assessment 
tools 
 Blood free risk scores 
 FINDRISC LA-FINDRISC 
Peruvian Risk 
Score 
Simplified 
FINDRISC 
aROC* 0.69 (0.64 – 0.74) 0.68 (0.63 – 0.74) 0.64 (0.58 – 0.70) 0.71 (0.66 – 0.76) 
EZSCAN 0.59 (0.53 – 0.66) 0.01 0.02 0.19 0.003 
Scotopic diameter 0.55 (0.49 – 0.62) 0.002 0.006 0.16 < 0.001 
Low mesopic diameter 0.55 (0.48 – 0.62) < 0.001 0.001 0.07 0.001 
High mesopic diameter 0.52 (0.45 – 0.59) < 0.001 0.001 0.01 < 0.001 
Pulp of hallux 0.55 (0.48 – 0.62) 0.002 0.004 0.04 < 0.001 
First metatarsal head 0.58 (0.51 – 0.65) 0.01 0.03 0.16 0.005 
Third metatarsal head 0.60 (0.53 – 0.67) 0.03 0.05 0.28 0.01 
Fifth metatarsal head 0.60 (0.52 – 0.67) 0.03 0.05 0.27 0.01 
 
P-values are shown to detail differences between risk scores and neuropathy assessment devices 
* aROC = Area under the ROC curve 
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Table VII-7: Association between the combination of EZSCAN and blood-free 
risk scores for undiagnosed T2DM 
 
 
 OR (95% CI) 
FINDRISC and EZSCAN  
FINDRISC <11 points, EZSCAN <26 1 (Reference) 
FINDRISC <11 points, EZSCAN ≥26 1.26 (0.54 – 2.95) 
FINDRISC ≥11 points, EZSCAN <26 4.29 (2.01 – 9.14) 
FINDRISC ≥11 points, EZSCAN ≥26 5.38 (2.73 – 10.60) 
LA-FINDRISC and EZSCAN  
LA-FINDRISC <10 points, EZSCAN <26 1 (Reference) 
LA-FINDRISC <10 points, EZSCAN ≥26 1.78 (0.75 – 4.24) 
LA-FINDRISC ≥10 points, EZSCAN <26 4.11 (1.88 – 8.96) 
LA-FINDRISC ≥10 points, EZSCAN ≥26 4.74 (2.29 – 9.80) 
Simplified FINDRISC and EZSCAN  
Simplified FINDRISC <3 points, EZSCAN <26 1 (Reference) 
Simplified FINDRISC <3 points, EZSCAN ≥26 1.59 (0.46 – 5.55) 
Simplified FINDRISC ≥3 points, EZSCAN <26 5.37 (2.03 – 14.23) 
Simplified FINDRISC ≥3 points, EZSCAN ≥26 7.27 (2.83 – 18.69) 
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Table VII-8: Combination of risk scores and EZSCAN: Diagnostic accuracy for undiagnosed T2DM 
 
 EZSCAN combined with... 
 FINDRISC LA-FINDRISC Simplified FINDRISC 
 Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) 
Sensitivity 83.1% (72.3%–91.0%) 85.9% (75.6%–93.0%) 93.0% (84.3%–97.7%) 
Specificity 40.2% (37.7%–42.8%) 36.6% (34.1%–39.1%) 28.3% (25.9%–30.7%) 
Positive predictive value 6.5% (5.0%–8.3%) 6.3% (4.9%–8.0%) 5.2% (2.1%–12.6%) 
Negative predictive value 98.0% (96.5%–98.9%) 98.1% (96.6%–99.1%) 98.8% (97.2%–99.6%) 
Likelihood ratio positive 1.4 (1.2 – 1.6) 1.4 (1.2 – 1.5) 1.3 (1.2 – 1.4) 
Likelihood ratio negative 0.4 (0.3 – 0.7) 0.4 (0.2 – 0.7) 0.2 (0.1 – 0.6) 
Diagnostic odd ratio 3.3 (1.8 – 6.2) 3.5 (1.8 – 6.8) 5.2 (2.1 – 12.6) 
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Table VII-9: Association between the combination of biothesiometer and blood-
free risk scores for undiagnosed T2DM 
 
 
 OR (95% CI) 
FINDRISC and Biothesiometer*  
FINDRISC <11 points, Biothesiometer <21 1 (Reference) 
FINDRISC <11 points, Biothesiometer ≥21 3.51 (1.40 – 8.80) 
FINDRISC ≥11 points, Biothesiometer <21 5.08 (2.73 – 9.44) 
FINDRISC ≥11 points, Biothesiometer ≥21 8.43 (4.00 – 17.76) 
LA-FINDRISC and Biothesiometer*  
LA-FINDRISC <10 points, Biothesiometer <21 1 (Reference) 
LA-FINDRISC <10 points, Biothesiometer ≥21 3.16 (1.20 – 8.35) 
LA-FINDRISC ≥10 points, Biothesiometer <21 3.64 (1.96 – 6.75) 
LA-FINDRISC ≥10 points, Biothesiometer ≥21 6.85 (3.30 – 14.22) 
Simplified FINDRISC and Biothesiometer*  
Simplified FINDRISC <3 points, Biothesiometer <21 1 (Reference) 
Simplified FINDRISC <3 points, Biothesiometer ≥21 2.51 (0.64 – 9.87) 
Simplified FINDRISC ≥3 points, Biothesiometer <21 5.13 (2.29 – 11.51) 
Simplified FINDRISC ≥3 points, Biothesiometer ≥21 13.15 (5.40 – 32.00) 
 
 * The third metatarsal head was used for analyses 
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Table VII-10: Combination of risk scores and biothesiometer: Diagnostic accuracy for undiagnosed T2DM 
 
 Biothesiometer* combined with... 
 FINDRISC LA-FINDRISC Simplified FINDRISC 
 Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) 
Sensitivity 78.9% (67.6%–87.7%) 78.9% (67.6%–87.7) 90.1% (80.7%–95.9%) 
Specificity 58.9% (56.3%–61.5%) 52.5% (49.9%–55.1%) 39.3% (36.7%–41.9%) 
Positive predictive value 8.7% (6.6%–11.1%) 7.6% (5.8%–9.8%) 5.9% (2.7%–12.8%) 
Negative predictive value 98.3% (97.1%–99.0%) 98.0% (96.8%–98.9%) 98.8% (97.5%–99.5%) 
Likelihood ratio positive 1.9 (1.7 – 2.2) 1.7 (1.5 – 1.9) 1.5 (1.4 – 1.6) 
Likelihood ratio negative 0.4 (0.2 – 0.6) 0.4 (0.3 – 0.6) 0.3 (0.1 – 0.5) 
Diagnostic odd ratio 5.4 (3.0 – 9.5) 4.1 (2.3 – 7.3) 5.9 (2.7 – 12.8) 
 
  * The third metatarsal head was used for analyses 
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Chapter VIII: Discussion of Findings 
 
There is a need to identify individuals with undiagnosed T2DM. Despite 
international recommendations, the application of blood markers, such as fasting 
glucose, oral glucose tolerance test or glycated haemoglobin, will not always be 
affordable in low- and middle-income countries such as Peru, as laboratory and 
human resources are needed to obtain appropriate results. Moreover, even if blood 
markers are used, stepwise approaches (using risk score or non-invasive methods 
including neuropathy assessment tools) could be a pragmatic and efficient way to 
reduce the number of invasive test needed for detecting T2DM cases.  
Thus, the inclusion of alternative methods such as blood-free risk scores needs to 
be evaluated in these contexts. In addition, there are many devices used to assess 
autonomic dysfunction, although most require well-trained staff. There are, 
however, some devices (EZSCAN, pupillometer and biothesiometer) that can be 
used to evaluate neuropathy dysfunction and that easy to use, are not time 
demanding, and do not require fasting. These devices may have a role in T2DM 
screening.  
A cross-sectional population-based study was conducted to assess the diagnostic 
accuracy of existing blood-free risk scores, mainly focused on the FINDRISC and 
the Peruvian Risk Score, and neuropathy assessment tools, mainly the EZSCAN, 
pupillometer and biothesiometer, for undiagnosed T2DM at the population level. 
To accomplish this, a random sample of more than 1500 participants was assessed 
using tablet-based questionnaires, anthropometric markers and blood samples to 
respond our hypotheses.  
In this chapter, the discussion of the findings overall are performed in the context 
of previous existing studies. 
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8.1  Main findings 
This study assessed the diagnostic accuracy of four blood-free risk scores 
(FINDRISC, LA-FINDRISC, the Peruvian Risk Score, and the simplified 
FINDRISC) and three different neuropathy assessment tools (EZSCAN, 
pupillometer and biothesiometer) for detecting cases of undiagnosed T2DM. 
Although we anticipated a sensitivity of at least 75% compared to OGTT as 
the gold standard, none of the tools or risk scores reached such sensitivity. A 
basic Boolean algebra combination using disjunction terms (OR), instead of 
conjunction terms (AND), of blood-free risk score models and neuropathy 
assessment tools was necessary in order to reach the proposed 75% 
sensitivity. 
 
8.2  Diagnostic accuracy of risk scores for undiagnosed T2DM 
8.2.1 Summary 
Our findings demonstrated that the diagnostic accuracy of the FINDRISC, 
LA-FINDRISC and the Peruvian Risk Score for undiagnosed T2DM were 
similar. However, a simplified version of the FINDRISC, including waist 
circumference, blood pressure treatment, history of high blood glucose levels, 
and family history of T2DM, could perform similar to the FINDRISC and 
LA-FINDRISC, but better than the Peruvian Risk Score. These four variables 
are easy to obtain in clinical practice and thus, can be implementable for 
detecting undiagnosed T2DM at the population level.  
8.2.2 Comparison with previous studies  
There are many risk scores created for detecting cases of undiagnosed T2DM 
worldwide, though many of them are for Caucasian [37-39] and Asian 
populations [56, 57, 123]. These risk scores can be blood-free models or can 
contain blood results such as glycated haemoglobin, fasting glucose or lipid 
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markers [26, 36, 124]. However, the interest of this thesis is focused on 
blood-free risk scores for undiagnosed T2DM. 
Among the existing blood-free risk models, the FINDRISC is a well-known 
score created initially for incident T2DM cases, but currently is used for 
T2DM screening [40]. However, previous experience has established that a 
risk score needs to be adapted, validated, or calibrated in the population 
where this is planned to be applied as prevalence and distribution of outcomes 
and risk factors are not similar between settings [125]. 
The FINDRISC had a moderate performance for detecting cases of 
undiagnosed T2DM in Peruvian population. Our results were similar to 
previous studies in Latin America [45, 113], although the diagnostic accuracy 
was lower than in Asian [111] or European [40, 126] populations. Moreover, 
according to our logistic regression model, the original FINDRISC can be 
simplified to only four variables to slightly improve the diagnostic accuracy 
but also facilitate its application and implementation. 
Of note, and in contrast with many other risk models [37, 38, 40, 41, 127-
131], age was not an independent factor associated with undiagnosed T2DM 
in our simplified FINDRISC. Age has been described as a risk factor related 
to type 2 diabetes mellitus with an increasing age associated with increasing 
probability of T2DM. However, only few risk scores has not included age in 
the final model [132-134]. Apparently, the probability of having undiagnosed 
T2DM can be considered similar between age groups in our population 
despite our study included a wide range of participant ages (i.e. from 30 to 69 
years). Moreover, the Peruvian Risk Score included age in the final model 
[46]. A post-hoc analysis of our data showed that in a crude model, an 
increase of one year in age was associated with an increase of 2% in the 
probability of having undiagnosed T2DM (p <0.05); but, in the multivariable 
model, this estimate dropped to 1% and was not significant (p = 0.39). This 
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finding can be important as apparently our results suggest that all individuals 
over 30 years should be screened, at least with a risk score, for T2DM. 
 
8.3 Neuropathy assessment tools for undiagnosed T2DM 
Three different neuropathy assessment tools (EZSCAN, pupillometer and 
biothesiometer) were assessed for detecting cases of undiagnosed T2DM. In 
the following lines, a discussion about the diagnostic accuracy of each of the 
devices as well as a comparison with existing literature is performed. 
 
8.3.1  Diagnostic accuracy of EZSCAN for undiagnosed T2DM 
Summary 
According to our study findings, the diagnostic accuracy of the EZSCAN was 
not as good in our population as expected. The trade-off between sensitivity 
and specificity using the Youden index did not reach the hypothesised 
sensitivity to detect cases of undiagnosed T2DM. Despite of this, the 
EZSCAN had, among the assessed neuropathy assessment tools, one of the 
best diagnostic accuracy for detecting cases of undiagnosed T2DM. 
Comparison with previous studies 
The EZSCAN has been proposed as an appropriate tool to detect individuals 
at risk of T2DM [100] and also cases of pre-diabetes and dysglycaemia [75, 
77, 135]. A relatively recent systematic review and meta-analysis [63] 
reported an EZSCAN sensitivity of 72%, but analyses only included 
information of studies from China, India and Mexico, countries with a higher 
prevalence of T2DM compared to Peru. Moreover, two of the four studies 
included in the meta-analysis reported a sensitivity ≥75% [75, 77], but as 
there is always a trade-off between sensitivity and specificity, it seems likely 
that these two latter studies sacrificed specificity to detect more cases.   
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Only one study from the systematic review was conducted using a 
population-based sample [75], whereas the other three studies enrolled 
individuals from routine health checkups. Besides, one study used fasting 
glucose as the gold standard instead of OGTT [78]. The update search of the 
systematic review found another study [83], but also with selection bias as 
participants were recruited for health check-ups, and because of that, results 
did not change markedly.  
In post-hoc analysis (HS-ROC), when our study findings were included in the 
meta-analysis (i.e. a total of 6 studies were analysed instead of the original 4 
and the updated version of 5 studies), summary sensitivity and specificity 
were 70.8% (95%CI: 62.5% – 78.0%) and 61.6% (95%CI: 49.4% – 72.5%), 
respectively. In addition, when this meta-analysis was conducted excluding 
the only study using fasting glucose [78], the sensitivity and specificity were 
70.2% (95% CI: 60.1% - 78.6%) and 59.7% (95% CI: 45.5% - 72.4%), 
respectively. These post-hoc results suggest than the diagnostic accuracy of 
the EZSCAN is not the same when evaluated using a population level 
approach compared to clinical settings.  
 
8.3.2 Diagnostic accuracy of pupillometry for undiagnosed T2DM 
Summary 
Three different pupil diameters, part of the response of pupil to light, were 
assessed in this study. Our findings indicate that none of the pupil 
measurements was different between individuals with and without T2DM; and 
for instance, none of them had adequate diagnostic accuracy for undiagnosed 
T2DM. 
Comparison with previous studies 
There are many studies reporting differences in several pupil measurements 
between individual with and without T2DM [136-141]. There are also many 
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techniques and devices utilised to determine pupil diameters, including the use 
of pupillometer [85, 86, 89-91, 93, 140], pupillography [84, 87, 137], infrared 
light reflex technique [88, 136, 139], photographic camera [141, 142], and 
pupil gauge [138]. Thus, there is also many pupil measurements reported, 
depending basically upon the utilization of static or dynamic pupillometry. 
The measurement of the pupil diameter is one of the most common parameters 
used to compare individuals with and without T2DM [85, 87, 93, 138] and has 
been used to predict the risk of diabetic neuropathy and cardiovascular 
autonomic neuropathy [85, 86, 88, 91, 141] more than for undiagnosed T2DM 
screening. Previous studies have reported obvious differences in pupil 
parameters between T2DM and non-T2DM subjects. These differences were 
not found in this study; probably because more severe cases (i.e. those with 
longer time of disease) were excluded and only undiagnosed T2DM (i.e. 
newly-diagnosed or screen-detected) cases were analysed. In the same line, 
there were significant differences in our three pupil diameters in the pilot study 
but not in our population study. This finding might be because T2DM cases in 
the pilot study were those who had confirmed diagnosis of type 2 diabetes 
mellitus (two glycaemia measures ≥ 126 mg/dL over a period of 3 years).  
Similarly, Kuroda et al [87] reported no differences in pupil diameter and 
pupil area between controls without T2DM and borderline T2DM, but these 
both categories were statistically different from overt non-insulin dependent 
T2DM cases. In this latter study, a borderline T2DM case was defined “by the 
results of a 50 grams oral glucose tolerance test and the criteria set out by the 
Japanese Diabetic Society” [87], a category almost comparable to the 
definition of newly-diagnosed T2DM. Thus, these findings suggest that, 
although there are some pupil changes due to glucose metabolism disorder 
from the beginning of the disease, these changes may be so small they cannot 
be detected by a static pupillometer. 
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To my knowledge, only one study reported the use of pupil indicators, utilizing 
dynamic pupillometry, as a screening tool of T2DM. Lerner et al found that 
diagnostic accuracy of several pupil measurements were fair enough for 
T2DM screening (area under the ROC curve ≥ 0.60), including pupil diameter, 
amplitude of pupil reaction, and constriction ratio [20]. However, cases with 
T2DM were not undiagnosed but instead a combination of patients with 
T2DM from healthcare facilities and general population defined using OGTT. 
This definition could have an impact on the differences reported as only 5% of 
the general population had more than 10 years of disease compared to 46% in 
the hospital-based group. What is more, the control group was defined in a 
community setting, which can increase the probability of finding differences 
between T2DM and non-T2DM groups. 
 
8.3.3 Diagnostic accuracy of biothesiometer for undiagnosed T2DM 
Summary 
As evaluated by the c-statistic as well as sensitivity, none of the vibration 
perception thresholds in the four foot areas was good enough to detect cases of 
undiagnosed T2DM. Thus, the biothesiometer alone could not be considered as 
an adequate screening tool; however, given their specificity, they could be 
used to discard T2DM. 
Comparison with other studies 
Biothesiometer is a device routinely used for peripheral neuropathy screening 
in patients with T2DM [96, 115, 116]. Its performance for detecting cases of 
large nerve fibre dysfunction in lower extremities has been previously 
described as superior to the tuning fork and the 10-g monofilament [143]; 
however, to our knowledge, it has not been used for detecting cases of 
undiagnosed T2DM.  
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Some studies have reported the presence of peripheral neuropathy and 
abnormal vibration perception threshold among cases of undiagnosed T2DM. 
For example, in a study conducted in India, about 30% of participants with 
undiagnosed T2DM had peripheral neuropathy and almost 45% had abnormal 
vibration perception threshold [107]. However, in this latter manuscript, a 
newly diagnosed T2DM case was defined as those individuals with a diagnosis 
of <6 months at the moment of the clinical evaluation. In addition, a cut-off of 
>9 mV in any of the first toes was used to define a participant as having 
abnormal vibration perception threshold. On the other hand, another study 
reported the presence of peripheral neuropathy among newly-diagnosed T2DM 
cases being lower than 10% [144], but only using monofilament and tuning 
fork for diagnosis.  
Studies suggest that peripheral neuropathy in T2DM is multifactorial, but the 
exact causes are not completely understood [104]. Currently, there are enough 
proofs to believe that oxidative and inflammatory stress can play an important 
role in the nerve cells damage, even when an individual has metabolic 
syndrome [145, 146]. Thus, a cascade of reactions with the subsequent nerve 
fibre loss is present even before having T2DM diagnosis [147]; but, 
apparently, this damage cannot be detected by a neuropathy assessment tool as 
the biothesiometer. 
 
8.4 Combination of risk scores and neuropathy assessment tools  
8.4.1 Summary 
Based on our findings, the combination of the simplified FINDRISC with the 
EZSCAN or biothesiometer improved sensitivity over 90%, without affecting 
the area under the ROC curve, but with reduced specificity. However, the 
combination of the original FINDRISC and biothesiometer had a sensitivity 
≥75% as originally proposed, and the specificity was close to 60%. 
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8.4.2 Comparison with previous studies 
According to literature, only one study assessed the potential benefit of adding 
a neuropathy assessment tool to a risk score. In a study conducted in China, 
using a population-based sample, a risk model was created using age, body 
mass index, family history of T2DM, history of cardiovascular disease, 
systolic blood pressure, diastolic blood pressure, high-density lipoprotein 
(HDL) cholesterol, triglycerides, and women who delivered a giant baby or 
who were diagnosed with gestational diabetes mellitus, and then combined 
with the EZSCAN to detect cases of undiagnosed T2DM [75]. The area under 
the ROC curve for the risk model without EZSCAN was 0.68 (95% CI: 0.66 – 
0.69), but including EZCAN only slightly improved (0.70; 95% CI: 0.69 – 
0.72), reaching similar values as our proposed EZSCAN and FINDRISC 
combination.  
A different report described a two-step approach for incident T2DM cases 
[118]. The authors used the San Antonio Diabetes Prediction Model as the 
initial screening, and then used the 1-hour plasma glucose after 75-grams 
OGTT. With this combination they demonstrated an increasing trend in the 
risk of developing T2DM when evaluated in two different cohort studies, with 
a sensitivity of 78% and a specificity of 77%. Similar to our findings, our 
model using a combination of the FINDRISC and the biothesiometer showed 
an increased sensitivity for detecting cases of undiagnosed T2DM, with a 
relatively acceptable specificity (Table VII-6).  
All these results suggest that, similar to blood markers (FG, 2-hour glucose 
tolerance test or HbA1c), T2DM cannot be easily detected by using one risk 
score model or one neuropathy assessment tool, but instead different tests 
seems to detect different T2DM cases. Recently, a paper reported that it was 
possible to create different subgroups of T2DM cases according to disease 
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progression [148]. For instance, results provided by neuropathy assessment 
tools can be linked to the risk of complications in these subgroups. 
According to the National Institute for Health and Clinical Excellence (NICE) 
guidelines [149], the use of non-invasive screening tools is recommended to 
identifying individuals at high risk of T2DM, and these screening tools can be 
undertaken as a self-assessment or as opportunistic assessment in clinical 
practice. Besides, the utilization of a multi-step approach may increase the 
response rate to the invitation to T2DM screening, reducing the number of 
tests needed for a definite diagnosis [27]. Thus, the combination of the 
FINDRISC and biothesiometer might help to identify individuals with T2DM. 
 
8.5 Prevalence of T2DM and undiagnosed T2DM 
8.5.1 Summary 
A T2DM prevalence of 11% of was found in this study. Out of all the cases 
with T2DM, 60% of individuals were aware of their diagnosis, and hence, 
40% had undiagnosed T2DM. 
8.5.2 Comparison with previous studies 
The International Diabetes Federation estimates that between 38% and 69% of 
individuals with T2DM are unaware of their diagnosis [5]. Previous studies, 
conducted in low- and middle-income countries, have reported similar results 
[150-152]. For example, Shen et al reported a prevalence awareness of 80% in 
South Asia and Latin America, whereas Africa had the lowest awareness 
(66%) [151]. Our results in a semi-urban setting are lower than those reported 
in Africa or those in urban settings as described in Argentina and Chile [150]. 
For example, a previous review reported that unawareness in rural and 
semiurban areas can reach values close to 100% [153]; pointing out the need to 
have appropriate strategies to reduce the burden of T2DM unawareness. 
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Chapter IX: Relevance of the Findings 
 
In this final chapter, a discussion of the strengths and limitations of this study as 
well as the relevance and implications for research are discussed. In addition, 
further research steps and conclusions are also presented. 
 
9.1 Strengths of the study 
- This study is the first study to my knowledge to use oral glucose tolerance 
test (OGTT) at the population level in Peru. The use of OGTT is time 
consuming and expensive in resource-constrained settings but it was needed 
to avoid verification bias [154]. The use of OGTT demanded appropriate 
logistics to guarantee adequate results. 
- A random sample of participants taken from general population and using 
the most updated census in the area was enrolled for this study. In addition, 
a sex-stratified sample was used to guarantee an appropriate and 
comparable number of individuals from both sexes. 
- Conduction of a pilot study to optimize the fieldwork activities for the 
larger study. Thus, the pilot study provided information to organize and 
structure our research activities using the two hours required by the OGTT. 
- Good response rates: more than 75% of invited participants were enrolled in 
the study. In addition, among the participants enrolled, almost all, but three, 
completed all the study procedures, including questionnaires, measurements 
and blood sampling. 
- High quality data generated using open-source software (ODK) and tablet-
based formats which guaranteed low rates of missing values and 
inconsistencies. In addition, the evaluation of three different neuropathy 
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assessment tools and well-established risk score models was conducted 
using standardised procedures.  
- Analysis conducted under standard international recommendations and 
guidelines: Standard for Reporting of Diagnostic Accuracy Studies 
(STARD) and the Transparent Reporting of a Multivariable Prediction 
Model for Individual Prognosis or Diagnosis (TRIPOD). 
 
9.2 Limitations of the study 
- Despite of the random sampling used, selection bias may have arisen as 
only one Peruvian region, with the highest prevalence of obesity and 
T2DM, was selected and evaluated for this study. As pointed out above, 
prevalence of the outcome as well as distribution of risk factors are not 
similar between settings [125], and can play an important role in the 
validation and especially the calibration of risk scores. In addition, as 23% 
of contacted individuals rejected participation in the study, participation 
bias may be another issue limiting generalisation of our findings. However, 
our results, especially those related with prevalence and awareness, are very 
similar to previous studies in the region [17, 151]. Although these two 
biases can have an impact on the generalization of results, our study adds 
value to previous findings by using OGTT as the gold standard for 
undiagnosed T2DM. 
- Some desirability and recall bias may be present especially in questions 
about lifestyle behaviours. For example, more than two thirds participants 
reported being physically active (i.e. exercise for at least 30 minutes per 
day) and almost half of them reported consuming fruits and vegetables at 
least once a day. These questions were included as the original FINDRISC, 
not using a validated scale. When compared to the International Physical 
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Activity Questionnaire (IPAQ), only a third of the population has high 
levels of physical activity compared to two thirds of the FINDRISC item. 
- Misclassification may be another problem in the study as only one test 
(OGTT) was carried out instead of the two tests (OGTT, fasting glucose or 
HbA1c) required for confirmation as recommended in guidelines [7]. Given 
the high number of participants enrolled in this study, as in other reports 
with huge sample size [155-157], it is very difficult to conduct population-
based studies using two tests for confirmation of T2DM.  
- Although the sample was originally stratified by sex, sample size was not 
enough to guarantee the evaluation of risk scores and neuropathy 
assessment tools by sex. As prevalence of risk factors was markedly 
different between sexes, further studies are needed to assess the diagnostic 
performance of the scores and devices used in the present study. 
- Our regression models were created based on the idea of risk stratification 
instead of individualization [134]; therefore, some variables (BMI and waist 
circumference, but also results of neuropathy assessment tools) were 
categorised instead of being kept as numerical in the risk score. Our original 
idea was to develop a simple score for detecting cases of undiagnosed 
T2DM as in the original FINDRISC instead of a complicate algorithm; thus, 
our score or combination of scores can easily be implemented. In addition, 
the simplified version of the FINDRISC was developed with the data of this 
study, and not external validation was conducted. This could explain why 
diagnostic accuracy of this version of the FINDRISC was better than other 
scores. Therefore, further validation and evaluation is required. 
 
9.3 Study relevance and implications 
9.3.1 Blood-free risk scores and undiagnosed T2DM 
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The implementation of the FINDRISC in our population might be useful to 
detect cases with undiagnosed T2DM. The advantage of the FINDRISC lies 
on its self-report nature (six items with yes/no responses) and the presence of 
two anthropometrical measurements (body mass index and waist 
circumference). Our simplified version of the FINDRISC contains only three 
self-reported items and waist circumference, an anthropometric marker that is 
easy to obtain, making this score implementable in clinical practice. The 
simplified version of the FINDRISC included waist circumference instead of 
body mass index as in the Peruvian Risk Score, as the first one provides a 
better indicator of accumulation of visceral fat and glucose metabolism 
deregulation [59]. As one of the main barriers to the uptake of risk scores by 
health practitioners includes the lack of practicality of using the scores and 
evaluate their components [158], a short version of the FINDRISC might 
facilitate its implementation despite of the use of waist circumference instead 
of body mass index. A recent systematic review reported that financial 
constraints were one of the main barriers to T2DM screening in health system 
[159], issue that can be easily overcome by using a risk score. Moreover, the 
FINDRISC and the simplified FINDRISC can be easily self-administered. 
The use of risk scores is only partly supported by different reports [160, 161] 
as there is no evidence of cardiovascular benefit. These recommendations are, 
however, based on the results of two trials [162, 163]. Although both trials 
had more than 10 years of follow-up, this can be a short time as the impact of 
a lifestyle intervention (Da Qing Diabetes Prevention Study) on all-cause and 
cardiovascular mortality of individuals with impaired glucose tolerance was 
detectable after 23 years of follow-up [164]. Thus, the benefit of T2DM 
screening needs to be further evaluated. 
On the other hand, the potential effect of lifestyle interventions has only been 
demonstrated on those with impaired glucose tolerance and not among those 
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with impaired fasting glucose alone [165, 166]. However, individuals with 
undiagnosed T2DM require lifestyle interventions but also medication to 
avoid or delay complications. 
In 2016, the Peruvian Ministry of Health published the Guide of Clinical 
Practice for Diagnosis, Treatment and Control of Type 2 Diabetes Mellitus in 
Primary Care. In that guideline, there is no recommendation about the use of 
risk scores for T2DM screening, but, it recommends using fasting plasma 
glucose among adults between 40 and 70 years with overweight or obesity 
[167]. The FINDRISC, and also the simplified FINDRISC, appears then as 
good alternatives to screen individuals, especially in areas (semiurban and 
rural settings) where laboratory (fasting glucose or other blood markers) or 
human resources are not always available. It is still pending, nonetheless, to 
estimate the cost of a two-step approach for detecting cases of undiagnosed 
T2DM in resource-constrained settings, although some evidence in favour of 
multi-step approach exists [27]. 
9.3.2 Neuropathy assessment tools and undiagnosed T2DM 
Among all the neuropathy assessments tool assessed in this study, the 
biothesiometer and the EZSCAN are the most likely to have some useful role 
in the detection of undiagnosed T2DM cases. However, based on sensitivity, 
the EZSCAN would perform better than the biothesiometer. 
The biothesiometer, a device used to evaluate the vibration sensation, is very 
simple to use applying from 0 to 50 mV to a probe to increase vibration 
intensity especially in foot. As the test can be affected by individual’s age, 
readings over 25 are considered as diagnostic of neuropathy [115, 116]. 
Although the pulp of hallux (toe) has been described as the best area to 
conduct the evaluation [116], our study reported that the third (or the fifth) 
metatarsal head has the best diagnostic accuracy for undiagnosed T2DM. On 
the other hand, the EZSCAN is a device based on the application of direct 
121 
 
current through nickel electrodes on palms of the hands and soles of the feet 
due to the fact that sweat glands are very numerous in these areas [168]. Thus, 
the process of evaluation with EZSCAN is fast and, hence, only requires a 
short time with bare feet. Its described reproducibility makes this device an 
acceptable option as a screening tool for T2DM [100].  
The impact of the implementation of these two neuropathy assessment tools to 
evaluate general population for looking cases of T2DM can be better 
appreciated using an example. In the case of the EZSCAN, using the cut-off of 
26 as suggested by our analysis, from 1000 participants assessed, a total of 479 
would be classified as having undiagnosed T2DM, with the subsequent 
detection of 65 cases and missing 45 (i.e. assuming a prevalence of T2DM of 
11%). Thus, almost half of the participants (48%) assessed by EZSCAN will 
require a second test (i.e. fasting glucose, HbA1c or OGTT) to confirm 
EZSCAN findings. On the other hand, if we used a cut-off of 24 (to improve 
sensitivity), from 1000 screened subjects, 87 would be detected and only 23 
would be missed. However, 692 (about 70%) individuals will require a second 
test to confirm T2DM. Thus, the change in the EZSCAN cut-off would impose 
an increment of 45% in the number of subjects to be tested after screening with 
the subsequent increase of costs and resources, but detecting 33% more T2DM 
cases. In the case of the biothesiometer, and using the vibration perception 
threshold of the third metatarsal head, from 1000 participants assessed, a total 
of 106 individuals would be classified as having undiagnosed T2DM, with the 
subsequent detection of only 34 cases and missing 76 (i.e. assuming a 
prevalence of T2DM of 11%). Thus, about 17% of the total participants 
assessed by the biothesiometer will require a second test.  
9.3.3 Combination of risk scores and neuropathy assessment tools 
One of the forms to improve diagnostic accuracy of different tests is the 
combination of them in a two-step approach [27, 118]; however, a balance 
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between sensitivity and specificity is required. According to study results, the 
combination of FINDRISC and biothesiometer (vibration perception threshold 
in the third metatarsal head) can improve the diagnostic accuracy of risk scores 
and neuropathy assessment tools alone. The other combinations would require 
a confirmatory test in almost two thirds of the population instead of <50% as 
the proposed combination. 
Again, an example can clarify the benefits of this approach (See Table IX-1 for 
details). If 1000 individuals were evaluated using a combination of FINDRISC 
and biothesiometer, 87 cases would be detected and 23 would be missing, 
assuming a T2DM prevalence of 11%. In addition, only 453 individuals would 
be classified as being at risk of T2DM (only 45% of the 1000 participants 
originally assessed). Thus, a confirmatory test (i.e. fasting glucose or glycated 
haemoglobin) would be carried out in <50% of the participants. If for example, 
a combination of FINDRISC and EZSCAN is used to detect cases of T2DM, a 
total of 625 individuals would need a confirmatory test (Table IX-1), an 
increment of 172 individuals with their respective costs and logistics, to detect 
only four more cases. 
Regardless of whether biothesiometer or the EZSCAN is used, new studies are 
required to evaluate the cost for detecting one more case of T2DM in Peruvian 
and other resource-constrained settings. Despite the fact that a recent 
systematic review has reported that using a multi-step approach reduces the 
number needed to have the final diagnostic test for a definite diagnosis [27], 
and for instance, should reduce individual and health system expenses, the 
inclusion of the cost of neuropathy assessment tools needs to be included in 
estimations. Overall, biothesiometer is cheaper than the EZSCAN (USD 1500 
vs. USD 18000, respectively), but the lifetime of these devices needs to be also 
considered. 
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Finally, it can be argued that positive and negative likelihood ratios found in 
this study are close to those related to minimal change in the likelihood of 
disease, as values >10 for LR+ and <0.1 for LR- are expected in this kind of 
studies [169]. However, the evaluation of such a kind of diagnostic test was 
not part of this study, instead of trying to find a real and implementable 
algorithm to detect cases of undiagnosed T2DM. 
Whether a T2DM screening program is implemented, it is relevant to discuss 
positive and negative aspects of that decision. Among the positive aspects, a 
screening program as that proposed in the present study will reduce costs and 
can be massively implemented. Using scores and neuropathy assessment 
devices will reduce staff training (i.e. the EZSCAN is almost an automatic 
process) as well as the need of costs related to confirmation tests [170]. In 
addition, as pointed out by Khunti et al [27], responses rates will improve 
response rate to T2DM screening. Nevertheless, negative aspects need to be 
also highlighted. It has been described anxiety and mental health issues as 
there could be a delay in obtained final results [171, 172]. Time between result 
of the screening and confirmatory test should be reduced to the minimum to 
guarantee patient health. Although a trial has reported that early provision of 
test results did not have impact on patient reassurance [173], delays have been 
also related to abandon and lost to follow-up as lack of disease awareness is 
common especially in resource-constrained (i.e. rural or semiurban) settings. 
 
9.4 Further steps in research 
Potential areas for subsequent research derived from this study include: 
- The evaluation of costs incurred when implementing a combination of risk 
scores and neuropathy assessment tools for detecting cases of T2DM. 
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- Determination of the lapse required for re-assessing participants, using our 
approach compared to risk scores alone or other combinations. Many 
studies are based on only one screening assessment and the potential impact 
on predicting T2DM.  
- Implementation of the FINDRISC, neuropathy assessment tools, and 
combination of them for T2DM screening in primary healthcare facilities, 
and the potential impact on T2DM awareness, treatment, and control, as 
well as the incidence of micro- and macro-vascular complications, 
including cardiovascular death. 
- The implementation of appropriate intervention strategies to reduce the 
burden of undiagnosed T2DM in resource-constrained settings, but also, to 
reduce complications, and improve treatment adherence. 
 
9.5 Overall conclusions 
The results of this thesis provide relevant information about the potential 
benefit of using risk score models, neuropathy assessment tools, and their 
combination to detect cases of undiagnosed T2DM. The combination of the 
FINDRISC score with the vibration perception threshold, obtained from the 
third metatarsal head, using a biothesiometer, can improve sensitivity of the 
FINDRISC and biothesiometer alone, without affecting specificity or the area 
under the ROC curve.  
This thesis also confirmed the high burden of T2DM in Peru with 40% of 
participants unaware of their diagnosis. Our proposed approach could help 
tackle the burden of T2DM in semiurban and resource-constrained settings. 
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Table IX-1: Assessment of combinations of risk scores and neuropathy assessment tools 
 
 
Combination Sensitivity Specificity At high risk of T2DM 
T2DM cases 
detected 
Subjects 
without T2DM 
EZSCAN with…      
FINDRISC  83.1% 40.2% 625 (62.5%) 91 (9.1%) 356 (35.6%) 
LA-FINDRISC  85.9% 36.6% 658 (65.8%) 94 (9.4%) 326 (32.6%) 
Simplified FINDRISC 93.0% 28.3% 740 (74.0%) 102 (10.2%) 252 (25.2%) 
Biothesiometer with…      
FINDRISC  78.9% 58.9% 453 (45.3%) 87 (8.7%) 524 (52.4%) 
LA-FINDRISC  78.9% 52.5% 510 (51.0%) 87 (8.7%) 467 (46.7%) 
Simplified FINDRISC 90.1% 39.3% 639 (63.9%) 99 (9.9%) 350 (35.0%) 
 
All the estimates were calculated assuming that 1000 individuals were screened and a prevalence of 11% of T2DM. 
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Objective. To develop and validate a risk score for detecting cases of undiagnosed diabetes in a resource-constrained country.
Methods. Two population-based studies in Peruvian population aged ≥35 years were used in the analysis: the ENINBSC survey
(𝑛 = 2,472) and the CRONICAS Cohort Study (𝑛 = 2,945). Fasting plasma glucose ≥7.0mmol/L was used to diagnose diabetes
in both studies. Coefficients for risk score were derived from the ENINBSC data and then the performance was validated using
both baseline and follow-up data of the CRONICAS Cohort Study. Results.The prevalence of undiagnosed diabetes was 2.0% in the
ENINBSC survey and 2.9% in the CRONICAS Cohort Study. Predictors of undiagnosed diabetes were age, diabetes in first-degree
relatives, andwaist circumference. Score values ranged from0 to 4, with an optimal cutoff≥2 and had amoderate performancewhen
applied in theCRONICASbaseline data (AUC=0.68; 95%CI: 0.62–0.73; sensitivity 70%; specificity 59%).Whenpredicting incident
cases, the AUC was 0.66 (95% CI: 0.61–0.71), with a sensitivity of 69% and specificity of 59%. Conclusions. A simple nonblood
based risk score based on age, diabetes in first-degree relatives, and waist circumference can be used as a simple screening tool for
undiagnosed and incident cases of diabetes in Peru.
1. Introduction
As of 2014, the worldwide prevalence of type 2 diabetes
mellitus (T2DM) was estimated to be 9% among adults aged
≥18 years with great impact on mortality, particularly in
low- and middle-income countries (LMIC) [1, 2]. Moreover,
globally, approximately 25% to 75% of diabetes cases remain
undiagnosed [3, 4], until further complications, especially at
the macro- and micro-vascular level, manifest clinically. In
Latin America, the proportion of undiagnosed diabetes at the
population level ranged from 33% to 50% [5].
An important strategy to prevent or delay T2DM com-
plications is the early identification of those with undiag-
nosed diabetes; yet, universal screening for diabetes at the
population level is not practical in resource-limited settings.
The American Diabetes Association recommends the use of
glucose test as T2DM screening in people with overweight
and obesity as well as in those with other risk factors [6].
As a result, risk assessment scores have been developed
to address this problem in a simple and inexpensive way.
Most of the available algorithms for diabetes screening have
been developed in Caucasian [7–9] and Asian populations
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[10–13] and very few in other ethnic groups [14, 15]. To date,
one diabetes risk score has been developed and validated
in Latin America so far which was derived from one urban
area in Brazil [16], thus bearing limited generalizability to the
wider region. Furthermore, it is well established that before
adopting existing risk scores as screening tools in different
populations and ethnic groups, their performance needs to
be evaluated, calibrated, or validated in local settings [17].
As the American Diabetes Association, the Peruvian
Ministry ofHealth recommends diabetes screening in general
population with fasting glucose in adults aged 40 to 70 years
with risk factors. However, fasting glucose is not always
available in primary care settings, especially in semiurban and
rural areas. As a result, a major challenge to be overcome in
many countries is the implementation of a simple, fast, and
laboratory-free based screening method.
Consequently, we aimed to develop a simple laboratory-
free risk score to identify people with undiagnosed diabetes
and incident diabetes in Peru, a Latin American country that
spans coastal, Andean, and rainforest settings. In order to do
so, this work benefited from two large-scale population-based
surveys: the first one, representative at the national level, was
used to develop the score, and the second one, a cohort study,
was utilized for external validation.
2. Methods
2.1. Study Design and Participants. Two different population-
based studies were used in this analysis. The National Survey
of Nutritional and Biochemical Indicators for Noncommu-
nicable Diseases (ENINBSC in Spanish), conducted by the
Peruvian National Institute of Health [18], was used to
develop our predictive model. This was complemented with
the CRONICAS Cohort Study [19], whose baseline and
longitudinal information was used to validate the risk score.
The ENINBSC is a national population-based survey
carried out in Peru between August 2004 and April 2005,
designed to estimate the prevalence of hypertension, type
2 diabetes mellitus, and other risk factors for noncom-
municable diseases at the national and regional level [18].
Potential participants were those aged ≥20 years, habitual
residents in the study area, and able to provide consent for
their participation in the study. Pregnant women and those
currently breastfeeding were excluded from the study. As
per design, the ENINBSC sample was stratified according to
Peru’s five major regions of the country: Lima, rest of the
Coast, urban Highlands, rural Highlands, and jungle. In each
stratum, cluster of blocks were chosen using single random
sampling techniques. Within each cluster, a random sample
of households and participants were selected.
The CRONICAS Cohort Study is an ongoing cardiopul-
monary project aimed to estimate the prevalence and inci-
dence of hypertension, diabetes mellitus, and obesity in
four different settings in Peru that differ in terms of their
urbanicity and altitude: Pampas de San Juan deMiraflores, in
the highly urbanized Lima, Puno in the altitude (3,825meters
above the sea level) contributing with rural and urban areas,
and Tumbes, a semiurban area in the northern coast of Peru
[19]. The study started in September 2010 and a follow-up
visit was completed in March 2014. A sex- and age-stratified
sample was selected at random for each of the settings and all
participants aged ≥35 years, full time residents in the study
area, and able to consent, were enrolled. Follow-up data used
for this analysis was collected, on average, at 30 months after
baseline.
2.2. Study Procedures. The procedures of the ENINBSC have
been described previously [18]. Briefly, after consent, two
different visits were scheduled.The first one lasted on average
40 minutes and was carried out to apply a face-to-face
questionnaire regarding data about household character-
istics, demographics, lifestyles behaviors, risk factors, and
blood pressure measurements. The second visit lasted 30
minutes on average and was planned to have an appropriate
period of fasting for blood sampling for glucose, total choles-
terol, HDL-cholesterol, and the remaining anthropometric
measures (height, weight, and waist circumference) using
standard procedures.
Similarly, the procedures of the CRONICAS study
has been published elsewhere [19]. In brief, participants
responded to a face-to-face questionnaire applied by trained
community health workers. Data collected comprised risk
factors for cardiovascular disease based on amodified version
of the WHO STEP approach questionnaire for surveillance
of noncommunicable disease [20]. A period of 8 to 12 hours
of fasting was required for blood sampling to collect fast-
ing glucose, total cholesterol, and HDL-cholesterol. Height,
weight, and waist circumference were also assessed, and
blood pressure was measured in triplicate after five minutes
of resting using an automatic monitor (OMRON HEM-780)
previously validated in adult’s population [21].
2.3. Variable Definitions. In both studies, diabetes was
defined as any of the following conditions: fasting glucose
≥7.0mmol/L (≥126mg/dL) and/or self-report of physician
diagnosis. Fasting glucose was assessed by an enzymatic
colorimetric method (glucose oxidase GOD-PAP) in both
studies. After excluding individuals without known diabetes,
undiagnosed diabetes was also estimated to develop and
validate the risk score [22].
Variables included in the analyses were built to guarantee
similarities between both studies: sex; age (<55 and ≥55
years); education (in years); self-reported smoking (current
versus never/former smoker); alcohol use (user versus never
user); self-reported diabetes in first-degree relatives (partici-
pant’s parents and/or siblings); and levels of physical activity
(low versus moderate/high levels, based on the transport-
related domain of the IPAQ). Anthropometricmeasurements
included in the analysis were body mass index ((BMI), <25,
25–29.9, and ≥30Kg/m2), waist circumference (<90, 90–
99.9, and ≥100 cm), waist-to-height ratio (<0.50, 0.50–0.59,
0.60–0.69, and ≥0.70) [23], and hypertension (measured or
previously diagnosed) [24].
2.4. Statistical Analysis. A total of 4,206 participants were
enrolled in the ENINBSC, but only 2,472 were included in
this analysis. Reasons for exclusion were 1,524 because of age
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<35 years to make both databases comparable, 129 because
of no data about fasting plasma glucose levels being available,
and 81 because of known diagnosis of diabetes. In the CRON-
ICAS study, 3,601 participants were enrolled at baseline but
only 2,948 records were analyzed as 465 had no data about
glucose levels, and 188 were excluded because of previous
diagnosis of diabetes. In addition, only data from 2,577 par-
ticipants was used in the longitudinal assessment of the risk
score (comparison of baseline characteristics among those
included and excluded from longitudinal analysis is shown
inOnline Supplement: E-Table 1; see SupplementaryMaterial
available online at http://dx.doi.org/10.1155/2016/8790235).
Initially, population characteristics of both studies were
tabulated using proportions in the case of categorical vari-
ables andmeans and standard deviation (SD) with numerical
variables. Then, the prevalence and 95% confidence intervals
(95% CI) of total diabetes and undiagnosed diabetes were
estimated in each study. After that, all cases of knowndiabetes
were excluded from subsequent analyses.
The risk score was derived from data of the ENINBSC
survey taking into account the multistage sampling strategy
of the study. Each potential risk factor (i.e., sex, age, family
history of diabetes, etc.) was assessed in bivariate models
using logistic regression and undiagnosed diabetes as the
dependent variable. Then, risk factors with a 𝑝 value <0.10
in the bivariate analysis were included in a multiple logistic
regression model using stepwise backward elimination with
a significance level of 5%.The Hosmer-Lemeshow goodness-
of-fit test was used to assess howwell the predicted prevalence
matched the observed prevalence of undiagnosed diabetes
(i.e., 𝑝 values over 0.20 indicate that model fits well) [25].
As we sought for an easily applicable and implementable
algorithm, the risk factors in the final model were each
assigned a weighted score by rounding up all regression
coefficients in the final model to the nearest integer as in a
previous report [26].
For the evaluation of the risk score, the area under the
receiver operating characteristic (ROC) curve, sensitivity,
specificity, and positive and negative predictive values (PPV
and NPV) were calculated. The optimal cut-point was deter-
mined using the Youden index, a single statistic that captures
the performance of a diagnostic test (i.e., sensitivity + speci-
ficity − 1) [27]. As one of the main aims of a nonlaboratory
risk score is to identify people who warrant having a blood
test (i.e., fasting glucose, glycated haemoglobin, etc.), the cut-
point with the highest sensitivity was also estimated and
described.
We assessed the performance of our score using bootstrap
techniques as well as carrying out an external validation
using the CRONICAS Cohort Study. Bootstrapping was
utilized to estimate confidence intervals for the AUC in our
study population. A total of 1,000 random samples with
replacement were taken from the development database.
The resulting 1,000 prediction models were then assessed to
estimate the bootstrap AUC using the bias-corrected version
of the confidence intervals [28]. In addition, using baseline
data from the CRONICASCohort Study, validationmeasures
(AUC, sensitivity, specificity, predictive values, and likelihood
ratios) were estimated.
To evaluate the performance of our algorithm, the Peru-
vian risk score was compared to previously published models
for undiagnosed diabetes including the Brazilian risk score
[16], the Qingdao score [10], the Indian risk score [11], the
Kuwaiti risk score [29], the patient self-assessment score
[26], and the Rotterdam risk score [7] using the c-statistic.
Finally, using the follow-up data of the CRONICAS Cohort
Study, the risk score was also evaluated to detect incident
cases of T2DM by excluding those with diabetes diagnosis
at baseline. Analyses were performed using STATA 13.0
(StataCorp, College Station, TX, USA).
2.5. Ethical Issues. The protocol and informed consent forms
of the ENINBSC study were reviewed and approved by
the Instituto Nacional de Salud and the Centro Nacional de
Alimentacio´n y Nutricio´n, both part of the Ministry of Health
in Lima, Peru. In the case of the CRONICAS Cohort Study,
protocol and consent forms were reviewed and approved
by the institutional review boards of the Universidad Peru-
ana Cayetano Heredia and the NGO Asociacio´n Bene´fica
PRISMA in Lima, Peru, and the Johns Hopkins University in
Baltimore, USA.
3. Results
The characteristics of participants in both studies are detailed
in Table 1. Overall, participants from the CRONICAS study
were 5 years older, reported consuming lower levels of
alcohol, and were less physically active than those from the
ENINBSC survey.
3.1. Prevalence of Diabetes and Undiagnosed Diabetes. The
overall prevalence of diabetes was 5.1% (129/2538; 95% CI:
4.2%–5.9%) in the ENINBSC survey and 8.7% (272/3135;
95% CI: 7.7%–9.7%) in the CRONICAS Cohort Study’s
baseline. After excluding those with known diabetes, undi-
agnosed diabetes was present in 2.0% (48/2457; 95%
CI: 1.4%–2.5%) in the ENINBSC survey and in 2.9%
(85/2948; 95% CI: 2.3%–3.5%) in the CRONICAS Cohort
Study.
3.2. Development of the Risk Score. After stepwise backward
logistic regression, age, diabetes in first-degree relatives,
and waist circumference were independently associated with
undiagnosed diabetes (Table 2). The Hosmer-Lemeshow test
showed that the final model fitted relatively well (𝑝 = 0.21).
The Peruvian diabetes risk score was constructed based on
the coefficients of that final regression model. The score gave
an AUC of 0.73 (95% CI: 0.65–0.78), and the optimal cut-
point for undiagnosed diabetes using the Youden index was
≥2 (Figure 1).With this cut-point, about 34.8% of participants
were categorized as at high risk of diabetes: sensitivity 69.6%,
specificity 65.8%, and PPV and NPV of 3.9% and 99.1%,
respectively.With a cut-point ≥1, 69.8% of participants would
be at high risk of diabetes with improved sensitivity (93.5%)
but lower specificity (30.6%). Table 3 shows the performance
of the risk score for detecting undiagnosed diabetes at
different cut-points.
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Table 1: Sociodemographic characteristics of participants without history of type 2 diabetes in the two involved studies.
ENINBSC study CRONICAS study
(𝑛 = 2,472) (𝑛 = 2,945)
Demographic variables
Sex (% females) 1,209 (48.9%) 1,500 (50.9%)
Age (mean (SD)) 50.5 (12.1) 55.3 (12.7)
Education in years (mean (SD)) 7.8 (4.9) 8.0 (4.9)
Behavioural variables
Current smoking (%) 391 (15.9%) 369 (11.5%)
Alcohol use (%) 2,323 (94.1%) 1,600 (54.3%)
Family history of diabetes (%) 268 (11.2%) 351 (11.9%)
Physical activity (% low level) 606 (24.5%) 938 (31.9%)
Anthropometric measures
Body mass index (mean (SD)) 25.7 (4.5) 27.6 (4.6)
Waist circumference (mean (SD)) 91.0 (11.4) 91.5 (11.0)
Waist-to-height ratio (mean (SD)) 0.58 (0.08) 0.59 (0.07)
Systolic blood pressure (mean (SD)) 114.5 (18.5) 117.2 (18.9)
Diastolic blood pressure (mean (SD)) 71.1 (11.9) 73.4 (11.1)
Hypertension (%) 579 (23.8%) 705 (24.0%)
Total cholesterol (mean (SD)) 174.2 (36.9) 199.7 (39.6)
HDL-cholesterol (mean (SD)) 43.5 (5.3) 41.7 (11.5)
SD: standard deviation and HDL: high-density lipoprotein.
Results may not add due to missing values.
Table 2: Risk factors and beta coefficients for undiagnosed diabetes: final regression model using CENAN database (𝑛 = 2,367).
Bivariate model Final model∗ Score
Coefficient (SE) OR (95% CI) Coefficient (SE) OR (95% CI)
Sex
Male (versus female) −0.39 (0.30) 0.68 (0.38–1.21)
Age
≥55 (versus <55 years) 0.72 (0.29) 2.05 (1.16–3.64) 0.61 (0.18) 1.85 (1.30–2.63) 1 (versus 0)
Current smoking
Current (versus never/former smoker) −1.06 (0.60) 0.34 (0.11–1.12)
Alcohol user
User (versus never user) 0.38 (0.74) 1.46 (0.34–6.27)
Diabetes in relatives
Yes (versus no) 1.06 (0.34) 2.90 (1.48–5.66) 0.85 (0.42) 2.34 (1.04–5.31) 1 (versus 0)
Physical activity
Low (versus moderate/high levels) 0.80 (0.30) 2.24 (1.25–4.01)
Body mass index
Overweight (versus normal) 0.07 (0.35) 1.07 (0.54–2.13)
Obese (versus normal) 0.80 (0.36) 2.23 (1.11–4.49)
Waist circumference
90.0 to <99.9 cm (versus <90 cm) 0.66 (0.38) 1.93 (0.91–4.10) 0.74 (0.33) 2.09 (1.09–4.02) 1 (versus 0)
100+ cm (versus <90 cm) 1.41 (0.37) 4.10 (1.99–8.44) 1.40 (0.23) 4.07 (2.60–6.40) 2 (versus 0)
Waist-to-height ratio
0.50–0.59 (versus <0.50) 0.34 (0.63) 1.41 (0.41–4.86)
0.60–0.69 (versus <0.50) 1.09 (0.62) 2.97 (0.88–10.0)
0.70+ (versus <0.50) 1.58 (0.68) 4.84 (1.27–18.5)
Hypertension
Yes (versus no) 0.52 (0.31) 1.68 (0.91–3.09)
∗Themodel was created using backward elimination from the initial full model until we reached a final model with statistically significant covariates.
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Table 3: Performance of different cut-points for detecting undiagnosed type 2 diabetes in the development database.
Total score At high risk∗ Sensitivity Specificity PPV NPV Correctly classified LR+ LR−
≥1 69.8% 93.5% 30.6% 2.6% 99.6% 31.8% 1.34 0.21
≥2 34.9% 69.6% 65.8% 3.9% 99.1% 65.9% 2.04 0.46
≥3 11.0% 30.4% 89.4% 5.4% 98.5% 88.3% 2.87 0.78
≥4 1.3% 2.2% 98.7% 3.2% 98.1% 96.8% 1.68 0.99
PPV: positive predictive value; NPV: negative predictive value; LR+: positive likelihood ratio; LR−: negative likelihood ratio.
∗Those at high risk are the proportion of participants over the total score.
Table 4: Performance of different diabetes risk scores compared to Peruvian diabetes risk score using the CRONICAS study (validation
sample).
Method (proposed cutoff) # of variables AUC Sensitivity Specificity PPV NPV LR+ LR−
Brazilian risk score (≥18) 3 0.65 66.7% 61.9% 4.9% 98.4% 1.75 0.54
Qingdao risk score (≥17 and ≥14)∗ 4 0.58 83.3% 33.3% 3.6% 98.5% 1.25 0.50
Indian risk score (≥21) 5 0.54 94.0% 15.5% 3.1% 98.9% 1.11 0.39
Kuwaiti risk score (≥32) 4 0.62 45.2% 78.4% 5.8% 98.0% 2.09 0.70
Patient self-assessment score (≥5) 6 0.64 61.4% 66.8% 5.1% 98.3% 1.85 0.58
Rotterdam risk score (≥36) 6 0.55 94.0% 16.8% 3.2% 99.0% 1.13 0.35
Peruvian risk score (≥2) 3 0.68 70.2% 58.9% 4.8% 98.5% 1.71 0.51
AUC: area under the ROC curve; PPV: positive predictive value; NPV: negative predictive value; LR+: positive likelihood ratio; LR−: negative likelihood ratio.
∗Different cutoffs for males (≥17) and females (≥14).
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Figure 1: Receiver operating characteristic (ROC) curve of the risk
score in predicting undiagnosed type 2 diabetes in the development
database. The area under the ROC curve was 0.73 (95% CI: 0.65–
0.78) for the risk score.
3.3. Cross-Sectional Validation of the Risk Score. When boot-
strap was used, the performance of our risk score was similar
to the obtained in the development model (AUC = 0.72;
95% CI: 0.65–0.78). In addition, when the risk score was
evaluated by applying the score to the CRONICAS Cohort
Study’s population, the AUC for undiagnosed diabetes was
0.68 (95% CI: 0.62–0.73). At the suggested cut-point of ≥2,
42% would be categorized as undiagnosed diabetes with
sensitivity, specificity, PPV, and NPV of 70.2%, 58.9%, 4.8%,
and 98.5%, respectively (Table 4). On the other hand, with
a cut-point ≥1, 80% would be categorized as undiagnosed
diabetes with sensitivity, specificity, PPV, and NPV of 94.0%,
20.0%, 3.3%, and 99.1%, respectively.
When previous published algorithms for undiagnosed
diabetes were applied to the CRONICAS Cohort Study, the
performance of the Rotterdam score (𝑝 < 0.001), Indian
score (𝑝 < 0.001), and Qingdao score (𝑝 < 0.01) was poorer
than our score; however, our algorithm performed similar to
the other assessed models, such as the Brazilian risk score
(𝑝 = 0.93), the Kuwaiti score (𝑝 = 0.26), and the patient self-
assessment score (𝑝 = 0.74), but having only three variables.
3.4. Longitudinal Assessment of the Risk Score. The per-
formance of this risk score was also assessed to predict
incident cases of diabetes using the longitudinal data from
the CRONICASCohort Study. One hundred twenty-one new
cases of diabetes were found accounting for 6,207 person-
years at risk, with an overall incidence of 1.95 (95% CI: 1.63–
2.33) cases per 100 person-years of risk.The AUC of the score
was 0.66 (95% CI: 0.61–0.71). With a cut-point ≥2, 42.5% of
participants were categorized as at high risk of developing
diabetes: sensitivity, specificity, PPV, and NPV were 69.4%,
58.9%, 7.8%, and 97.4%, whereas, for a cut-point ≥1, the
respective values were 79.9%, 91.9%, 20.7%, 5.5%, and 98.1%.
4. Discussion
4.1. Main Findings. Using a national population-based sur-
vey, a simple nonblood based risk score based on age, history
of diabetes in first-degree relatives, and waist circumference
was built and shown to perform moderately in detecting
undiagnosed diabetes when externally validated. Moreover,
the performance of the score was almost similar for detecting
incident cases of diabetes in the Peruvian population.
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4.2. Comparison with Other Risk Scores. A relatively recent
systematic literature search found 23 different blood-free
prevalent diabetes risk scores: ten from Europe, nine for
Asian populations, two from the United States, and two
from Middle East [30]. In addition, and not included in the
aforementioned review, only one risk score was developed
in Latin America using Brazilian urban population [16]. The
same systematic review reported that AUC for these predic-
tive models was greater in the development studies (range:
0.65 to 0.88) than in the validation studies (range: 0.63 to
0.80) [30], similar to our findings. Another systematic review
found that several noninvasive algorithms were created using
variables such as age, gender, waist circumference and/or
BMI, and family history of diabetes in the final model [31].
As impracticality due to use of the algorithms was a common
barrier to the uptake of risk scores by healthcare staff and
individuals [32], our model, created with three of these more
common variables, reached a moderate-to-high sensitivity
depending on the used cut-point. Moreover, two of these
variables are easily evaluable during medical appointment or
through individual’s self-assessment, and only a measuring
tape and no calculations are required to be implemented in
clinical practice or at the population level.
From a cross-sectional point of view, with a cut-point
≥2, from 1000 participants assessed by the Peruvian diabetes
risk score, a total of 420 would be classified as undiagnosed
diabetes with the detection of 20 cases and only 6 will be
missing. On the other hand, with a cut-point ≥1, from 1000
screened individuals, a total of 804 would be categorized
as having undiagnosed diabetes with the detection of 27
cases and only 7 will be missing. Thus, the reduction of
the cut-point of the risk score would increase sensitivity but
reducing the specificity and imposing the need of performing
a confirmatory test (i.e., fasting glucose) to almost the double
of individuals, with the benefit of having only 7 more people
diagnosed.
Longitudinally, the same risk score would detect an
important number of participants at risk of developing
diabetes: 43% of screened individuals would be classified
at high risk of diabetes, and of them, 8% would develop
diabetes in the next 2.5 years. According to a previous study
[33], 17 reports described a noninvasive model to predict the
development of diabetes and included a median of six risk
predictors, ranging from 2 to 11 [34]. Although our score
did not perform as good as other well-known longitudinal
models in the literature such as the FINDRISC or the ARIC
scores [35, 36], it only included three variables and was
built using cross-sectional information. In addition, some
variables used in the aforementioned studies are difficult to
standardize within a country as Peru, that is, food portions,
physical activity, or sedentarism, limiting therefore its use on
a wider scale and in a simple pragmatic fashion.
Our algorithm performed better than the Rotterdam, the
Indian, and the Qingdao risk scores in our population, which
highlights the need of calibration and/or development of a
specific score for different ethnic groups before its adoption.
As there are ethnic differences in risk factors for diabetes
and Peru is considered a multiethnic country, it is necessary
to create specific scores or recalibrate existing algorithms
before applying in specific contexts. In addition, with only
three variables included, the performance of our predictive
model was similar to the other assessed scores included in
the analyses. Taken together, the score developed has the
potential to augment, in a pragmatic manner, initial rapid
screening for diabetes, especially at various nonspecialized
primary healthcare services.
Our findings also demonstrate that approximately 35% of
cases of T2DM (39% in the ENINBSC survey and 33% in the
baseline of the CRONICAS Cohort Study) are not aware of
their disease. Results are similar to those reported in previous
studies in our context [37] and in similar settings in Latin
America [38].
4.3. Public Health Relevance and Implications. As the devel-
oped risk score is simple, it does not require a blood test or
laboratory services, and it might be easily implemented in
clinical practice.Moreover, because our score asks for general
information in the form of age and diabetes in first-degree
relatives and is complemented by a simple anthropometric
measure of waist, there is potential for the score to be self-
administered.
According to our results, any patient aged 55 years and
above and having at least one first-degree relative with T2DM
has greater probability of having undiagnosed diabetes but
also is at risk of developing diabetes in the future. In addition,
a greater central obesity, that is, 100 cm ormore, independent
of the other terms of the score is alone a good predictor of
diabetes as reported in previous studies [23]. Our algorithm
included waist circumference instead of body mass index as
other risk scores, providing a better indicator of accumulation
of visceral fat and metabolic dysfunction in our context [39].
Recently, the Peruvian Ministry of Health has published
the Guide of Clinical Practice for Diagnosis, Treatment
and Control of Diabetes Mellitus in Primary Care [40]
and only recommends screening in general population with
plasma glucose among adults between 40 and 70 years with
obesity or overweight as suggested by the American Diabetes
Association [6]. As in other LMIC, plasma glucose is not
always available in primary care, especially in semiurban and
rural areas; therefore, a major challenge to be overcome in
many countries is the implementation of a simple, fast, and
laboratory-free based screening method. Moreover, within
the Peruvian context, no risk score has been proposed as part
of the aforementioned guide. Thus, our algorithm might fill
a gap to facilitate further specialized assessment of high risk
individuals for diabetes, an approach that may be of utility to
various other countries facing similar challenges.
4.4. Strengths and Limitations. The strengths of this study
include the use of a national population-based survey, includ-
ing urban and rural areas across major geographical regions,
to develop the Peruvian diabetes risk score, as well as its
validation using bootstrap but also an independent longi-
tudinal cohort study. Additionally, it is only based on three
variables ensuring its simplicity to be used and implemented.
However, the study has also some limitations. First, we
have utilized fasting plasma glucose as the gold standard
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for diagnosing diabetes instead of an oral glucose tolerance
test (OGTT). Although the OGTT is more sensitive and
specific than the fasting plasma glucose, more cases would
have been detected with the overload of glucose; it is rarely
performed as part of the routine clinical practice. Second, the
CRONICAS Cohort Study did not include information from
the Amazon rainforest as did the ENINBSC survey. When
a sensitivity analysis was performed excluding individuals
from the jungle from ENINBSC data, results were similar
to those presented in this manuscript (data not shown).
In addition, the score was created using a national survey
to be applicable to the entire Peruvian population. Third,
some variables were not assessed in our logistic regression
model such as dietary intake or history of gestational diabetes
as such data was not available. As a result, some caution
should be made when our algorithm is compared to other
risk scores. Fourth, our model is based on the idea of risk
stratification instead of individualisation [41]; for instance,
variables were categorized instead of being preserved as
numerical. Nevertheless, the performance of our score did
not change when age and waist circumference were treated
as numerical variables (data not shown). Moreover, our idea
was to develop a simple and easily applicable score instead
of a complex algorithm for predicting undiagnosed and
incident diabetes. Finally, as other diabetes risk scores, the
model warrants further scrutiny before it can be used in other
populations.
5. Conclusions
ThePeruvian diabetes risk score, built using age, self-reported
diabetes in first-degree relatives, and waist circumference,
proves to be a simple pragmatic screening tool for undiag-
nosed and incident cases of diabetes in Peru.This experience
in generating such simple, easy-to-use approaches for the
identification of T2DM can serve to inform other similar
LMIC efforts who are on early stages of diabetes prevention.
This tool, due to its simplicity, can facilitate various initiatives
oriented to introduce and scale up early preventative and
management strategies on a wider scale.
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Abstract
Objectives
The EZSCAN is a non-invasive device that, by evaluating sweat gland function, may detect
subjects with type 2 diabetes mellitus (T2DM). The aim of the study was to conduct a sys-
tematic review and meta-analysis including studies assessing the performance of the EZS-
CAN for detecting cases of undiagnosed T2DM.
Methodology/Principal findings
We searched for observational studies including diagnostic accuracy and performance
results assessing EZSCAN for detecting cases of undiagnosed T2DM. OVID (Medline,
Embase, Global Health), CINAHL and SCOPUS databases, plus secondary resources,
were searched until March 29, 2017. The following keywords were utilized for the systematic
searching: type 2 diabetes mellitus, hyperglycemia, EZSCAN, SUDOSCAN, and sudomotor
function. Two investigators extracted the information for meta-analysis and assessed the
quality of the data using the Revised Version of the Quality Assessment of Diagnostic
Accuracy Studies (QUADAS-2) checklist. Pooled estimates were obtained by fitting the
logistic-normal random-effects model without covariates but random intercepts and using
the Freeman-Tukey Arcsine Transformation to stabilize variances. Heterogeneity was also
assessed using the I2 measure. Four studies (n = 7,720) were included, three of them used
oral glucose tolerance test as the gold standard. Using Hierarchical Summary Receiver
Operating Characteristic model, summary sensitivity was 72.0% (95%CI: 60.0%– 83.0%),
whereas specificity was 56.0% (95%CI: 38.0%– 74.0%). Studies were very heterogeneous
(I2 for sensitivity: 79.2% and for specificity: 99.1%) regarding the inclusion criteria and bias
was present mainly due to participants selection.
Conclusions
The sensitivity of EZSCAN for detecting cases of undiagnosed T2DM seems to be accept-
able, but evidence of high heterogeneity and participant selection bias was detected in most
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Introduction
Worldwide, the burden of type 2 diabetes mellitus (T2DM) is rising rapidly. Currently,
approximately 9% of adults in the world are living with T2DM [1, 2]. Many of the conse-
quences of T2DM affect mainly low- and middle-income countries (LMIC): 1.5 million deaths
worldwide were directly attributable to T2DM in 2012, and more than 80% of these deaths
occurred in LMIC [3, 4]. In addition, about USD$ 548 billion in healthcare expenditures were
due to T2DM in 2013 [5], imposing a large economic burden on individuals and families as
well as health systems, particularly in resource-constrained settings.
Oral glucose tolerance test (OGTT) is considered the gold standard for T2DM diagnosis
according to guidelines [6]. However, conventionally, fasting glucose (FG) is used in most of
healthcare facilities. OGTT and FG require 8 hours of fasting and, in addition, OGTT also
needs the participant to drink a 75-gram glucose solution and wait two hours before a second
blood sample is obtained. In 2009, the American Diabetes Association suggested that glycated
hemoglobin (HbA1c) could be used as a diagnostic tool for T2DM [7]. HbA1c does not require
fasting, but can be expensive and requires a certified laboratory process [8]. Despite the recom-
mended cutoff of 6.5% (48 mmol/mol) for T2DM diagnosis [9], discrepancies between HbA1c
and glycemia in different racial and ethnic groups have been described [10–13].
An important approach to prevent or delay diabetes complications is to identify those indi-
viduals with undiagnosed T2DM [14]. Although universal T2DM screening at the population
level is not practical; there are alternative methods reported in the literature. As early damage
of small nerves can be found since the onset of T2DM [15], some devices have emerged to
assess small-fiber autonomic dysfunction [16]. Among these devices, the EZSCAN (Impeto
Medical, Paris, France), a non-invasive device that performs electrochemical reactions of
eccrine sweat glands, may help to detect participants with diabetes mellitus [17, 18]. The
advantage of the EZSCAN is that its use does not require trained personnel, delivers result
quickly, and does not require active participation of the participants (i.e. fasting). Some studies
have evaluated the potential impact of this device in pre-diabetes, dysglycemia and T2DM
screening [17, 19, 20], but there is limited information regarding its potential for detecting
cases of undiagnosed T2DM. Consequently, we conducted a systematic review and meta-anal-
ysis of observational studies to assess the performance of the EZSCAN for undiagnosed
T2DM. Our hypothesis was focused on sensitivity, expecting at least a performance of 75%.
Materials and methods
Study selection
We searched for observational studies including diagnostic accuracy results assessing EZSCAN
for undiagnosed T2DM, conducted in different parts of the world, but reported in English.
Studies were excluded if they were only abstracts or review articles, enrolled individuals aged
<18 years or cases with type 1 diabetes mellitus, and defined type 2 diabetes mellitus (T2DM)
by using blood markers other than OGTT or FG (i.e. HbA1c). The rationale for this decision
was based on discrepancies between HbA1c and glycemia in different racial and ethnic groups
and that HbA1c is not commonly used for undiagnosed T2DM.
EZSCAN and undiagnosed diabetes
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Data sources and searches
A comprehensive literature search using the Ovid database (PubMed-Medline, Embase, Global
Health, and Health Management Information Consortium) as well as CINAHL, and SCOPUS,
until March 29, 2017, was conducted. The following keywords were utilized for the systematic
searching: type 2 diabetes mellitus, hyperglycemia, EZSCAN, SUDOSCAN, and sudomotor
function [16]. The term SUDOSCAN was also included in the search strategy as it uses the
same principle (i.e. sudomotor function assessment) for detecting diabetic neuropathy [21,
22]. The search strategy of Ovid is available in S1 Table. The Impeto Medical website was also
searched to find other published manuscripts [19].
Data extraction and quality assessment
Titles and abstracts of retrieved articles were reviewed independently by two investigators to
select potentially relevant articles, and disagreements were discussed and solved by consensus.
Using a standardized data extraction form, we collected information on lead author, publica-
tion year, country, study design, inclusion criteria, used gold standard, sample size, mean age,
percentage of male participants, and different indicators of the performance of the EZSCAN to
detect undiagnosed T2DM (outcome, area under the curve, cut-off, sensitivity, specificity,
among others).
Quality assessment of individual studies was performed to identify potential sources of bias
and to limit, if possible, the effect of these biases on the conclusions of the review. For this, the
Revised Version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2)
checklist was used [23]. This tool included risk of bias assessment (i.e. participant selection,
index test, reference standard, and flow and timing) as well as applicability.
Data synthesis and analysis
The primary outcome of interest was undiagnosed T2DM (i.e. newly-diagnosed T2DM) iden-
tified by OGTT or FG. Secondary outcomes included other glucose metabolism disorders such
as impaired glucose tolerance, impaired fasting glucose and, dysglycemia.
Statistical analyses were performed using Stata version 13 for Windows (StataCorp, College
Station, TX, US). Our systematic review followed the Preferred Reporting Items for Systematic
Review and Meta-Analysis (PRISMA, See S1 Checklist), the Guidelines for Meta-Analyses and
Systematic Reviews of Observational Studies (MOOSE) [24] as well as the Cochrane Hand-
book for Diagnostic Test Accuracy Reviews [25]. Initially, the studies included in the system-
atic review were described, including: publication year, country, study design, inclusion
criteria, gold standard, sample size, mean age, and proportion of males. In addition, the perfor-
mance of the EZSCAN in each study was tabulated, and the area under the receiver operating
characteristic (ROC) curve (AUC), best cut-off, sensitivity, and specificity, and their respective
95% confidence intervals (95%CI) were reported, if available.
A meta-analysis of the performance of the EZSCAN was conducted using data from studies
with undiagnosed T2DM as outcome. Information used in meta-analysis was taken as pro-
posed by manuscripts according to the best EZSCAN threshold cut-off reported. The “meta-
prop” command in STATA was used to estimate sensitivity, specificity and positive (PPV) and
negative (NPV) predictive values and their respective 95%CI [26]. The “metaprop” command
obtains a pooled estimate as a weighted average, by fitting the logistic-normal random-effects
model without covariates but random intercepts. The pooled estimate was then calculated
using the Freeman-Tukey Arcsine Transformation to stabilize the variances as suggested in lit-
erature [27]. In addition, a graph containing the plot of the Hierarchical Summary Receiver
Operating Characteristic (HS-ROC) model [28], a summary point of sensitivity and specificity
EZSCAN and undiagnosed diabetes
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and the 95% confidence region for that point was obtained by using the “metandiplot” com-
mand [29]. Heterogeneity of estimates and 95%CI was determined using the I2 measure [30].
Results
Study characteristics
A total of 1,461 citations were identified through our systematic search, with a further 16 cita-
tions identified using the Impeto Medical website. After excluding duplicates (n = 330), a total
of 1,147 citations were independently screened, of which 31 were retrieved for detailed assess-
ment (agreement between reviewers, 97.2%, kappa = 0.61, p<0.001). Of the 31 revised manu-
scripts, 27 did not fit our inclusion criteria (Fig 1); therefore, four studies were included in the
systematic review.
The characteristics of the studies included in the systematic review are shown in Table 1.
All the four studies were cross-sectional in nature. A total of 7,720 individuals were included
Fig 1. Flowchart of database searches and articles included in the systematic review. T2DM: Type 2
diabetes mellitus, HbA1c = glycated hemoglobin, IGM = impaired glucose metabolism.
https://doi.org/10.1371/journal.pone.0187297.g001
Table 1. Characteristics of the studies included in the systematic review.
Study, publication year Country Study
design
Inclusion criteria Gold
standard
Size Mean
age
%
male
Chen X, 2015 [32] China Cross-
sectional
Subjects in routine health check visiting a Community
Hospital, at risk of T2DM (age 45 years).
OGTT 270 58.6 32%
Ramachadran A, 2010
[33]
India Cross-
sectional
Individuals in specific clinics aged between 21–75 years. OGTT 212 43.4 45%
Sanchez-Hernandez O,
2015 [34]
Mexico Cross-
sectional
Individuals recruited in a clinic in Mexico;18 years,
apparently healthy and attending a full check-up.
FG 1,414 44.7 50%
Yang Z, 2013 [31] China Cross-
sectional
Individuals from two communities in Shanghai aged 40
+ years.
OGTT 5,824 58.3 40%
FG = fasting glucose; OGTT = oral glucose tolerance test.
https://doi.org/10.1371/journal.pone.0187297.t001
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from all the studies, but 5,824 subjects came from a single study [31]. This latter study enrolled
individuals from the general population, whereas the remaining three studies recruited partici-
pants at clinics, mainly individuals going for healthy check-ups.
Risk of bias
Overall, participant selection bias was present in 3 out of 4 of the studies included in the meta-
analysis [32–34]: individuals under healthy check-ups were enrolled in the original studies (S2
Table). In addition, flow and timing was unclear in the same three studies, and the gold stan-
dard (i.e. OGTT) was not used in one of the studies [34].
Meta-analysis: EZSCAN performance for undiagnosed T2DM
Undiagnosed T2DM was the outcome of interest in the four studies (Table 2). Other outcomes
evaluated in these papers included impaired glucose tolerance [32, 33], impaired fasting glu-
cose [34] and dysglycemia [31].
When undiagnosed T2DM was the outcome, only two studies reported results of AUC
ranging from 53% to 73% [32, 34]. In addition, 2 studies used 50% as the suggested EZSCAN
cut-off for undiagnosed T2DM screening [32, 33], whereas one used 34% [34], and the last one
utilized 30% [31]. Sensitivity varied from 53% to 81%, whilst specificity ranged from 43% to
70%. Finally, positive predictive values (PPV) varied from 10% to 40%, whereas negative pre-
dictive values (NPV) ranged from 71% to 98%.
When using HS-ROC (Fig 2), summary sensitivity was 72.0% (95%CI: 60.0%– 83.0%), spec-
ificity was 56.0% (95%CI: 38.0%– 74.0%), PPV was 24% (95%CI: 12.0%– 37.0%), and NPV was
89% (95%CI: 82.0%– 97.0%). In addition, positive and negative likelihood ratios were 1.68
(95%CI: 1.35–2.10) and 0.48 (95%CI: 0.36–0.66), respectively, whereas the DOR was 3.49 (95%
CI: 2.18–5.57). Heterogeneity for sensitivity was 79.2% (95%CI: 44.0%– 92.0%), whereas for
specificity was 99.1% (95%CI: 98.5%– 99.6%).
Table 2. Performance of the EZScan in the studies included in the systematic review.
Study, publication year Outcome AUC Cut-off Sensitivity Specificity
Chen X, 2015 [32] IGT 78%
(72%–83%)
37% 82%
(72%–90%)
63%
(55%–71%)
Chen X, 2015 [32] T2DM 53%
(43%–62%)
50% 53% (36%–69%) 59%
(47%–70%)
Ramachadran A, 2010 [33] IGT — 50% 70%
(not reported)
54%
(not reported)
Ramachadran A, 2010 [33] T2DM — 50% 75%
(not reported)
54%
(not reported)
Sanchez-Hernandez O, 2015 [34] IFG 65%
(not reported)
27% 69%
(not reported)
56%
(not reported)
Sanchez-Hernandez O, 2015 [34] T2DM 73%
(not reported)
34% 73%
(not reported)
70%
(not reported)
Yang Z, 2013 [31] IFG, IGT or T2DM — 30% 73%
(71%-75%)
46%
(45%-48%)
Yang Z, 2013 [31] T2DM — 30% 81%
(78%-83%)
43%
(42%-44%)
IFG = Impaired fasting glucose; IGT = Impaired glucose tolerance; T2DM = type 2 diabetes mellitus; AUC = area under the curve.
Values in brackets are 95% confidence intervals (95%CI).
https://doi.org/10.1371/journal.pone.0187297.t002
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Discussion
Summary of evidence
According to the results of this systematic review and meta-analysis, the performance of the
EZSCAN in the detection of cases undiagnosed T2DM can be considered acceptable especially
in the case of sensitivity, and even comparable to different well-known T2DM risk scores [35,
36]. To put in context our findings, the sensitivity of HbA1c, using a cut-off6.5% (48 mmol/
mol), for detecting undiagnosed diabetes was 52.8% using OGTT as the gold standard [37].
Thus, apparently, the EZSCAN might perform better that HbA1c although other studies are
needed to corroborate this.
There are, however, some limitations that need to be highlighted. First, there is a risk of bias
based on participant selection that can complicate extrapolation of results: many of the studies
were performed in clinical context (i.e. clinical check-ups) instead of using population level
assessments. Second, a high level of heterogeneity between studies was found (greater than
75%) in all estimations (i.e. sensitivity, specificity, etc). Since a small number of studies were
included in the meta-analysis; results need to be cautiously interpreted despite of the fact that
random effect models were used in calculations [38]. In addition, heterogeneity in results of the
EZSCAN performance can be secondary to characteristics of the context and individuals: pre-
dictive values as well as likelihood ratios can depend on baseline risk of evaluated subjects. For
example, the association of body mass index–one of the variables used in scoring individuals
Fig 2. Performance of EZScan in the screening of T2DM: Meta-analysis using HSROC. Sensitivity =
72.0% (95%CI: 60.0%–83.0%); specificity = 56.0% (95%CI: 38.0%–74.0%); likelihood ratio positive = 1.68
(95%CI: 1.35–2.10); likelihood ratio negative = 0.48 (95%CI: 0.36–0.66); DOR = 3.49 (95%CI: 2.18–5.57).
HSROC curve is shown only for sensitivities and specificities at least as large as the smallest study-specific
estimates.
https://doi.org/10.1371/journal.pone.0187297.g002
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through EZSCAN–with the risk of diabetes may vary in different populations [39], and explain
variability found in this report. Finally, although there is a suggested EZSCAN cut-off for defin-
ing T2DM in the population (50%), our results showed heterogeneity of this cut-off between
studies and populations assessed: only two studies used the proposed 50% cut-off [32, 33],
whereas the other studies were below that value. Thus, the device needs to be validated in differ-
ent populations.
The principle of the EZSCAN, based on the evaluation of sudomotor function, relies on the
assessment of chloride concentrations using reverse iontophoresis and chronoamperometry to
detect insulin resistance and T2DM [18]. The EZSCAN has showed reproducible results in sev-
eral conditions with low impact of usual physiological variations due to its focus on chloride
concentrations, instead of sweat rates as used by other methods [40]. This device deliver results
rapidly (i.e. in 2 to 3 minutes) and does not require invasive blood testing or fasting. Moreover,
no safety problems have been reported during its use. Of note, although the EZSCAN has been
designed to detect individuals with undiagnosed T2DM [18], some of the studies have focused
on the ability of the device to detect impaired fasting glucose [17, 41, 42], dysglycemia [31, 33],
metabolic syndrome [20], or even, complications related to T2DM [43, 44]. On the other hand,
a relatively recent paper combined the performance of this device with conventional risk scores
and reported limited improvement in the model given by the sum of EZSCAN plus risk score in
Chinese population [31]. However, authors claimed that other studies are needed to determine
the clinical relevance of EZSCAN in detecting cases of diabetes.
Public health relevance
Sensitivity and specificity estimates from this review may be used to better understand EZS-
CAN testing in real practice. For example, in a given setting with a prevalence of undiagnosed
T2DM of 10% and assuming a cut-off value of 50% as suggested by the provider, if 1,000 indi-
viduals were screened using the EZSCAN, based on tool sensitivity, the device would detect 72
undiagnosed T2DM cases and 28 would be missing (false negatives). On the other hand, from
the 900 individuals without the disease, 396 would be false positives and classified as having
T2DM with the subsequent need of a confirmatory test. Thus, we would only need to perform
468 OGTT for those positive for EZSCAN, instead of the total population. If the prevalence
were higher (i.e. 20% instead of 10%), of the 1,000 individuals, the device would detect 144
individuals based on its sensitivity, but 56 cases would be missing (false negatives). Of the 800
subjects without the disease, 352 would be false positives and classified as having T2DM with
the need of a confirmatory test. Therefore, 496 OGTT would be needed but missing 56 cases as
false negatives. On the other hand, summary estimates of the positive and negative likelihood
ratios were very similar to values compatible with minimal change in the likelihood of disease.
Thus, if positive and negative likelihood ratios of>10 and<0.1, respectively, were available,
this would provide strong evidence to confirm and discard undiagnosed T2DM [45].
Using EZSCAN for detecting undiagnosed T2DM cases can have some advantages includ-
ing the short time spent in conducting the test, the fact that fasting is not required, and the
repeated used of the device can compensate its cost. However, some disadvantages also arise.
Although, the EZSCAN can potentially reduce the resources implied in assessing populations
for detecting T2DM cases, the number of false negatives (i.e. individuals with undiagnosed
T2DM that are not detected by the device) increased when the prevalence of diabetes in-
creased. On the other hand, literature suggested that EZSCAN cutoff should be estimated by
each population instead of only using the cut-off given by the provider [31, 34, 46].
To our knowledge there is no information regarding the cost-effectiveness of the EZSCAN
for detecting one undiagnosed case of T2DM in addition to the lack of data related to the
EZSCAN and undiagnosed diabetes
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potential performance for future risk of T2DM. Only one study has assessed the utility of this
device longitudinally (2-year follow-up) but in a small sample [17]. In this study, the authors
found an association between the EZSCAN score and T2DM progression although results
needed further confirmation. Thus, the EZSCAN might have potential implications for T2DM
prevention although population-based validation may be necessary to define appropriate cut-
off for appropriate results interpretation.
Limitations
One of the limitations of this review is the representativeness of the results characterized by
bias in participants’ selection as well as the lack of a true gold standard in some of the studies
(i.e. FG was used in one study instead of OGTT). In addition, characteristics of the study popu-
lation were poorly reported and this is reflected in the quality assessment. As all the studies
assessing EZSCAN were recently published (from 2010 and onwards); authors should have
been utilized the Standards for Reporting Diagnostic Accuracy Studies (STARD) to guide their
manuscripts’ writing [47]. Future studies should follow these guidelines to guarantee an appro-
priate reporting of diagnostic studies.
Given the limited number of studies assessed, EZSCAN threshold was not meta-analyzed as
the performance of the diagnostic test depends on the population in which the test is used.
Thus, for our analyses, pooled sensitivity and specificity were calculated using the best cut-off
reported by studies and not the same in all cases. In addition, there is limited data evaluating
the potential impact of EZSCAN for undiagnosed T2DM at the population level. Future stud-
ies should be focused on population-based samples instead of referral health facilities, but also
in different ethnic groups as only studies from China and India were used in this review. A
study from Mexican population was also included in the meta-analysis, but the sample was
biased and FG was used as gold standard [34]. Moreover, as the number of studies included in
the analysis was small, publication bias was not assessed (usual tests for publication bias are
underpowered when <10 studies are evaluated).
In summary, the sensitivity of the EZSCAN for undiagnosed T2DM screening seems to be
acceptable but the evidence is limited because of the presence of participant selection bias in
most of the included studies in the meta-analysis. The performance of the EZSCAN warrants
confirmation in different populations, using the appropriate gold standard, and population-
based samples. Moreover, adequate report of findings and longitudinal utility of the EZSCAN
is also compulsory.
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APPENDIX C 
 
Figure: Performance of EZSCAN for undiagnosed T2DM: Updated meta-analysis 
using HS-ROC (using all studies, n = 5) 
 
Sensitivity = 73.6% (95%CI: 65.6% - 80.3%); specificity = 63.2% (95%CI: 49.1% 
- 75.4%); likelihood ratio positive = 2.00 (95%CI: 1.40 – 2.86); likelihood ratio 
negative = 0.42 (95%CI: 0.31 – 0.57); DOR = 4.80 (95%CI: 2.60 – 8.87).  
169 
 
APPENDIX D 
 
Figure: Performance of EZSCAN for undiagnosed T2DM: Updated meta-analysis 
using HS-ROC (using studies with OGTT, n = 4) 
 
Sensitivity = 73.0% (95%CI: 62.8% - 81.3%); specificity = 61.3% (95%CI: 44.0% 
- 76.2%); likelihood ratio positive = 1.89 (95%CI: 1.24 – 2.88); likelihood ratio 
negative = 0.44 (95%CI: 0.30 – 0.65); DOR = 4.30 (95%CI: 2.02 – 9.15).  
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APPENDIX E: 
 
Table: English version of the scoring of the FINDRISC and LA-FINDRISC for 
undiagnosed T2DM 
 
 FINDRISC LA-FINDRISC 
Age:   
<45 years 0 points 0 points 
45 – 54 years 2 points 2 points 
55-64 years 3 points 3 points 
65+ years 4 points 4 points 
Body mass index:   
< 25 kg/m
2
 0 points 0 points 
Between 25 and < 30 kg/m
2
 1 point 1 point 
≥30 kg/m2 3 points 3 points 
Waist circumference:   
Men: <94 cm; women: <80 cm 0 points 0 points 
Men: 94 – 102 cm; women: 80 – 88 cm 3 points 
4 points 
Men: >102 cm; women: >88 cm 4 points 
Physical activity (at least 30 min/day):   
Yes 0 points 0 points 
No 2 points 2 points 
Fruits and vegetables intake:   
Every day 0 points 0 points 
Not every day 1 point 1 point 
Regular medication for hypertension:   
No 0 points 0 points 
Yes 2 points 2 points 
History of high glucose levels:   
No 0 points 0 points 
Yes 5 points 5 points 
Diabetes in relatives:   
No 0 points 0 points 
Yes, grandparents, cousins, uncle, aunt 3 points 3 points 
Yes, parents, siblings, son, daughter 5 points 5 points 
 
The difference between FINDRISC and LA-FINDRISC is based on score 
on waist circumference. 
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APPENDIX F: 
 
Table: Spanish version of the questionnaire for participants enrolled in the study 
 
  
 
Código del Participante: 
 
─ 
 
─ 
 
Código de trabajador: 
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CRÓNICAS - PERU 
CENTRO DE EXCELENCIA EN ENFERMEDADES CRÓNICAS 
 
Evaluación de dos métodos alternativos para el diagnostico de diabetes: 
un estudio piloto para mejorar el tamizaje a nivel poblacional 
 
Por favor, confirmar la siguiente información para asegurar el 
adecuado enrolamiento del participante  
 
Por favor preséntese verbalmente antes de empezar: 
 
“Buenos días / tardes, mi nombre es (decir su nombre y presentar su carnet). Soy personal de 
salud del Centro de Salud Global de la Universidad Peruana Cayetano Heredia. Estamos 
realizando un estudio de investigación sobre enfermedades crónicas como presión alta y diabetes. 
Nos gustaría hacerle una preguntas sobre sus datos generales y posteriormente le proporcionaré 
una hoja informativa sobre las razones del estudio, luego de eso Ud. decidirá si desea participar 
en el presente estudio” 
 
 
Criterios de inclusión (1 = Si; 2 = No) Respuesta 
1 Edad entre 35 y 69 años 
 
2 Capaz de entender los procedimientos 
 
3 Capaz de dar consentimiento informado 
 
4 Residencia a tiempo completo en área de estudio (≥6 meses) 
 
 
Criterios de exclusión (1 = Si; 2 = No) Respuesta 
1 ¿Está usted embarazada? 
 
2 ¿Está usted postrado en cama? 
 
Exclusión para EZScan (1 = Si; 2 = No) Respuesta 
3 ¿Usa usted un marcapasos cardiaco? 
 
4 ¿Es usted alérgico al níquel? 
 
Exclusión para pupilometría (1 = Si; 2 = No) Respuesta 
5 ¿Ha sido usted diagnosticado de enfermedad de Parkinson? 
 
6 ¿Ha sido usted diagnosticado de enfermedad de Alzheimer? 
 
7 ¿Ha sido usted diagnosticado de esclerosis múltiple? 
 
8 ¿Presenta usted algún problema ocular severo (cataratas, glaucoma)? 
 
9 ¿Presenta usted alguna lesión en la cornea? 
 
 
 
 
Código del Participante: 
 
─ 
 
─ 
 
Código de trabajador: 
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Preguntas de supervisión (1 = Si; 2 = No) Respuesta 
¿El cuestionario está completo? 
 
¿Las medidas antropométricas fueron realizadas? 
 
¿Las medidas de presión arterial fueron realizadas? 
 
¿Las medidas de EZScan fueron realizadas? 
 
¿Las medidas de pupilometría fueron realizadas? 
 
¿Las medidas de biotensiómetro fueron realizadas? 
 
¿Las muestras de sangre fueron tomadas? 
 
¿Las muestras de sangre están completas? 
 
Código del Participante: 
 
─ 
 
─ 
 
Código de trabajador: 
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Sección 1: Formato de Evaluación Demográfica 
 
DNI del entrevistado 
 
 
Módulo: Lugar y fecha Respuestas 
1 Identificación de entrevistadora (iniciales)  
 
2 Fecha (DD-MMM-20AA)  
 
- 
 
- 
 
3 Nombre de la villa donde se hace la entrevista 
Nombre de villa  
Vivienda #  
 
Módulo: Consentimiento Respuestas 
4 Se ha leído el consentimiento al entrevistado 
Si 1 
No 2  Si NO, leer consentimiento 
5 Se ha obtenido el consentimiento (escrito) 
Si 1 
No 2  Si NO, terminar la entrevista 
 
Módulo: Información de contacto 
6 Apellidos completos 
 
7 Nombres completos 
 
8 Teléfonos de contacto 
Celular 
 
─ 
 
Domicilio fijo:  
 
Nombre (pariente)  
Parentesco (1)  
Celular (1) 
 
─ 
 
Domicilio Fijo (1)  
 
Amigo o vecino  
Celular (2) 
 
─ 
 
Domicilio fijo (2)  
 
 
La información contenida en esta sección debe guardarse separada del cuestionario ya que contiene información confidencial. 
Código del Participante: 
 
─ 
 
─ 
 
Código de trabajador: 
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Sección 2: Formato de Evaluación Socio-demográfica 
 
Módulo: Información de entrevistadora Respuesta 
1 Identificación de entrevistadora (iniciales) 
 
2 Fecha (DD – MMM – AA) 
 
- 
 
- 
 
 
Módulo: Información demográfica Respuesta 
3 Sexo (registre de acuerdo a lo observado) 1 Hombre 
2 Mujer 
4 Fecha de nacimiento (DD – MMM - AA) 
 
- 
 
- 
 
5 Su fecha de nacimiento es… 1 Exacta  Pase a la pregunta 8 
2 Aproximada 
99 No sabe / No responde 
6 Años cumplidos a la fecha  
 
Años 
7 Su edad es… 1 Exacta 
2 Aproximada 
99 No sabe / No responde 
8 ¿Cuál es su estado civil? 1 Soltero 
2 Casado 
3 Conviviente 
4 Separado 
5 Divorciado 
6 Viudo(a) 
99 No sabe / No responde 
9 ¿Cuál es el nivel de educación más alto que ha alcanzado? 1 Sin nivel 
2 Inicial 
3 Primaria  
 
4 Secundaria 
5 Superior no universitaria 
6 Superior universitaria 
99 No sabe / No responde 
10 Actualmente, ¿Está trabajando? 1 Si 
2 No 
11 En el último mes, ¿a cuánto ascendió su ingreso (no 
incluya el apoyo de otros familiares)? 
Ingrese "99999" si no responde 
 
 
 
Soles 
Código del Participante: 
 
─ 
 
─ 
 
Código de trabajador: 
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12 Tomando como referencia los últimos 12 meses: ¿Cuál fue 
su ingreso mensual (no incluya el apoyo de otros 
familiares)? 
1 No recibe ingresos 
2 Hasta 100 soles 
3 Entre 101 y 450 soles 
4 Entre 451 y 750 soles 
5 Entre 751 y 1000 soles 
6 Entre 1001 y 1500 soles 
7 Más de 1500 soles 
99 No sabe / No responde 
13 Tomando como referencia los últimos 12 meses: ¿Cuál fue 
el ingreso familiar mensual incluyendo el apoyo de todos los 
familiares? 
 
Observación:  
Corroborar este dato con el de la pregunta anterior 
(este valor debe ser mayor o igual a la pregunta 12) 
1 Hasta 100 soles 
2 Entre 101 y 450 soles 
3 Entre 451 y 750 soles 
4 Entre 751 y 1000 soles 
5 Entre 1001 y 1500 soles 
6 Entre 1501 y 2000 soles 
7 Más de 2000 soles 
99 No sabe / No responde / Rehúsa responder 
14 Usted se considera como: 
 
(Leer todas las respuestas) 
1 Nativo Amazónico 
2 Nativo Quechua o Aymara 
3 Mestizo 
4 Afro-descendiente / Negro 
5 Caucásico / Blanco 
6 Asiático / Amarillo 
7 Otro 
99 No sabe / No responde 
15 ¿Ha vivido en este lugar toda su vida? 1 Si  Pasar al siguiente módulo  
2 No  
16 ¿Qué edad tenía cuando llegó a esta ciudad? 
 
 
Años 
 
Módulo: Cobertura de salud Respuesta 
17 Actualmente ¿se encuentra Ud. afiliado a algún sistema de 
salud? 
1 Si 
2 No  Pasar a la siguiente sección 
18 Especifique a cuál de estos sistemas de salud se encuentra 
afiliado. 
 
(Acepte una o más alternativas) 
1 ESSALUD 
2 Seguro Integral de Salud 
3 Seguro privado / Entidad prestadora de salud 
4 Otro seguro 
99 No sabe / No responde 
 
Código del Participante: 
 
─ 
 
─ 
 
Código de trabajador: 
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Sección 3: Formato de Evaluación de la Vivienda 
 
Módulo: Características de la familia  Respuesta 
1 ¿Cuántas personas en total, incluyéndolo a Ud., viven en su casa? 
 
Personas 
2 ¿Cuántas de estas personas son mayores de 18 años? (inclúyase Ud.) 
 
Personas 
3 ¿Cuántas familias que cocinan sus propios alimentos viven en su vivienda? 
 
Número de familias 
4 ¿Cuántos ambientes de su vivienda se usan solo para dormir? 
 
Número de ambientes 
 
Módulo: Posesiones en la vivienda 
5 Tiene en su hogar… 
 
(Leer las opciones, verificar si funcionan y marcar todas 
las que apliquen) 
1 Cocina a gas 
2 Inodoro con desagüe 
3 Radio / equipo de sonido 
4 Horno microondas 
5 Licuadora 
6 Plancha 
7 TV a color 
8 Refrigerador 
9 Lavadora 
10 Computadora 
11 Teléfono fijo 
12 Celular 
13 Conexión a cable 
14 Conexión a Internet 
15 Bicicleta para adultos 
16 Motocicleta 
17 Carro 
99 Rehúsa responder 
 
Módulo: Facilidades en la vivienda Respuesta 
6 ¿Cuál es la fuente principal de abastecimiento de agua que 
utilizan en su hogar?  
 
(Leer todas las opciones y marcar la que aplica) 
1 Caño dentro de la vivienda 
2 Pozo en la casa o lote 
3 Caño o pilón de uso público 
4 Pozo público 
5 Manantial 
6 Río/acequia 
7 Camión, tanque o aguatero 
8 Otro: ___________________________ 
99 Rehúsa responder 
 
Código del Participante: 
 
─ 
 
─ 
 
Código de trabajador: 
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7 ¿Cuál es el material predominante de los pisos de su 
vivienda? 
1 Piso natural: tierra o arena 
2 Piso rústico: entablado 
3 Piso de cemento no acabado 
4 Parquet, vinílicos, losetas, cemento 
99 Rehúsa responder 
8 ¿Cuál es el material predominante en los techos de su 
vivienda? 
1 Esteras, paja, hojas de palmera 
2 Calamina, madera, caña, fibra de cemento 
3 Tejas  
4 Concreto armado o cemento 
99 Rehúsa responder 
9 Mayormente, ¿qué tipo de combustible utiliza para cocinar? 1 Leña 
2 Estiércol, bosta, heces, etc. 
3 Carbón 
4 Kerosene 
5 Gas propano 
6 Electricidad 
7 Otro 
99 Rehúsa responder 
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Sección 4: Formato de Evaluación de Estilos de Vida (LAF) 
 
Módulo: Consumo de tabaco Respuesta 
1 Actualmente…  1 No fumo  
2 Fumo ocasionalmente  
3 Fumo diariamente (al menos uno al día) 
99 Rehúsa responder 
2 ¿Cuál describe mejor su historia de consumo de tabaco? 1 Nunca fumó  Pase al siguiente modulo 
2 Fumo anteriormente  
3 Fuma actualmente  
99 Rehúsa responder 
3 ¿Qué edad tenía cuando comenzó a fumar o probó 
cigarrillos por primera vez en su vida? 
 
 
Años  
(99 = No sabe/no recuerda) 
4 ¿Cuándo fue la última vez que fumó un cigarrillo? 1 Menos de 1 mes 
2 Entre 1 y 6 meses  Pase al siguiente modulo 
3 Entre 6 y 12 meses  Pase al siguiente modulo 
4 Un año y más  Pase al siguiente modulo 
99 No sabe / No responde 
5 ¿Cuántos cigarrillos fumó en total en los últimos treinta 
días?  
Número de cigarrillos  
(999 = No sabe/no responde) 
 
Módulo: Uso de alcohol Respuesta 
6 ¿Con qué frecuencia consume alguna bebida alcohólica?   1 Nunca  Pase a la pregunta 16 
2 Una o menos veces al mes 
3 De 2 a 4 veces al mes 
4 De 2 a 3 veces a la semana 
5 4 o más veces a la semana 
99 Rehúsa responder 
7 ¿Cuántas botellas de cerveza o su equivalente en otras 
bebidas puede beber en un día normal de consumo?   
1 1 ó 2  
2 3 ó 4 
3 5 ó 6 
4 7 a 9 
5 10 ó mas 
99 Rehúsa responder 
8 ¿Con qué frecuencia toma 6 o más botellas de cerveza o 
su equivalente en bebidas alcohólicas en una misma 
ocasión de consumo?   
1 Nunca 
2 Menos de 1 vez al mes 
3 Mensualmente 
4 Semanalmente 
5 A diario o casi a diario 
99 Rehúsa responder 
 
Código del Participante: 
 
─ 
 
─ 
 
Código de trabajador: 
 
 
Bernabe-Ortiz A; Abril 7, 2016 (v1.0)    
 
9 ¿Con qué frecuencia en el curso del último año ha sido 
incapaz de parar de beber una vez que había empezado?   
1 Nunca 
2 Menos de 1 vez al mes 
3 Mensualmente 
4 Semanalmente 
5 A diario o casi a diario 
99 Rehúsa responder 
10 ¿Con qué frecuencia en el curso del último año no pudo 
hacer lo que otros esperaban de usted porque había 
bebido?   
1 Nunca 
2 Menos de 1 vez al mes 
3 Mensualmente 
4 Semanalmente 
5 A diario o casi a diario 
99 Rehúsa responder 
11 ¿Con qué frecuencia en el curso del último año ha 
necesitado de beber en ayunas para recuperarse 
después de haber bebido mucho el día anterior?   
1 Nunca 
2 Menos de 1 vez al mes 
3 Mensualmente 
4 Semanalmente 
5 A diario o casi a diario 
99 Rehúsa responder 
12 ¿Con qué frecuencia en el curso del último año ha tenido 
remordimientos o sentimientos de culpa después de 
haber bebido?   
1 Nunca 
2 Menos de 1 vez al mes 
3 Mensualmente 
4 Semanalmente 
5 A diario o casi a diario 
99 Rehúsa responder 
13 ¿Con qué frecuencia en el curso del último año no ha 
podido recordar lo que sucedió la noche anterior porque 
había estado bebiendo?   
1 Nunca 
2 Menos de 1 vez al mes 
3 Mensualmente 
4 Semanalmente 
5 A diario o casi a diario 
99 Rehúsa responder 
14 ¿Con qué frecuencia tiene Ud. resaca? 1 Nunca 
2 Menos de 1 vez al mes 
3 Mensualmente 
4 Semanalmente 
5 A diario o casi a diario 
99 Rehúsa responder 
15 Si tuviera que calificar su consumo de alcohol, Ud. diría 
que mayormente es:  
1 Acompañando las comidas  
2 Mayoría de fines de semana o vacaciones 
3 Momentos o motivos ocasionales 
99 Rehúsa responder 
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16 ¿Usted o alguna persona han resultado heridos porque 
usted había estado bebiendo?   
1 No 
2 Sí, pero no durante el último año 
3 Sí, durante el último año 
99 Rehúsa responder 
17 ¿Algún familiar, amigo, médico o profesional sanitario 
han mostrado preocupación por su consumo de bebidas 
alcohólicas o le han indicado que deje de beber?   
1 No 
2 Sí, pero no durante el último año 
3 Sí, durante el último año 
99 Rehúsa responder 
 
Módulo: Actividad física Respuesta 
18 ¿Considera usted que es físicamente activo? 1 Si 
2 No 
99 Rehúsa responder 
19 ¿Comparando su actividad física con otros sujetos de la 
misma edad, considera usted que físicamente activo? 
1 Si 
2 No 
99 Rehúsa responder 
20 ¿Realiza habitualmente al menos 30 minutos de 
actividad física, en el trabajo y/o en su tiempo libre? 
1 Si 
2 No 
99 Rehúsa responder 
21 ¿Cuánto tiempo (en horas) diría usted que gasta 
usualmente sentado o reclinado en un día típico?  
Número de horas por día  
99 No sabe/ Rehúsa responder 
 
Módulo: Actividad física intensas Respuesta 
LEA: Piense en todas las actividades físicas intensas que usted realizó en los últimos 7 días. Las actividades físicas 
intensas se refieren a aquellas que implican un esfuerzo físico intenso y que lo hacen respirar mucho más intensamente 
que lo normal. Piense solo en aquellas actividades físicas que realizó durante por lo menos 10 minutos seguidos. 
22 Durante los últimos 7 días, ¿en cuántos días realizó 
actividades físicas intensas tales como levantar pesos 
pesados, cavar, hacer ejercicios aeróbicos o andar 
rápido en bicicleta? 
 
Días por semana Si 00 pase a p24 
99 No sabe/ Rehúsa responder  Pase a p24 
23 Habitualmente, ¿cuánto tiempo en total dedicó a una 
actividad física intensa en uno de esos días?  
: 
 
Tiempo (HH:MM) por día 
99 No sabe/ Rehúsa responder 
 
Módulo: Actividad física moderadas Respuesta 
LEA: Piense en todas las actividades físicas moderadas que usted realizó en los últimos 7 días. Las actividades físicas 
moderadas son aquellas que requieren un esfuerzo físico moderado que lo hacen respirar algo más intensamente que lo 
normal. Piense solo en aquellas actividades físicas que realizó durante por lo menos 10 minutos seguidos. 
24 Durante los últimos 7 días, ¿en cuántos días realizó 
actividades físicas moderadas como transportar pesos 
livianos, andar en bicicleta a velocidad regular, subir 
cerros? No incluya caminar 
 
Días por semana Si 00 pase a p26 
99 No sabe/ Rehúsa responder  Pase a p26 
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25 Habitualmente, ¿cuánto tiempo en total dedicó a una 
actividad física moderada en uno de esos días?  
: 
 
Tiempo (HH:MM) por día 
99 No sabe/ Rehúsa responder 
 
Módulo: Actividad física leves Respuesta 
LEA: Piense en el tiempo que usted dedicó a caminar en los últimos 7 días. Esto incluye caminar en el trabajo o en la 
casa, para trasladarse de un lugar a otro, o cualquier otra caminata que usted podría hacer solamente para la recreación, el 
deporte, el ejercicio o el ocio. 
26 Durante los últimos 7 días, ¿en cuántos días caminó 
durante por lo menos 10 minutos seguidos?  
Días por semana Si 00 pase a p28 
99 No sabe/ Rehúsa responder  Pase a p28 
27 Habitualmente, ¿cuánto tiempo en total dedicó a caminar 
en uno de esos días?  
: 
 
Tiempo (HH:MM) por día 
99 No sabe/ Rehúsa responder 
 
Módulo: Ausencia de actividad física Respuesta 
28 Durante los últimos 7 días,  de lunes a viernes, ¿Cuánto 
tiempo pasó sentado viendo TV?  
Horas por día (Colocar 00 si es <1 hora) 
99 No sabe/ Rehúsa responder 
29 Durante los últimos 7 días,  en el fin de semana, 
¿Cuánto tiempo pasó sentado viendo TV?  
Horas por día (Colocar 00 si es <1 hora) 
99 No sabe/ Rehúsa responder 
 
Módulo: Patrones de dieta Respuesta 
Instrucciones: Pregunte al participante que tan frecuentemente consume comida de cada una de las siguientes 
categorías. Coloque en el recuadro según la frecuencia: 
   1 = Nunca     2 = 1 a 3 veces/mes 
   3 = 1 vez por semana    4 = 2 a 4 veces por semana 
   5 = 5 a 6 veces por semana   6 = 1 vez por día 
   7 = Mas de 1 vez por día  
Durante el último mes, en promedio con qué frecuencia consumió: Frecuencia Número de veces 
30 Vegetales verdes: lechuga, espinaca, espárragos, brócoli, etc. 
 
Si 7  
 
31 Vegetales crudos (no verdes): zanahorias, tomates, etc. 
 
Si 7  
 
32 Vegetales cocidos (no verdes): zanahorias, tomates, etc. 
 
Si 7  
 
33 Frutas: plátanos, naranjas, manzanas, fresas, frutas secas, etc. 
 
Si 7  
 
34 Jugos y néctares artificiales: Frugo’s, Pulp, Cifrut, Aquarius, etc. 
 
Si 7  
 
35 Bebidas gaseosas: Coca Cola, Inka Cola, Fanta, etc. 
 
Si 7  
 
36 Bebidas rehidratantes: Sporade, Gatorade, etc. 
 
Si 7  
 
37 Té y otras infusiones (hierbaluisa, anis, etc.) 
 
Si 7  
 
38 Café  
 
Si 7  
 
39 Refrescos: limonada, agua de manzana, etc. 
 
Si 7  
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Durante el último mes, en promedio con qué frecuencia añadió azúcar a alguna bebida: 
  # cucharaditas Al ras Normal Colmada 
40 Té y otras infusiones (hierbaluisa, anis, etc.) 
    
41 Café  
    
42 Refrescos: limonada, agua de manzana, etc. 
    
 
Módulo: Horas de sueño 
43 ¿Cómo promedio, en el último año, cuántas horas durmió en un día 
(incluyendo siestas)?  
Número de horas 
(99 = No sabe/no recuerda) 
44 Durante el último mes, ¿ha tenido dificultades para poder 
dormir? 
1 Casi nunca 
2 A veces 
3 Con frecuencia 
45 Durante el último mes, ¿qué tan frecuentemente se despierta 
durante la noche? 
1 Casi nunca 
2 A veces 
3 Con frecuencia 
 
Módulo: Escala de Epworth (Versión peruana modificada) 
46 ¿Usted maneja vehículos motorizados (auto, camioneta, 
ómnibus, micro, combi, etc.)? 
1 Si 
2 No 
Instrucciones: ¿Qué tan probable es que usted cabecee o se quede dormido en las siguientes situaciones? No se 
refiere a sentirse cansado debido a actividad física. Aunque no haya realizado últimamente las siguientes situaciones 
descritas, considere como le habrían afectado. Use la siguiente escala y marque la opción más apropiada para cada 
situación: 
0 = Nunca cabecearía,  
1 = Poca probabilidad de cabecear,  
2 = Moderada probabilidad de cabecear,  
3 = Alta probabilidad de cabecear. 
47 Sentado leyendo 
 
48 Viendo televisión  
 
49 Sentado (por ejemplo en el teatro, en una reunión, en el cine, en una conferencia, o en misa o culto) 
 
50 Como pasajero en un automóvil, ómnibus, micro o combi durante una hora o menos de recorrido 
 
51 Recostado en la tarde si las circunstancias lo permiten 
 
52 Sentado conversando con alguien 
 
53 Sentado luego del almuerzo y sin haber bebido alcohol 
 
54 Conduciendo el automóvil cuando se detiene algunos minutos por razones de tráfico   
 
55 Parado y apoyándose o no en una pared o mueble  
 
 
Módulo: Ronquidos y apnea 
56 ¿Alguna vez le han dicho que Ud. ha roncado (ahora o en 
cualquier momento en el pasado)? 
1 Si 
2 No  Pase a la pregunta 59 
99 No sabe /rehúsa responder 
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57 ¿Qué tan frecuente Ud. ronca?  
 
(Marcar solo una respuesta) 
1 No he roncado nunca 
2 Rara vez – Menos de 1 noche por semana 
3 Algunas veces – 1 a 2 noches por semana 
4 Frecuentemente – 3 a 5 noches por semana 
5 Siempre o casi siempre 
99 No sabe /rehúsa responder 
58 ¿Qué tan fuerte es su ronquido? 
 
(Marcar solo una respuesta) 
1 Un poco más fuerte que respiración profunda 
2 Tan fuerte como murmurar o hablar 
3 Más fuerte que hablar 
4 Muy fuerte – se escucha tras una puerta cerrada 
99 No sabe /rehúsa responder 
59 Basado en lo que Ud. ha notado o los otros miembros de su 
vivienda le han dicho, ¿hay veces que su respiración se 
detiene mientras Ud. duerme? 
1 Si 
2 No 
99 No sabe /rehúsa responder 
60 ¿Algún miembro de su familia le ha dicho que durante su 
sueño Ud. suena como si se estuviera ahogando? 
 
1 Si 
2 No 
99 No sabe /rehúsa responder 
 
Módulo: Calidad de sueño 
Lea: “Las siguientes preguntas solo tienen que ver son sus hábitos de sueño durante el último mes. En sus respuestas 
debe reflejar cual ha sido su comportamiento durante la mayoría de los días y noches del pasado mes“. 
61 Durante el último mes, ¿cuál ha sido, normalmente, su hora de 
acostarse?  
: 
 
(Colocar en sistema 
de 24 horas) 
62 ¿Cuánto tiempo habrá tardado en dormirse, normalmente, 
las noches del último mes?  
1 Menos de 15 minutos 
2 Entre 16 y 30 minutos 
3 Entre 31 y 60 minutos 
4 Más de 60 minutos  
63 Durante el último mes, ¿a qué hora se ha levantado habitualmente por 
la mañana?  
: 
 
(Colocar en sistema 
de 24 horas) 
64 ¿Cuántas horas calcula que habrá dormido verdaderamente cada 
noche durante el último mes?  
Número de horas 
65 Lea: “Durante el último mes, ¿Cuántas veces ha tenido usted problemas para dormir a causa de…” 
Marque según corresponda:   0 = Ninguna vez en el último mes   
     1 = Menos de una vez a la semana 
     2 = Una o dos veces a la semana  
     3 = Tres o más veces a la semana 
a. No poder conciliar el sueño en la primera media hora 
 
b. Despertarse durante la noche o de madrugada 
 
c. Tener que levantarse para ir al servicio 
 
d. No poder respirar bien 
 
e. Toser o roncar ruidosamente 
 
f. Sentir frio  
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g. Sentir demasiado calor 
 
h. Tener pesadillas o malos sueños  
 
i. Sufrir dolores 
 
j. Otras razones (describir): 
 
66 Durante el último mes, ¿Cómo valoraría en conjunto, la 
calidad de su sueño?  
1 Muy buena 
2 Bastante buena 
3 Bastante mala 
4 Muy mala 
67 Durante el último mes, ¿Cuántas veces habrá tomado 
medicinas (por su cuenta o recetadas por el médico) para 
dormir?  
1 Ninguna vez en el último mes 
2 Menos de una vez a la semana 
3 Una o dos veces a la semana 
4 Tres o más veces a la semana 
68 Durante el último mes, ¿Cuántas veces ha sentido 
somnolencia mientras conducía, comía o desarrollaba 
alguna otra actividad?  
1 Ninguna vez en el último mes 
2 Menos de una vez a la semana 
3 Una o dos veces a la semana 
4 Tres o más veces a la semana 
69 Durante el último mes, ¿Ha representado para usted mucho 
problema el tener ánimos para realizar alguna de las 
actividades detalladas en la pregunta anterior?  
1 Ningún problema  
2 Solo un leve problema 
3 Un problema 
4 Un grave problema 
70 ¿Duerme usted solo o acompañado? 1 Solo 
2 Con alguien en otra habitación  
3 En la misma habitación, pero en otra cama 
4 En la misma cama 
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Sección 5: Formato de Evaluación de Salud mental (MHF) 
 
Módulo: Síntomas depresivos Respuesta 
Instrucciones: Escoja una de las opciones de acuerdo a las respuestas del participante: 
0 = Nunca 
1 = Varios días 
2 = Más de la mitad de los días 
3 = Casi todos los días 
Pregunta: Durante las últimas 2 semanas, ¿con qué frecuencia le han molestado los siguientes problemas? 
1 Tener poco interés o placer en hacer las cosas 
 
2 Sentirse desanimado/a, deprimido/a, triste o sin esperanza 
 
3 Problemas en dormirse o mantenerse dormido/a, o en dormir demasiado 
 
4 Sentirse cansado/a o tener poca energía 
 
5 Tener poco apetito o comer en exceso 
 
6 
Sentirse mal acerca de sí mismo/a – o sentir que es un/una fracasado/a o que se ha fallado a si 
mismo/a o a su familia  
7 Dificultad para poner atención, concentrarse en cosas tales como leer el periódico o ver televisión 
 
8 
Moverse o hablar tan despacio que otras personas lo pueden haber notado – o lo contrario: estar tan 
inquieto/a o intranquilo/a que se ha estado moviendo mucho más de lo normal  
9 Pensamientos de que sería mejor estar muerto/a o que quisiera hacerse daño de alguna forma 
 
 
Módulo: Ansiedad Respuesta 
Lea: “A continuación me gustaría hacerle algunas preguntas para saber si ha tenido alguno de los siguientes 
síntomas en las últimas dos semanas.” 
10 ¿Se ha sentido muy excitado, nervioso o tensión? 1 Si 
2 No 
11 ¿Ha estado muy preocupado por algo? 1 Si 
2 No 
12 ¿Se ha sentido muy irritable? 1 Si 
2 No 
13 ¿Ha tenido dificultad para relajarse? 1 Si 
2 No 
14 ¿Ha dormido mal, ha tenido dificultades para dormir? 1 Si 
2 No 
15 ¿Ha tenido dolores de cabeza o nuca? 1 Si 
2 No 
16 ¿Ha tenido alguno de los siguientes síntomas: temblores, 
hormigueos, mareos, sudores, diarrea?  
1 Si 
2 No 
17 ¿Ha estado preocupado por su salud? 1 Si 
2 No 
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18 ¿Ha tenido alguna dificultad para conciliar el sueño, para 
quedarse dormido? 
1 Si 
2 No 
 
Módulo: Calidad de vida Respuesta 
Instrucciones: Marque la respuesta que mejor describe su estado de salud en el día de hoy. 
19 Movilidad 1 No tengo problemas para caminar 
2 Tengo algunos problemas para caminar 
3 Tengo que estar en cama 
20 Cuidado personal 1 No tengo problemas con mi cuidado personal 
2 Tengo algunos problemas para lavarme o vestirme solo 
3 Soy incapaz de lavarme o vestirme solo 
21 Actividades habituales (por ejemplo, estudiar, hacer 
tareas domésticas, actividades familiares o 
realizadas durante el tiempo libre) 
1 No tengo problemas para realizar mis actividades  
2 Tengo algunos problemas para realizar mis actividades 
3 Soy incapaz de realizar mis actividades habituales 
22 Dolor o malestar 1 No tengo dolor ni malestar 
2 Tengo dolor o malestar moderado 
3 Tengo mucho dolor o malestar 
23 Ansiedad o depresión 1 No estoy ansioso ni deprimido 
2 Estoy moderadamente ansioso o deprimido 
3 Estoy muy ansioso o deprimido 
 
Módulo: Termómetro de Autovaloración del Estado de Salud (Calidad de vida) 
Para ayudar a la gente a describir lo bueno o malo que es su estado de salud hemos dibujado una escala parecida a un 
termómetro en el cual se marca con un 100 el mejor estado de salud que pueda imaginarse y con un 0 el peor estado de 
salud que pueda imaginarse. Nos gustaría que nos indicara en esta escala, en su opinión, lo bueno o malo que es su 
estado de salud el día de hoy. 
Instrucciones: Muestre la hoja al participante y coloque el valor del termómetro en el cuadro provisto (al lado de “Su 
estado de salud hoy”). 
 
 
 
 
 
 
 
 
Su estado de salud HOY: 
 
 
Módulo: Situaciones importantes 
Instrucciones: En el último año, alguna vez experimentó algo de lo siguiente: 
1 = Si   2 = No   9 = No responde 
24 Separación / divorcio  
25 Pérdida del empleo / jubilación  
26 Pérdidas en su negocio  
Peor estado de salud 
que pueda imaginarse 
Mejor estado de salud 
que pueda imaginarse 
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27 Conflicto familiar importante  
28 Lesión o enfermedad importante   
29 Muerte de cónyuge (esposo/a)  
30 Muerte de hijo o algún familiar cercano  
 
Módulo: Estrés percibido Respuesta 
Lea: “Las preguntas a continuación se refieren a los sentimientos y pensamientos que ha tenido durante el último mes.” 
Instrucciones: Marque según corresponda: 
1 = Nunca 2 = Casi nunca 3 = De vez en cuando 4 = Frecuentemente 5 = Casi siempre 
31 En el último mes, ¿te has sentido molesto a causa de alguna situación inesperada?  
32 En el último mes, ¿te has sentido incapaz de controlar hechos importantes en tu vida?  
33 En el último mes, ¿te has sentido continuamente tenso?  
34 En el último mes, ¿resolviste de manera exitosa las discusiones desagradables en tu vida?  
35 En el último mes, ¿sentiste que enfrentaste exitosamente los cambios que estaban ocurriendo en tu vida?  
36 En el último mes, ¿confiaste en tu capacidad para manejar tus problemas personales?  
37 En el último mes, ¿sentiste que las cosas te estaban resultando como tú querías?  
38 En el último mes, ¿encontraste que no podías resolver todas las situaciones que tenias que enfrentar?  
39 En el último mes, ¿has podido controlar los hechos desagradables de tu vida?  
40 En el último mes, ¿sentiste que estabas colapsado con las situaciones que te ocurrieron?  
41 En el último mes, ¿te has sentido molesto por situaciones que estaban fuera de tu control?  
42 En el último mes, ¿te has encontrado pensando en las situaciones que tienes que resolver?  
43 En el último mes, ¿has sido capaz de manejar tu tiempo según tus propias necesidades?  
44 En el último mes, ¿sentiste que los problemas se te iban acumulando?  
 
Módulo: Soporte social  Respuesta 
Instrucciones: En la siguiente lista se muestran algunas cosas que otras personas hacen por nosotros o nos proporcionan. 
Elija para cada una la respuesta que mejor refleje su situación, según los siguientes criterios: 
1 = Mucho menos de lo que deseo 
2 = Menos de lo que deseo 
3 = Ni mucho ni poco 
4 = Casi como deseo 
5 = Tanto como deseo 
45 Recibo visitas de mis amigos y familiares 
 
46 Recibo ayuda en asuntos relacionados con mi casa 
 
47 Recibo elogios y reconocimientos cuando hago bien mi trabajo 
 
48 Cuento con personas que se preocupan de lo que me sucede 
 
49 Recibo amor y afecto 
 
50 Tengo la posibilidad de hablar con alguien de mis problemas en el trabajo o en la casa 
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51 Tengo la posibilidad de hablar con alguien de mis problemas personales y familiares 
 
52 Tengo la posibilidad de hablar con alguien de mis problemas económicos  
 
53 Recibo invitaciones para distraerme y salir con otras personas 
 
54 Recibo consejos útiles cuando me ocurre algún acontecimiento importante en mi vida 
 
55 Recibo ayuda cuando estoy enfermo en la cama 
 
 
Módulo: Parkinsonismo Respuesta 
Instrucciones: Estamos intentando evaluar la utilidad de este cuestionario. Quisiéramos que nos ayudara contestando a 
las siguientes preguntas:  
56 ¿Tiene Ud. problemas para levantarse de una silla? 1 Si 
2 No 
57 ¿Ha notado si su escritura se ha hecho más pequeña que 
antes? 
1 Si 
2 No 
58 ¿Le han comentado sobre si el volumen de su voz es 
menos potente que antes? 
1 Si 
2 No 
59 ¿Ha notado que su equilibrio está alterado? 1 Si 
2 No 
60 ¿Ha notado que los pies se le quedan pegados al suelo al 
cruzar el umbral de las puertas? 
1 Si 
2 No 
61 ¿Le parece que su cara es ahora menos expresiva? 1 Si 
2 No 
62 ¿Le tiemblan los brazos y piernas? 1 Si 
2 No 
63 ¿Tiene dificultad para abrocharse los botones? 1 Si 
2 No 
64 ¿Arrastra los pies y da pasitos cortos al andar? 1 Si 
2 No 
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Sección 6: Formato de Antecedentes Cardiovascular (HAF) 
 
Módulo: Antecedentes personales Respuesta 
1 ¿Ha sufrido o le han dicho que tiene alguna vez de estas 
enfermedades? 
 
(Por algún profesional de salud) 
Fue diagnosticado: 
 
1 = Si 
2 = No 
9 = NS/NR 
Quién fue: 
1 = Médico 
2 = Enfermera 
3 = Farmacéutico 
4 = Otro 
9 = NS/NR 
# años desde el 
diagnóstico 
(00 si es < 1 año) 
(Leer las opciones y marcar 
todas las que aplican) 
Presión arterial alta 
   
Derrame cerebral 
   
Infarto (ataque) cardiaco 
   
Insuficiencia cardiaca 
   
Colesterol alto 
   
Diabetes 
   
Cáncer  
   
Especifique el tipo de cáncer:  
 
Módulo: Diagnóstico y tratamiento de diabetes Respuesta 
2 ¿Alguna vez algún doctor (o cualquier otro profesional de 
salud) le ha medido la glucosa (azúcar) en la sangre? 
1 Si 
2 No  Pasar a la pregunta 5 
3 ¿Alguna vez le han encontrado niveles de glucosa (azúcar 
en sangre) altos (en un examen médico, durante alguna 
enfermedad, o durante el embarazo)? 
1 Si 
2 No 
4 ¿Cuándo fue la última vez que le midieron la glucosa 
(azúcar) en la sangre? 
1 Menos de 1 año 
2 Entre 1 y 2 años  
3 Más de 2 años  
9 No recuerda 
5 En estos momentos, ¿algún médico le ha indicado algún 
tratamiento para controlar el azúcar en su sangre 
(diabetes)? 
1 Si 
2 No  Pasar al siguiente módulo  
6 ¿Tiene Ud. indicado algún tratamiento con 
medicamentos para controlar la diabetes? 
1 Si 
2 No  Pasar al siguiente módulo 
7 Enumere otros medicamentos que está actualmente 
tomando para controlar la diabetes. 
 
Por favor, pida el medicamento y copie el nombre y 
presentación. 
1                                                  
2  
3  
4  
5  
8 ¿Toma los medicamentos para controlar la diabetes en el 
horario establecido? 
1                                                  Siempre 
2 Casi siempre 
3 A veces 
4 Casi nunca 
5 Nunca 
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9 ¿Toma los medicamentos para controlar la diabetes en 
las dosis indicadas? 
1                                                  Siempre 
2 Casi siempre 
3 A veces 
4 Casi nunca 
5 Nunca 
10 En el último año, ¿ha sido hospitalizado debido a su 
diabetes?  
1 Si 
2 No  Pasar a la pregunta 12 
11 En el último año, ¿Cuántas veces ha sido hospitalizado 
debido a su diabetes?   
Número de veces 
12 ¿Algún médico le ha dicho que presenta complicaciones 
debido a la diabetes? 
1 Si 
2 No  Pasar al siguiente módulo 
13 ¿En qué parte del cuerpo le han dicho que presenta 
dichas complicaciones? 
 
(Marque todas las que aplican) 
1 Ojos (retina) 
2 Cardiaca (presión arterial o corazón) 
3 Renal (riñones) 
4 Pies (neuropatía) 
5 Otros (especifique) 
 
Módulo: Antecedentes familiares de diabetes Respuesta 
14 ¿Alguno de los miembros de su familia ha sido 
diagnosticado con diabetes? 
1 Si 
2 No  Pasar al siguiente módulo 
15 ¿Quién de su familia fue diagnosticado con diabetes? 
 
 
(Solo considere aquellos familiares de sangre, y marque 
todas las que aplican) 
Padre 
 
Madre 
 
Hermano o hermana 
 
Hijo o hija 
 
Abuelos 
 
Tíos o tías 
 
Primos de primer grado 
 
 
Módulo: Otros antecedentes de importancia Respuesta 
16 Enumere todos los medicamentos que está actualmente 
tomando al menos una vez por semana durante el último 
mes para controlar 
 
 
TOMA PARA… 
1 = Si 
2 = No 
9 = NR 
MEDICAMENTO 
Indicar nombre 
Presión arterial alta 
 
 
Derrame cerebral 
 
 
Infarto(ataque) cardiaco 
 
 
Insuficiencia cardiaca 
 
 
Colesterol alto 
 
 
Arritmia cardiaca 
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17 Enumere otros medicamentos que está actualmente 
tomando al menos una vez por semana en el último 
mes. 
Por favor, pida el medicamento y copie el nombre 
y presentación. 
1                                                  
2  
3  
4  
 
Módulo: Accidente cerebro-vascular Respuesta 
Instrucciones: Escribir en el recuadro según corresponda: 
   1 = Si   2 = No   9 = No responde 
18 ¿Se ha desmayado alguna vez, quedando con problemas para caminar o ha tenido pérdida de 
fuerza en alguno de sus miembros?  
19 ¿Ha perdido alguna vez la fuerza en alguno de sus brazos o piernas o en toda la mitad del cuerpo 
por tiempo prolongado?  
20 ¿Ha presentado alguna vez “entumecimiento”, “adormecimiento” o pérdida de sensibilidad en la 
mitad de la cara o del cuerpo?  
21 ¿Ha tenido dificultad para entender lo que dicen, para expresar lo que quiere decir o ha notado 
cambios en su voz?  
22 ¿Ha tenido dificultad para tragar, visión doble o mareos, acompañado con dificultad para caminar, en 
forma transitoria o prolongada?  
23 ¿Le han dicho alguna vez que ha tenido “derrame”? 
 
24 ¿Ha visto borroso alguna vez o ha perdido bruscamente la visión en uno o ambos ojos? 
 
25 ¿Le han dicho alguna vez que tuvo trombosis, hemorragia o “derrame”? 
 
 
Módulo: Enfermedad gingival Respuesta 
26 ¿Piensa usted que tal vez sufra de enfermedad de las 
encías? 
1 Si 
2 No 
99 No sabe/no responde 
27 En general, ¿cómo diría que es el estado de salud de sus 
dientes y encías?  
1 Excelente 
2 Muy buena 
3 Buena 
4 Regular 
5 Mala 
99 No sabe/no responde 
28 ¿Alguna vez ha recibido tratamiento de las encías tipo 
raspado o alisado de las raíces, que a veces se conoce 
como “limpieza profunda”? 
1 Si 
2 No 
99 No sabe/no responde 
29 ¿Alguna vez se le ha aflojado algún diente por si solo sin 
haber tenido una lesión? 
1 Si 
2 No 
99 No sabe/no responde 
30 ¿Alguna vez un dentista le ha dicho que usted ha perdido 
hueso alrededor de los dientes? 
1 Si 
2 No 
99 No sabe/no responde 
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31 En los últimos tres meses, ¿ha notado usted un diente 
que no parece verse bien? 
1 Si 
2 No 
99 No sabe/no responde 
32 Aparte del cepillado de sus dientes, ¿cuántas veces ha 
usado hilo dental o algún otro medio o utensilio para 
limpiarse entre los dientes en los últimos siete días? 
 
Número de días 
99 No sabe/ no responde 
33 Aparte del cepillado de sus dientes, ¿cuántas veces ha 
usado un enjuague bucal u otro producto líquido para el 
tratamiento de enfermedades o problemas dentales en 
los últimos siete días? 
 
Número de días 
99 No sabe/ no responde 
 
Módulo: Síntomas autonómicos  
Síntoma/problema de salud 
Q1. Durante los últimos 
6 meses, ¿ha tenido 
usted alguno de los 
siguientes síntomas? 
1 = Si  Pasar a Q2 
2 = No 
Q2. ¿Cuánto diría usted 
que el síntoma le molesta? 
1 = No me molesta 
2 = Un poco 
3 = Algo 
4 = Moderadamente 
5 = Bastante 
34 ¿Tiene mareos?   
35 ¿Tiene la boca o los ojos secos?   
36 ¿Tiene sus pies pálidos?   
37 ¿Tiene los pies más fríos que el resto de su cuerpo?   
38 
¿Está el sudor de sus pies disminuido en comparación 
con el resto de su cuerpo?   
39 
¿Está el sudor de sus pies disminuidos o ausentes (por 
ejemplo, después de ejercicio o en clima cálido)?   
40 
¿Está el sudor en sus manos aumentado en comparación 
con el resto de su cuerpo?   
41 
¿Tiene nauseas, vómitos o distensión abdominal después 
de comer una comida pequeña?   
42 
¿Tiene diarrea persistente (más de 3 deposiciones 
blandas por día)?   
43 
¿Tiene estreñimiento persistente (más de 1 deposición 
cada dos días)?   
44 ¿Se le escapa la orina?   
 Esta pregunta es solo para varones: 
45 ¿Tiene dificultad para obtener una erección?   
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Sección 7: Formato de Evaluación Cognitiva (CAF) 
 
Módulo: Leganés Respuesta 
Los problemas con la memoria preocupan mucho a los pacientes y a sus médicos. Disponemos de una prueba que consiste 
en una serie de preguntas que nos puede ayudar a diagnosticar esos problemas de memoria. Estas preguntas deberá 
responderlas usted solo, sin ayuda de su acompañante.  
Instrucciones: Por cada una de las siguientes preguntas, anotar la respuesta del participante, y colocar 1 en el puntaje si 
la respuesta es correcta y 0 si no es correcta. 
1 Por favor contésteme, ¿qué fecha es hoy? 
 
 
 Respuesta Puntaje 
DD/MM/AÑO   
2 ¿Qué hora es? 
 
 
 Respuesta Puntaje 
Hora   
3 ¿Qué día de la semana es? 
 
 
 Respuesta Puntaje 
Día    
4 ¿Cuál es su dirección completa? 
 
 
Respuesta Puntaje 
  
5 ¿En qué ciudad estamos? 
 
 
Respuesta Puntaje 
  
6 ¿Qué edad tiene? 
 
 
Respuesta Puntaje 
  
7 ¿Cuál es su fecha de nacimiento? 
 
 
Respuesta Puntaje 
  
8 ¿Cómo se llamaba su madre? 
 
 
Respuesta Puntaje 
  
Instrucciones: Ahora le voy a enseñar algunos dibujos para que usted me diga lo que son: 
 Por cada una de las siguientes preguntas colocar 1 en el 
puntaje si la respuesta es correcta y 0 si no es correcta. 
Respuesta Puntaje 
9 Vaca 
 
  
10 Barco   
11 Cuchara   
12 Avión    
13 Botella   
14 Camión   
Instrucciones: Por favor, repita que objetos ha visto e intente recordarlos porque dentro de un rato se los voy a volver a 
preguntar.  
 Dar un punto por respuesta correcta, si no dar cero Respuesta Puntaje 
15 Vaca 
 
  
16 Barco   
17 Cuchara   
18 Avión    
19 Botella   
20 Camión   
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Instrucciones: Voy a leerle una historia corta. Preste mucha atención porque solo se la voy a leer una vez. Cuando haya 
terminado esperaré unos segundos y después le pediré que me diga todo lo que recuerda de ella. La historia es: 
 (Leer despacio) 
“Tres niños estaban solos en una casa y la casa se incendió. Un valiente bombero logró entrar por una ventana trasera y 
los llevó a un lugar seguro. Quitando pequeños cortes o rasguños todos estaban bien”. 
Instrucciones: Dar como máximo dos minutos para que diga lo que recuerda de la historia. 
 Dar un punto por respuesta correcta, si no dar cero Respuesta Puntaje 
21 Tres niños  
 
  
22 Casa se incendió    
23 Bombero entró   
24 Los niños fueron rescatados   
25 Pequeñas heridas   
26 Todos bien   
Instrucciones: Cinco minutos más tarde de que se le ensenaran los dibujos 
(Durante este tiempo puede hacer una toma de presión arterial) 
 ¿Podría repetirme los objetos que vio en los dibujos hace 
un rato? 
Respuesta Puntaje 
27 Vaca 
 
  
28 Barco   
29 Cuchara   
30 Avión    
31 Botella   
32 Camión   
 
Módulo: Tu memoria Respuesta 
33 En comparación con hace 5 años, su memoria… 1 … ha mejorado 
2 … es la misma 
3 … es casi tan buena 
4 … está peor 
5 … está mucho peor 
Código del Participante: 
 
─ 
 
─ 
 
Código de trabajador: 
 
 
Bernabe-Ortiz A; Abril 7, 2016 (v1.0)    
 
Sección 8: Formato de Evaluación Antropométrica (AAF) 
 
Fecha 
Fecha (DD-MMM-20AA) 
     -          -    
 
Talla 
Talla parado  
 .  
[cm] 
 
Peso 
Peso  
 .  
[Kg] Ropa: 
 
1 = Mínimo / No usa 
2 = Ropa completa 
Número de máquina  
 
 
Circunferencias Medición 1 Medición 2 Medición 3 
Cintura (abdominal) 
 .  
[cm] 
 .  
[cm] 
 .  
[cm] 
Número del centímetro 
 
 
 
Presión arterial [brazo]
 
 Medición 1 Medición 2 Medición 3 
Presión sistólica (brazo) 
 
[mm Hg] 
 
[mm Hg] 
 
[mm Hg] 
Presión diastólica (brazo) 
 
[mm Hg] 
 
[mm Hg] 
 
[mm Hg] 
Pulso 
 
[lat./min] 
 
[lat./min] 
 
[lat./min] 
Manguito usado 
 
 [1 = Pequeño; 2 = Mediano; 3 = Grande] 
Número de aparato 
 
  
Medidas en lado derecho 
 
 [1 = Si; 2 = No] 
 
Pupilómetro: Medidas 
 Escotópico L Mesópico H Mesópico 
Ojo Derecho Diámetro  
 .  
[mm] 
 .  
[mm] 
 .  
[mm] 
 STD 
.  
[mm] 
.  
[mm] 
.  
[mm] 
Ojo Izquierdo Diámetro  
 .  
[mm] 
 .  
[mm] 
 .  
[mm] 
 STD 
.  
[mm] 
.  
[mm] 
.  
[mm] 
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Agudeza Visual 
 Ojo Derecho Ojo Izquierdo 
Angulo de resolución mínimo (MAR) 
 .  
LogMAR 
 .  
LogMAR 
 
EZScan
 
 
Intolerancia a la glucosa: 
P[IGT] 
Resistencia a la insulina:  
P[IR] 
Resultado final 
Porcentajes (%) 
 
% 
  
% 
 
% 
 
Evaluación final 
Medidas adecuadas 
 
[1 = Si; 2 = No] 
Si marcó NO, especificar  
Observaciones: 
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APPENDIX G: 
 
Table: Behavioural characteristics of the study population by sex 
 
 
Behavioural characteristic 
Males Females 
N = 754 N= 750 
 N (%) N (%) 
T2DM in first-degree relatives Yes 226 (30.0%) 242 (32.3%) 
Smoking    
Current smoking Do not smoke 561 (74.4%) 734 (97.9%) 
 Smoke occasionally 111 (14.7%) 12 (1.6%) 
 Smoke daily 82 (10.9%) 4 (0.5%) 
Self-reported history of smoking  Never smoked 241 (32.0%) 682 (90.9%) 
 Smoked before 311 (41.2%) 54 (7.2%) 
 Currently smoke 202 (26.8%) 14 (1.9%) 
Alcohol use    
Alcohol consumption Never 150 (19.9%) 468 (62.4%) 
 < One per month 458 (60.7%) 278 (37.1%) 
 1+ times per month 146 (19.4%) 4 (0.5%) 
Alcohol disorder Yes 119 (15.8%) 2 (0.3%) 
Physical activity    
Physically active (≥ 30min/day) Yes  557 (73.9%) 479 (63.9%) 
MET score (IPAQ) Low 179 (23.7%) 371 (49.5%) 
 Moderate 240 (31.8%) 279 (37.2%) 
 High 335 (44.4%) 100 (13.3%) 
Watching television (hours/day) < 2 hours/day 220 (29.2%) 321 (42.8%) 
 ≥2 but <4 hours/day 269 (35.7%) 244 (32.5%) 
 4+ hours/day 265 (35.1%) 185 (24.7%) 
Diet patterns    
Fruits and vegetables  At least one per day 356 (47.2%) 433 (57.7%) 
Sweetened juices consumption ≥ Once per week 95 (12.6%) 62 (8.3%) 
Soda consumption ≥ Once per week 166 (22.0%) 113 (15.1%) 
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APPENDIX H: 
 
Table: Anthropometrical characteristics of the study population by sex 
 
 
 Males Females 
 N = 754 N= 750 
Anthropometric characteristic N (%) N (%) 
Weight (kg) Mean (SD) 75.8 (12.8) 69.1 (12.9) 
Height (m) Mean (SD) 1.67 (0.1) 1.54 (0.1) 
Body mass index (kg/m
2
) Mean (SD) 27.1 (4.3) 28.9 (4.8) 
Body mass index (categories) Normal 245 (32.5%) 154 (20.5%) 
 Overweight 340 (45.1%) 315 (42.0%) 
 Obese 169 (22.4%) 281 (37.5%) 
Waist circumference (cm) Mean (SD) 93.8 (10.1) 93.4 (10.7) 
Waist circumference (IDF categories) Normal 253 (33.6%) 65 (8.7%) 
 Obese 501 (66.4%) 685 (91.3%) 
Systolic blood pressure (mmHg) Mean (SD) 124.3 (14.9) 114.7 (16.3) 
Diastolic blood pressure (mmHg) Mean (SD) 81.0 (10.2) 77.9 (10.2) 
Blood pressure treatment Yes 41 (5.4%) 65 (8.7%) 
Hypertension status Yes 200 (26.5%) 170 (22.7%) 
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APPENDIX I: 
 
Table: Comparison of results of risk scores and neuropathy assessment tools by sex 
 
 
 Results by sex 
p-value*  
Males  
(N = 754) 
Females 
(N = 750) 
 Mean (SD) Mean (SD) 
Risk score     
FINDRISC 7.7 (4.1) 10.1 (3.9) < 0.001 
LA-FINDRISC 8.0 (4.3) 9.1 (4.5) < 0.001 
Peruvian Risk Score 1.5 (1.1) 1.4 (1.1) 0.06 
Neuropathy assessment tool   
EZSCAN 25.7 (9.3) 28.8 (10.8) < 0.001 
Scotopic diameter 4.5 (0.9) 4.5 (0.8) 0.30 
Low mesopic diameter 4.5 (0.8) 4.5 (0.8) 0.62 
High mesopic diameter 4.3 (0.8) 4.3 (0.8) 0.29 
Pulp of the hallux 16.5 (9.4) 14.2 (7.6) < 0.001 
First metatarsal head 14.5 (8.4) 12.9 (7.2) < 0.001 
Third metatarsal head 14.4 (8.7) 13.0 (7.4) < 0.001 
Fifth metatarsal head 14.3 (8.6) 12.8 (7.2) < 0.001 
 
 
